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Abstract 
Herpes simplex virus type 1 (HSV-1) Immediate-early protein ICP0 is important for 
regulating the balance between lytic and latent infections.  The RING finger domain of 
ICP0 acts as an E3 ubiquitin ligase, binding to E2-ubiquitin conjugating enzymes and 
target proteins, promoting their polyubiquitination and subsequent degradation.  ICP0 
localises to cellular nuclear sub-structures known as ND10 at early stages of infection, and 
the RING finger domain induces the degradation and dispersal of ND10 proteins, which 
form part of the cell’s intrinsic antiviral defence mechanism.  The RING finger domain of 
ICP0 consists of an alpha-helix, and this and the loop regions are involved in interactions 
with the E2 ubiquitin-conjugating enzymes UBE2D1 and UBE2E1.  Previous work using 
an ICP0-inducible cell line system found a mutation (N151D) in ICP0’s alpha-helix, which 
allowed complementation of an ICP0-null mutant virus plaque formation but caused a 
substantial defect in the induction of reactivation of quiescent HSV-1.  This raised the 
possibility that the mechanisms controlling lytic infection and reactivation may be 
separable.  The main focus of this study was to investigate the N151D mutation and other 
mutations located within the alpha-helix (including K144E and K144E/N151D) using an 
inducible ICP0 expression cell system and virus infection studies.  The phenotypes of these 
alpha-helix mutants were characterised to investigate if complementation/lytic infection 
and reactivation involve differential activities of ICP0.  Additionally, these alpha-helix 
mutants were analysed for their in vitro E3 ligase ability and ability to interact with 
components of the ubiquitin pathway, focusing on E2 ubiquitin-conjugating enzymes.    
 
The results from this study using the inducible ICP0 cell system confirmed previous 
results.  The alpha-helix mutants had a greater defect during reactivation than 
complementing the plaque forming defect of an ICP0-null mutant virus, and this was more 
noticeable for the K144E mutant.  The virus infection studies showed a greater correlation 
between the effects of the mutations on the degradation of ND10 proteins, plaque 
formation and replication at low multiplicity of infection.  The defect of the K144E 
mutation was more profound than N151D in all the assays, and the activity of a double 
mutant including mutations at both K144 and N151 (KE/ND) was reduced to levels 
comparable with the RING finger deletion mutant.  Infection with mutants K144E and 
KE/ND greatly reduced the efficiency of reactivation of quiescent HSV-1 even at 
multiplicities of infection where their lytic infection was not severely affected, whereas 
N151D showed an intermediate phenotype.   
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Furthermore, this study showed that ICP0 has the potential to interact with multiple E2 
ubiquitin-conjugating enzymes, and the alpha-helix mutations may affect these 
interactions.  Further investigation will be required to examine the roles that these E2 
ubiquitin-conjugating enzymes play during HSV-1 infection.  The data in this study 
indicate that there is no strong evidence to suggest that ICP0 utilises differential activities 
of its RING finger to mediate reactivation and the stimulation of lytic infection, despite the 
likely dissimilar nature of the viral chromatin structure in the two situations.  These 
findings, however, provide an insight into the biological importance of the RING finger 
alpha-helix of ICP0 during the course HSV-1 infection and especially during reactivation 
from quiescence. 
 
In addition, motifs present within ICP0 that may be involved in interactions with other 
cellular proteins were analysed.  These included the PPEYPTAP motif present within 
retroviral Gag proteins, the SIAH-1 interaction motif and residue T67 (which are all 
involved in interactions with cellular E3 ubiquitin ligases), and the CoREST binding 
region.  Furthermore, a region of homology between alphaherpesvirus ICP0 proteins 
downstream of the RING finger domain, which had not previously been investigated in 
detail, was studied.  These studies indicated that the region downstream of the RING finger 
domain (residues 211-222) may contribute to ICP0’s activity, but no major role was 
detected for the other motifs studied.      
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1 Introduction 
1.1 Family Herpesviridae 
1.1.1 Overview 
Herpesviruses are pathogens that have evolved with their hosts for millions of years, 
infecting a wide range of vertebrate and invertebrate hosts.  The order Herpesvirales is 
composed of three families; the Herpesviridae (infecting mammals, birds and reptiles), the 
Alloherpesviridae (infecting fish and frogs), and the most recently discovered 
Malacoherpesviridae family that consists of the ostreid herpesvirus 1 that infects oysters 
(Davison et al., 2009; Davison et al., 2005).  The Herpesviridae family is based on virion 
morphology and is divided into three subfamilies; the Alpha-, Beta-, and Gamma-
herpesvirinae (Davison et al., 2005).   
 
There are eight herpesviruses that are known to infect humans; herpes simplex virus type 1 
(HSV-1), HSV-2, varicella-zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-
Barr virus (EBV), human herpesvirus 6 (HHV6, which is the collective name for the two 
closely related viruses, HHV6A and HHV6B) and HHV7 and HHV-8 (Kaposi’s sarcoma-
associated herpesvirus, KSHV) (Davison et al., 2005).  A common feature of all 
herpesviruses is their ability to establish a life-long latent infection following primary 
infection.   
 
1.1.2 Subfamilies 
The Herpesviridae family is divided into three subfamilies and the characteristics of each 
family will be discussed briefly below (Roizman & Pellett, 2001).   
 
The subfamily Alphaherpesvirinae (alphaherpesviruses) contains the genera Simplexvirus 
(HSV-1, HSV-2) and Varicellovirus (VZV).  These viruses have a variable host range and 
can infect a variety of cells including epithelial cells and mucous membranes, making them 
easy to study in a laboratory setting.  They also have a short replication cycle, cause the 
destruction of infected cells, and establish latency in sensory ganglia.     
 
The subfamily Betaherpesvirinae (betaherpesviruses) contains the genera Cytomegalovirus 
(HCMV) and Roseolovirus (HHV-6 and HHV-7).  The betaherpesviruses are characterised 
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by a restricted host range and a long reproductive cycle making them difficult to study as 
they replicate slowly in cell culture. 
 
The subfamily Gammaherpesvirinae (gammaherpesviruses) is divided into two genera, 
Lymphocryptovirus (EBV) and Rhadinovirus (KSHV).  EBV and KSHV replicate in 
lymphoblastoid cells and latency is established in lymphoid tissue.  Gammaherpesviruses 
have the narrowest host range compared to the other herpesviruses and spread slowly in 
cell culture.  Infections with gammaherpesviruses have been associated with the 
development of lymphomas, carcinomas and sarcomas.  
 
1.2 Pathogenesis of herpesvirus infections 
1.2.1 HSV infections (HSV-1 and HSV-2) 
HSV-1 and HSV-2 are transmitted by personal contact with infected individuals.  The virus 
infects mucosal surfaces or abraded skin producing vesicular lesions.  However, infection 
maybe asymptomatic in healthy individuals.  It has been traditionally thought that HSV-1 
is transmitted via oral contact and primary infection usually occurs in the oral mucosa, 
whereas HSV-2 infection is transmitted sexually and infects the genital areas causing 
genital herpes.  However, there is increasing overlap between these two viruses, with HSV-
1 commonly detected from genital herpes (Whitley et al., 2007).  This was highlighted by a 
study of samples collected over a 14 year period (1986-2000), which found that 49% of 
genital herpes in the West of Scotland were typed as HSV-1 and 51% as HSV-2 (Scoular et 
al., 2002). 
 
HSV infections can also infect other areas of the skin and mucosal membranes.  
Gingivostomatitis, an HSV infection of the mouth and gums, leads to sores and swelling, 
and HSV can also infect the skin on fingertips (herpetic whitlow).  HSV-1 infection of the 
eye can cause keratoconjunctivitis, which can led to scarring of the cornea and progressive 
vision loss and blindness from frequent reactivation and the host response.  Close contact 
sports such as rugby and wrestling can also spread HSV, leading to scrum pox and herpes 
gladiatorum respectively (reviewed in Whitley et al., 2007).  HSV can also be transmitted 
from infected mothers to newborns during delivery (or less commonly in utero), and this 
can lead to a localised or disseminated infection with over 1500 infections of newborns 
each year in the United States (Kimberlin, 2004).  The risk of transmission to newborns is 
higher with primary infection of genital herpes than recurrent episodes.  However the risk 
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can be prevented or minimised by caesarean delivery and the use of antivirals such as 
acyclovir (ACV) (see section 1.2.7) (Kimberlin, 2004).  In severe cases, HSV can invade 
and replicate in the central nervous system, leading to encephalitis.  In 
immunocompromised individuals, reactivation of HSV can be problematic, with many 
episodes of infection over the year (reviewed in Whitley et al., 2007).   
 
1.2.2 VZV 
VZV is the causative agent of varicella (chickenpox), which primarily infects musocal 
epithelial cells of the upper respiratory tract.  VZV infection commonly occurs in 
childhood, and the disease is characterised by a rash with vesicular cutaneous lesions.  
Chickenpox is a highly contagious disease that is spread by the respiratory route through 
infected air droplets or by contact with infected vesicle fluid from skin lesions.  
Chickenpox is usually self-limiting and can be controlled by an effective immune 
response.  However, it can lead to bacterial infections of the skin and in severe cases 
pneumonia.  VZV establishes latency in the sensory nerve ganglia, and the virus can 
reactivate and replicate to cause zoster (shingles).  Shingles is characterised by a vesicular 
rash and severe pain to an area of the skin that is served by the infected nerve ganglia.  
Shingles mainly affects immunocompromised or older patients with a weaker immune 
system.  Chickenpox and shingles can both transmit VZV to susceptible individuals, 
leading to chickenpox (Gershon & Gershon, 2013).     
   
There is a live attenuated vaccine available against VZV, which is derived from the Oka 
strain of the virus that was attenuated by serial passage in cell culture.  The vaccine has 
been licenced for use in the US since 1995 and is part of the childhood immunisation 
programme.  The vaccine is used routinely in many other countries, but in the UK is given 
only to at risk groups.  The vaccine induces immunity to VZV, but the virus enters latency 
and can reactivate to produce shingles.  There is also a vaccine against shingles, the zoster 
vaccine that was licensed for use in the US in 2006.  The zoster vaccine uses the same Oka 
strain as the VZV vaccine but contains a greater dose.  The vaccine is targeted at 
individuals usually over 60 or 70 years of age that have already had primary VZV infection 
in order to reduce the frequency or severity of shingles.  However the vaccine does not 
fully prevent VZV reactivation leading to shingles (Oxman, 2010).     
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1.2.3 HCMV 
HCMV is ubiquitous and is transmitted through bodily fluids including saliva, breast milk, 
semen, blood products and urine.  HCMV replicates in a variety of differentiated cell types 
and latency is maintained in CD34+ haematopoietic stem cells. Primary infection with 
HCMV is usually asymptomatic and only causes problems in individuals that are 
immunocompromised (for example HIV-infected individuals or transplant recipients) or in 
congenital infections.  In immunocompromised individuals, reactivation of latent HCMV 
or primary infection with a different stain can cause retinitis which can lead to blindness, 
gastritis, encephalitis, pneumonitis or hepatitis.  In severe cases, HCMV can cause a 
systemic infection that can be life threatening.  The severity of the disease often depends 
on the degree of immunosuppression and the viral load (Reddenhase, 2013). 
 
HCMV can also be transmitted transplacentally during pregnancy, during childbirth or via 
breastfeeding.  Transplacental infection can be due to primary infection or recurrent 
infection of the mother.  The risk of transmission to the foetus is higher with primary 
infection, where this leads to a 30-40% chance of transplacental transmission to the foetus, 
whereas with reactivation the risk is about 1-3%.  Congenital HCMV infection can lead to 
a number of health problems for the newborns, including mental retardation, cerebral 
palsy, hearing loss, impaired vision and damage to the central nervous system, with more 
severe consequences associated with infection early in pregnancy (Malm & Engman, 
2007).  
 
1.2.4 HHV-6 and HHV-7 
HHV-6 and HHV-7 infect a variety of cell types, including T lymphocytes. HHV-6 
establishes latency in macrophages and CD34+ haematopoietic stem cells, whereas HHV-7 
causes a persistent infection in the salivary glands and establishes latency in CD4+ cells.  
Infection with HHV-6B and HHV-7 usually occurs during childhood and causes 
exanthema subitum (roseola). Roseola is characterised by a sudden fever that lasts several 
days and the appearance of a rash once the fever subsides.  HHV-6 infection is also 
associated with encephalitis, pneumonitis and hepatitis in immunocompromised 
individuals (Mori & Yamanishi, 2007).   
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1.2.5 EBV 
EBV infects over 90% of the world’s population. Primary infection is usually 
asymptomatic and generally occurs in early childhood, however if delayed until 
adolescence it can lead to the development of infectious mononucleosis (glandular fever).  
Infectious mononucleosis is characterised by the acute onset of fever, sore throat, enlarged 
lymph glands and severe fatigue.  Following primary infection, EBV establishes latency in 
B lymphocytes, where it persists for the life of the host with intermittent low level 
excretion of virus in the saliva, which is the main transmission route.  Under certain 
conditions such as immunodeficiency, latent EBV genes can moderate B-cell proliferation 
and are implicated in the development of several EBV-associated malignancies, including 
Hodgkin’s lymphoma, Burkitt’s lymphoma and nasopharyngeal carcinoma.  Burkitt’s 
lymphoma is typically associated with tumours of the jaw in children and shows a high 
incidence in equatorial Africa where malaria is present.  Hodgkin’s lymphoma arises in 
young adults and is characterised by the presence of large multinucleate Reed-Sternberg 
cells, while nasopharyngeal carcinoma affects middle aged infected individuals and is a 
tumour of the squamous epithelium (reviewed in Crawford, 2001).      
 
1.2.6 KSHV 
The KSHV (or HHV-8) DNA sequence was first identified in 1994 in Kaposi’s sarcoma 
tissue from an AIDS patient (Chang et al., 1994).  Since then, HHV-8 has been shown to 
be a causative agent of Kaposi’s sarcoma and is associated with Castleman’s disease and 
primary effusion lymphoma, all of which are proliferative disorders.  HHV-8 establishes 
latency in lymphoid tissue, and latent gene expression promotes cell cycle progression, 
cellular proliferation and inhibits apoptosis.  Kaposi’s sarcoma is the most common cancer 
of untreated HIV-1 patients, and is characterised by formation of spindle-shaped cells 
(reviewed in Ganem, 2007; Kaplan, 2013).   
 
1.2.7 Treatments 
ACV and penciclovir and their prodrugs valacyclovir and famciclovir are used to treat 
herpesvirus infections.  ACV and penciclovir are guanosine analogues that are 
phosphorylated by the viral thymidine kinase and then subsequently by the cellular kinases 
GMP kinase and nucleoside diphosphate kinase.  The triphosphate form of ACV is a 
competitive substrate of the viral DNA polymerase, and is incorporated into newly 
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synthesised DNA, resulting in chain termination as it lacks a hydroxyl group in the 3’ 
position.  ACV is effective and has low toxicity, and is used to treat HSV, VZV and EBV 
infections, but is not sufficient for the treatment of HCMV (Piret & Boivin, 2011).         
Ganciclovir (a nucleoside analogue) was the first line drug used for prophylaxis and 
treatment of HCMV.  Ganciclovir is phosphorylated by the HCMV gene UL97 (Sullivan et 
al., 1992), a protein kinase, and this phosphorylated ganciclovir is incorporated into newly 
synthesised DNA where it slows and eventually stops chain elongation. Second line drugs 
for the treatment of HCMV include foscarnet, an inhibitor of the viral DNA polymerase, 
and cidofovir, a nucleoside analogue similar to ACV but that does not require initial 
activation by viral thymidine kinase (Piret & Boivin, 2014).  
 
Long term treatment or prophylaxis with ACV and its derivatives can lead to the 
development of viral resistance mutations within the viral thymidine kinase or viral DNA 
polymerase, which can be a problem in immunocompromised patients.  Therefore, there is 
a need for anti-virals with different modes of action, or preventative vaccines (reviewed in 
Piret & Boivin, 2011; 2014).  At present, a live attenuated VZV vaccine is the only human 
herpesvirus vaccine licenced for use (see section 1.2.2). 
 
 
1.3 Virion structure and organisation of HSV-1 genome 
The HSV-1 virion (Figure 1.1) is approximately 185 nm in diameter and consists of 
double-stranded DNA genome encased within an icosahedral capsid.  A protein layer 
termed the tegument surrounds the capsid and is enclosed within a lipid envelope derived 
from the host cell with viral glycoproteins embedded on the surface.  The main features of 
each component are described below.   
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Figure 1.1 HSV-1 virion structure.   
The main components of the HSV-1 virion are the nucleocapsid containing the double-
stranded DNA genome, the protein tegument layer and lipid envelope containing 
embedded glycoproteins. 
 
 
 
1.3.1 Double-stranded DNA core  
The core consists of a single copy of linear, double-stranded DNA, which circularises on 
release from the viral capsids.  The HSV-1 genome is 152 kbp and has a G+C content of 
68% (McGeoch et al., 1988).  The genome consists of two unique coding regions termed 
unique long (UL) and unique short (US) (Figure 1.2). UL and US are both flanked by 
inverted repeat sequences termed ‘b’ for UL and ‘c’ flanking US.  ‘a’ repeat sequences are 
present at both ends of the genome and an inverted copy is present between UL and US.  UL 
and US can invert producing four possible sequence orientations.  Three origins of 
replication are present within the genome, one within UL region (oriL) and two within the c 
repeat region flanking US (oriS).  The origins of replication are composed of A+T-rich 
sequences flanked by binding sites for the viral origin-binding protein UL9 that is 
important for viral DNA replication (section 1.4.1.3) (Ward & Weller, 2011).        
 
 
 
 
 
26 
 
 
Figure 1.2 Organisation of the HSV-1 genome.   
The unique coding regions UL and US are flanked by inverted repeat sequences.  The 
repeats flanking UL are TRL (ab) and IRL (b’a’), and those flanking US are IRL (a’c’) and 
TRS (ca).   
 
 
1.3.2 Nucleocapsid 
The HSV-1 nucleocapsid structure has been resolved by cryo-electron microscopy to 8.5 Å 
(Zhou et al., 2000).  The nucleocapsid is composed of 150 hexons and 11 pentons and one 
portal and is arranged in T=16 icosahedral symmetry.  The outer capsid is composed of the 
viral proteins UL19 (VP5), UL35 (VP26), UL18 (VP23) and UL38 (VP19C).  The major 
capsid protein UL19 is present in five or six copies in each penton or hexon, and six copies 
of UL35 form a ring on top of the UL19 subunits of each hexon.  One UL38 protein and 
two copies of UL18 form the triplexes (Zhou et al., 2000).  The capsid also contains the 
UL6 protein which forms a 12 subunit ring structure, which forms a pore known as the 
portal through which the viral DNA is packaged (section 1.4.1.4) (Chang et al., 2007; 
Newcomb et al., 2001).   
 
1.3.3 Tegument layer 
The tegument layer occupies the space in between the capsid and lipid envelope.  The 
tegument layer is composed of proteins that are transported into the newly infected cell and 
play roles in affecting host protein synthesis and inhibiting cellular defences, and many are 
important for efficient infection (Kelly et al., 2009).  Analysis of the proteins present in the 
tegument layer by mass spectrometry found 23 potential tegument proteins (Loret et al., 
2008).   
 
Tegument proteins include VP16, which stimulates viral immediate-early (IE) gene 
expression and plays a role in particle assembly, UL31, UL34, multifunctional VP22, IE 
proteins ICP0 and ICP4, the virion host shut off protein UL42 (vhs), which regulates 
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host/viral translation, and UL36, which plays roles in release of viral DNA into the nucleus 
and capsid envelopment (Kelly et al., 2009).   
 
1.3.4 Envelope  
The envelope is composed of a lipid bilayer containing up to 13 viral envelope 
glycoproteins, including gB, gC, gD, gE, gG, gH, gI, gL and gM (Loret et al., 2008).  
Cryo-electron tomography showed that each HSV-1 virion has between 600 to 750 
glycoprotein spikes embedded in the lipid envelope, and these range in length from 10-25 
nm (Grünewald et al., 2003).  Five of the viral envelope proteins (gB, gC, gD, gH and gL) 
are involved in virus attachment to host cells and entry, and their roles are discussed in 
section 1.4.1.1.  
 
1.4 HSV-1 life cycle 
1.4.1 Lytic infection 
The HSV-1 life cycle is characterised by two distinct phases: primary infection, which can 
result in a lytic infection, and long periods of latency, during which the virus can 
periodically reactivate to create a lytic infection.  The virus life cycle during lytic infection 
and the latent state are discussed below.     
 
1.4.1.1 Recognition and entry into cell 
HSV-1 entry into host cells involves fusion of the viral envelope with the host cell plasma 
membrane, and requires multiple viral proteins in a multi-step process.  Firstly, the virus 
attaches to the host cell by the interaction of gC and/or gB with heparan sulphate 
proteoglycans on the cell surface (Herold et al., 1991).  This attachment step is not 
essential but enhances virus infectivity by concentrating virus on the cell surface.  This 
binding step does not lead to changes in the cell membrane that are required for membrane 
fusion.  After attachment, gD interacts with cellular receptors called nectins, herpesvirus 
entry mediator (HVEM) or O-sulphated moieties on heparan sulphate, and these 
interactions, together with the interactions of the fusion proteins gB and gH/gL 
heterodimer, trigger fusion with the plasma membrane (reviewed in Campadelli-Fiume et 
al., 2007; Heldwein & Krummenacher, 2008).  
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After membrane fusion, the viral capsid and tegument proteins are released into the 
cytoplasm.  The capsids are transported to the nuclear pore along microtubules, through 
interaction with the cellular microtubule dynein/dynactin complex (Dohner et al., 2002).  
The viral proteins that are responsible for interacting with the dynein/dynactin complex 
include the tegument proteins UL36 and UL37 (Wolfstein et al., 2006).  UL36 has also 
been implicated in localisation of the nucleocapsid to the nuclear membrane and 
interacting with the nuclear pore to allow the release of viral DNA into the cell nucleus 
(reviewed in Kelly et al., 2009).    
  
1.4.1.2 Viral gene expression 
HSV-1 gene expression is a temporally regulated cascade that can be divided into three 
phases; IE (or α), early (β) and late (γ) genes.  IE genes are the first viral genes to be 
transcribed during infection and the proteins encoded by them play a crucial role in the 
regulation of gene expression.  The IE genes encode five proteins ICP0, ICP4, ICP22, 
ICP27 and ICP47, which are described in section 1.5.  The promoter region of the IE genes 
contains a TAATGARAT sequence motif (where R indicates a purine), and downstream of 
this is a TATA box and transcription factor-binding sites.  Transcription of IE genes 
involves the viral tegument protein VP16, which forms a complex with the cellular 
proteins host cell factor (HCF) and Oct-1 that binds to the consensus TAATGARAT 
sequence present in all IE promoters, allowing the C-terminal activation domain of VP16 
to activate transcription (reviewed in Wysocka & Herr, 2003).   
 
IE gene products are involved in activating expression of the early and late genes.  The 
early genes encode enzymes and DNA-binding proteins that promote viral DNA 
replication, and include viral thymidine kinase.  Expression of early genes requires the 
presence of ICP4.  The early gene promoter regions contain cellular transcription factor 
binding sites upstream of a TATA box, and generally do not have distinctive virus-specific 
elements.  Following DNA replication, increased viral template numbers enhance late gene 
expression to produce large amounts of structural proteins that are involved in the 
assembly of the progeny virions.  Late genes can be further classified into two classes, 
leaky late genes of which expression is enhanced by viral DNA synthesis, and true late 
genes that are transcribed only after viral DNA synthesis has taken place.  Late gene 
promoters are the simplest, containing only an initiator region downstream of the TATA 
box (Rajčáni et al., 2004; Weir, 2001). 
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1.4.1.3 The replication of viral DNA 
Replication of HSV-1 DNA takes place in the nucleus and requires seven essential viral 
proteins; the origin binding protein UL9, the single-stranded DNA-binding protein UL29 
(ICP8), the DNA helicase/primase complex composed of UL5, UL52 and UL8, and a two-
subunit DNA polymerase composed of the catalytic subunit UL30 and the DNA 
polymerase processivity factor UL42 (Ward & Weller, 2011). 
 
DNA replication initiates at the origin of replication sequences oriS or oriL with the binding 
of UL9.  ICP8 acts together with UL9 to distort and destabilise this region.  The 
helicase/primase complex is then recruited to the replication fork, where it further acts to 
unwind the DNA and synthesises short RNA primers for the initiation of DNA replication.  
The viral DNA polymerase is recruited to the replication fork to catalyse leading and 
lagging strand DNA synthesis, which then continues in a rolling circle model to generate 
linear concatemers (reviewed in Weller & Coen, 2012).      
 
1.4.1.4 Capsid assembly and packaging 
Capsid formation requires essential viral proteins, including the major capsid protein 
UL19, the triplex proteins UL18 and UL38, and the maturational protease UL26.  Capsid 
assembly takes place in the nucleus, where the interaction of UL19 and UL6 (which forms 
the portal) with scaffolding protein UL26.5 leads to autocatalytic assembly of a procapsid 
(Mettenleiter et al., 2006; 2009). 
 
Replication of the viral genome produces linear concatemers of DNA, which are cleaved 
during packaging into unit length monomers by the terminase complex composed of UL15, 
UL28 and UL33.  The terminase complex is located at the portal complex (UL6) 
positioned at a single capsid vertex.  The DNA is packaged and enters the capsid at this 
portal complex (Conway & Homa, 2011).       
 
1.4.1.5 Maturation and egress 
The widely accepted model of maturation and egress of HSV involves envelopment, de-
envelopment, and re-envelopment.  After assembly in the nucleus, mature nucleocapsids 
undergo primary envelopment through the inner nuclear membrane to the perinuclear 
space, and viral proteins UL31 and UL34 play a role in this process.  The UL31/UL34 
complex is required for efficient budding of the nucleocapsids through the inner nuclear 
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membrane, and is involved in disrupting the nuclear lamina and recruitment of viral 
proteins to the inner nuclear membrane.  The UL31/UL34 complex recruits cellular protein 
kinase C and interacts with tegument protein kinase US3, which are both involved in 
phosphorylation of nuclear lamins, thereby disrupting the integrity of inner nuclear 
membrane.  The immature enveloped nucleocapsids then fuse with the outer nuclear 
membrane, resulting in the loss of their primary envelope (de-envelopment).  In the 
cytoplasm, inner tegument viral proteins are acquired by the capsid.  The addition of the 
outer tegument proteins and secondary envelopment by membranes including the viral 
glycoproteins occurs at the Golgi.  Virions are released from the cell by exocytosis 
(reviewed in Kelly et al., 2009; Mettenleiter et al., 2009).   
 
1.4.2 Latency 
All herpesviruses, including HSV-1, establish a life-long latent infection in the host.  After 
primary infection of epithelial cells in the oral mucosa, the virus enters the sensory 
neurones and then undergoes retrograde axonal transport along the microtubules to the 
neuronal cell bodies in the trigeminal ganglion, where the virus establishes latency.  
Latency is characterised by an absence of gene expression, which is believed to be a 
consequence of failure of IE gene expression.  During latency, the genomes exist in a non-
replicating state in a circular episome configuration that associate with non-acetylated 
histones, and transcription is restricted to the latency associated transcripts (LATs, see 
section 1.4.2.2).  Through latency, HSV-1 limits recognition by the immune system, and 
this is likely to be a major factor in establishing life-long persistence.  The virus can 
reactivate in response to stimuli such as stress, fever, ultraviolet (UV) light and immune 
suppression, resulting in productive viral replication.  The virus then travels down the axon 
by anterograde transport to create a lytic infection at the original primary infection site.  
This may be an asymptomatic infection or can appear as epithelial lesions, thereby 
facilitating viral transmission (reviewed in Efstathiou & Preston, 2005; Nicoll et al., 2012).   
 
1.4.2.1 Establishment, maintenance and reactivation from latency 
Latency may result from a failure of IE gene expression.  As described in detail in section 
1.4.1.2, the transcription of IE genes involves viral protein VP16 forming a complex with 
the cellular proteins HCF and Oct-1 to activate transcription (Wysocka & Herr, 2003).  
However, in neurones, VP16, HCF and Oct-1 expression and localisation are altered.  In 
sensory neurones, HCF is detected in the cytoplasm rather than its normal nuclear 
31 
 
localisation (Kristie et al., 1999) and this may affect the nuclear localisation of VP16, 
which lacks a nuclear localisation signal and is dependent on HCF for its nuclear import 
(Boissière et al., 1999).  Oct-1 has been shown to be down regulated in neurones (Lakin et 
al., 1995).  The availability and localisation of VP16, Oct-1 and HCF may impair viral 
gene transcription in sensory neurones (reviewed in Nicoll et al., 2012).   
 
Latently infected mouse neurones contain a variable number of HSV genomes per cell, 
ranging from less than 10 to more than 1000 (Sawtell, 1997). A study by the Efstathiou 
group investigated whether the variable number of genomes in latently infected neurones 
was due to gene expression prior to the establishment of latency.  Using Cre reporter mice 
containing a LacZ gene and infected with Cre-expressing HSV-1 mutants, it was 
determined that viral gene expression can occur before the establishment of latency 
(Proença et al., 2008).  IE gene expression was detected in around a third of latently 
infected neurones, and in a small number of neurones there was activation of early and late 
gene promoters (Proença et al., 2011).  The number of latent viral genomes per cell may 
influence the likelihood of reactivation, with cells infected with high number of latent 
genomes showing a higher probability of reactivation (Sawtell, 1998).  Reactivation is a 
response to cellular or external signals that bring about the activation of viral gene 
expression and lytic infection.  However, the mechanisms controlling the balance between 
lytic and latent infections and factors that affect the establishment, maintenance and 
reactivation from latency remain poorly understood despite extensive research (reviewed in 
Efstathiou & Preston, 2005; Nicoll et al., 2012).    
 
1.4.2.2 Transcript expression during latency 
During lytic infection, the whole viral genome is actively transcribed, whereas viral 
genomes are repressed during latency and transcription is restricted to the LATs.  LATs are 
non-coding RNA transcripts that are produced from the repeat regions flanking the UL 
region of the viral genome (IRL/TRL) (Stevens et al., 1987).  Their transcription produces 
an 8.3 kb primary transcript, which undergoes splicing to produce a 2.0 kb LAT that is 
further spliced to yield a 1.5 kb LAT.  The LATs are transcribed antisense to the IE gene 
encoding ICP0 (Farrell et al., 1991).  The major LAT shows a nuclear distribution and 
accumulates to high levels in the nucleus of latently infected neurones (Thomas et al., 
2002).  The LATs have been proposed to have many roles, including enhancing the 
establishment of latency, reactivation and promoting neuronal survival.  The main 
phenotype of LAT deletion mutants is reduced efficiency of reactivation, which may be 
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related to fewer viruses establishing latency.  However, the general consensus is that LATs 
are not essential for the establishment of latency, maintenance or reactivation (reviewed in 
Efstathiou & Preston, 2005; Nicoll et al., 2012).  
 
1.4.2.3 Models of HSV-1 latency and quiescent infections 
Latency is an important part of the HSV-1 life cycle and is central to the survival strategy 
of the virus.  It is important to research this stage of the virus life cycle, as the virus is not 
visible to the immune system so remains undetected.  The broad host range of HSV-1 has 
allowed experimental models to be developed for studying viral latency.  The models do 
not recreate all aspects of the human disease, as this is not possible.  Animal models such 
as inoculation of the footpad/eye of mice or the eye of rabbits produces a local infection, 
and the virus is then transported to the trigeminal ganglia or dorsal root ganglia (depending 
on the site of inoculation), where latency is established.  In very few cases using these 
animal models, the virus sporadically reactivates.  However, reactivation can be induced 
by addition of epinephrine to the eye of rabbits, induction of hyperthermia in mice or 
explanting the mouse ganglia that are then grown in culture to test for reactivation.  In vitro 
systems using neuronal and non-neuronal cells for studying latency have also been 
developed.  In some aspects, these cell-based systems in some aspects are advantageous to 
animal models as they are easier, cheaper and more controllable.  These systems rely on 
replication-deficient viruses or the use of drugs such as ACV to prevent replication and IE 
gene expression and to enable the virus to establish quiescence, and the virus can be 
reactivated or de-repressed under specific conditions.  These models have provided an 
insight into the mechanisms of latency and reactivation (reviewed in Nicoll et al., 2012; 
Wagner & Bloom, 1997).   
 
1.5 Immediate-early gene expression 
The IE genes are the first viral genes to be transcribed during infection and they can be 
expressed in the absence of de novo viral protein synthesis.  The IE genes encode five 
proteins ICP4, ICP22, ICP27 and ICP47, which are described in detail below, and ICP0 in 
section 1.6. 
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1.5.1 ICP4 
ICP4 a protein of 175 kDa apparent molecular weight is encoded by the RS1 gene within 
the IRS/TRS region of the genome therefore is present as two copies.  ICP4 is essential for 
viral infection and functions as a transcriptional activator of early and late genes (Watson 
& Clements, 1980).  Viral gene expression does not proceed past the IE stage in cells 
infected with an ICP4 mutant virus, and there is an accumulation of IE gene products 
(Preston, 1979).  ICP4 contains a DNA-binding domain that enables it to bind to locations 
within the viral genome, including specific sequences on some IE, early and late promoter 
sites (Kuddus & DeLuca, 2007; Sampath & DeLuca, 2008).  However, it is the general 
DNA-binding ability of ICP4, rather than the presence of specific binding sequences, that 
is important for its activity. ICP4 binds to viral DNA and forms a tripartite complex with 
the cellular transcription factors TATA-binding protein and transcription factor 11B 
(TF11B), which are required for transcription by RNA polymerase II (Smith et al., 1993).     
 
1.5.2 ICP27 
ICP27 (UL54 gene) is also essential for viral replication and functions at multiple post-
transcriptional levels, including mRNA splicing, nuclear export of viral transcripts and 
increasing late gene expression (extensively reviewed in Sandri-Goldin, 2011).  ICP27 
binds to and recruits RNA polymerase II to viral replication sites, thus increasing the 
transcription of early and late genes (Dai-Ju et al., 2006).  Early in infection, ICP27 also 
inhibits pre-mRNA splicing by interacting with cellular proteins, thereby reducing host cell 
protein synthesis (Hardy & Sandri-Goldin, 1994).  This is believed to be advantageous to 
the virus, as only four of the viral transcripts contain introns.  ICP27 additionally binds to 
RNA and plays a role in viral mRNA export from the nucleus by interacting with nuclear 
export adaptor proteins and with the cellular mRNA export receptor (reviewed in Sandri-
Goldin, 2011).  Furthermore, ICP27 stimulates the translation of viral mRNAs, including 
VP16, by the recruitment of translation initiation factors to these mRNAs (Ellison et al., 
2005).  
 
ICP27 may also play a role in HSV-1 evading the immune response.  ICP27 expression 
induces the expression of type I IFN antagonising protein and down regulates the 
phosphorylation of STAT1, both of which prevent the accumulation of STAT1 in the 
nucleus (Johnson & Knipe, 2010; Johnson et al., 2008).      
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1.5.3 ICP22 
ICP22 (US1 gene) is not required for viral replication in all cell types, but in some cells it 
is required for efficient viral replication and the expression of some late genes (reviewed in 
Weir, 2001).  ICP22 is phosphorylated by the protein kinase UL13, and can alter the 
phosphorylation status of the large subunit of RNA polymerase II, thereby promoting viral 
transcription (Long et al., 1999; Rice et al., 1995). 
 
1.5.4 ICP47 
ICP47 (US12 gene) is involved in evading the immune response by disrupting antigen 
presentation.  ICP47 achieves this by binding to the transporter associated with antigen 
processing protein (TAP).  TAP transports antigenic peptides into the endoplasmic 
reticulum for presentation at the cell surface to activate the T cell response.  The binding of 
ICP47 to TAP inhibits presentation of viral peptides by major histocompatibility complex 
(MHC) class I, enabling the virus to evade the cytotoxic T cell response (Fruh et al., 1995; 
Hill et al., 1995).   
 
1.6 ICP0 
ICP0, the product of the IE1 gene, contains 775 amino acids.  The gene is located with the 
long repeat element (IRL/TRL), and is therefore present as two copies within the genome 
(Perry et al., 1986).  The ICP0 gene contains three exons, divided by two introns of 767 
and 136 bases, and thus ICP0 is translated from one of the few HSV-1 mRNAs that 
undergo splicing (Perry et al., 1986).  The coding region of ICP0 has a high G+C 
composition of 75.4% (Perry et al., 1986).       
 
ICP0 is a multi-functional protein that acts to relieve cell-mediated transcriptional 
repression, and therefore it stimulates viral gene expression in general.  ICP0 contains 
several functional domains and has been implicated in many diverse cellular pathways that 
are discussed below.    
 
1.6.1 Overview of ICP0 protein structure  
ICP0 contains several domains and motifs (Figure 1.3) that have been studied extensively 
and have functions assigned to them.  Some of these will be explained in more detail in 
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subsequent sections of this chapter.  The N-terminal third of ICP0 (residues 116-156) 
contains a zinc-binding RING finger domain that shows sequence homology to the related 
proteins expressed by other alphaherpesviruses (Barlow et al., 1994).  The regions 
downstream of the RING finger contain three distinct sequences at residues 224-234, 365-
371 and 508-518 that are phosphorylation sites (Davido et al., 2005), but in general this 
region of the protein has been poorly characterised. The third phosphorylation site is in 
proximity to the nuclear localisation signal (NLS) located at residues 500-509 (Everett, 
1988; Mullen et al., 1994).  The C-terminal third of ICP0 contains a cellular ubiquitin 
specific protease (USP7) interaction motif between residues 618-634 (Meredith et al., 
1995).  This region also contains a domain required for ICP0 self-interaction or 
dimerisation (Ciufo et al., 1994) and sequences between residues 634-719 that are required 
for ICP0’s localisation to ND10 (Maul & Everett 1994).   
 
 
 
 
Figure 1.3 Domains and motifs present within ICP0.   
The N-terminal third of ICP0 contains a RING finger domain.  The C-terminal third 
contains a nuclear localisation signal (NLS), a USP7-binding motif, and sequences 
required for localisation at ND10.     
 
 
 
1.6.2 ICP0-null mutant phenotype 
The phenotype of an ICP0-null HSV-1 mutant has been shown to be highly dependent on 
cell type.  Stow and Stow generated an ICP0-null mutant dl1403, which contains a 2 kb 
deletion within both copies of the gene (Stow & Stow, 1986).  Although dl1403 was able 
to replicate and produce plaques in baby hamster kidney (BHK) cells, the yield of 
infectious virus compared to wild-type (wt) was 20- to 100-fold lower (Stow & Stow, 
1986). Subsequent experiments have shown that human fibroblasts (HFs) are one of the 
most restrictive cell types for an ICP0-null mutant virus, having a 1000-fold defect (Everett 
et al., 2004a), whereas in HepaRG cells the defect is around 500-fold (Everett, 2010; 
Everett et al., 2009), and in other cells such as Vero, HeLa and BHK the defect is between 
30- to 100-fold (Chen & Silverstein, 1992; Everett et al., 2004a).  In some cells, such as 
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the osteosarcoma cell line U2OS, the ICP0-null mutant virus replicates as efficiently as 
wild-type (wt) virus, meaning that ICP0 is not required for HSV-1 replication in this cell 
type (Yao & Schaffer, 1995).  The reasons for lack of requirement of ICP0 in U2OS cells 
is not known, but may be due to the cells lacking an antiviral mechanism that is targeted by 
ICP0 (Yao & Schaffer, 1995), including lower levels of PML and lack of ATRX 
expression (Lukashchuk & Everett, 2010). Alternatively, U2OS cells may lack signalling 
or chromatin assembly pathways that are present in restrictive cell types (Hancock et al., 
2010; Hancock et al., 2006).  Due to the lack of requirement of ICP0, U2OS cells are used 
to calculate viral titres of wt and ICP0 mutant virus stocks in a truly comparative manner.     
 
Plaque formation efficiency (PFE) of an ICP0-null mutant virus and apparent phenotype is 
also dependent on the input multiplicity of infection (MOI), as well as the cell type.  In 
non-permissive cells, infection with an ICP0-null mutant virus can cause a reduction in 
PFE.  However, above a certain input multiplicity ICP0-null mutant viruses replicate as 
efficiently as wt (Everett et al., 2004a; Stow & Stow, 1986).  Therefore, compared to wt 
virus, the ICP0-null mutant virus has a high virus particle to plaque forming unit ratio. In 
restrictive cell types, the virus also has a high probability of entering a non-productive 
infection leading to quiescence (Everett et al., 2004a).  
 
1.6.3 The RING finger of ICP0 
The N-terminal third of ICP0 between residues 116 to 156 contains a C3HC4 RING finger 
domain (Barlow et al., 1994; Everett et al., 1993a).  At present, there is no solved crystal 
structure of ICP0 in HSV-1.  The closest related structure is the RING finger domain of the 
homologous equine herpesvirus 1 IE protein (EHV-63) determined by H-NMR (Figure 
1.4).  The tertiary structure of the RING finger domain showed it consists of an 
amphipathic alpha-helix that lies between the second and third strands of triple-stranded 
antiparallel beta-sheets.  A hydrophobic core is formed from conserved residues within the 
alpha-helix, beta-sheets and loop regions (Barlow et al., 1994).  The RING finger domain 
is important for ICP0’s activity, as deletion of the RING finger domain causes a defect in 
replication and PFE as severe as complete deletion of the ICP0 gene (Everett, 1989; 
Everett et al., 2004a; Lium & Silverstein, 1997). 
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Figure 1.4 The RING finger domain of EHV EICP0.   
The RING finger domain of EICP0 consists of an amphipathic alpha-helix (green) that lies 
between the second and third strands of the triple-stranded anti-parallel beta-sheets 
(brown).  Conserved cysteine and histidine residues within the RING finger domain 
coordinate the binding of two zinc atoms (Figure 1.5).  The residues in yellow are the 
positions of the K144E and N151D residues that are the focus of this study.      
 
 
Conserved cysteine residues at position 116, 119, 139, 142, 143, 153 and 156, and a 
histidine residue at position 136, coordinate the binding of two zinc atoms in a tetrahedral 
geometry (Figure 1.5).  The first and third pairs of residues bind one zinc atom, while the 
second and fourth pair of residues bind the other zinc molecule (Barlow et al., 1994; 
Everett et al., 1993a; Lium & Silverstein, 1997).  Mutations in these conserved cysteine 
and histidine residues show they are essential for the transactivation properties of ICP0, 
whereas the non-conserved cysteine 129 and histidine 126 residues are not involved in zinc 
binding but may play a role in the layout of the RING finger domain (Lium & Silverstein, 
1997).     
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Figure 1.5 Zinc coordinating residues within the RING finger domain of ICP0.  
Conserved cysteine and histidine residues coordinate the binding of two zinc (Zn
2+
) atoms 
within the RING finger domain of ICP0.  The first and third pairs of residues bind one zinc 
atom, while the second and fourth pair of residues bind the other zinc molecule. 
 
 
 
Between the third and fourth pair of zinc coordinating residues lies the alpha-helix, from 
which several polar and charged side chains extend from the RING finger domain. By site-
directed mutagenesis, it has been shown that these side chains are involved in ICP0 activity 
(Barlow et al., 1994; Everett et al., 1995; Vanni et al., 2012).  Mutations K144E and 
N151D, which are located in the charged side chains that are exposed on the surface of the 
alpha-helix, will be one of the focuses of this thesis.  It was found that these mutations 
affected ICP0’s activity in gene expression reporter assays and also the limited number of 
virus infection assays that were available at the time (Barlow et al., 1994; Everett et al., 
1995).  More recently, using an inducible ICP0 expression system, mutation N151D was 
shown to have a slight defect in complementing the plaque formation ability of an ICP0-
null mutant HSV-1 but was defective in inducing reactivation of quiescent HSV-1 (Vanni 
et al., 2012).  Therefore, as these residues are exposed on the surface of the alpha-helix, 
they may have a role in forming an interface with ICP0 interaction partners. 
 
Proteins containing RING finger domains were shown to be involved in the ubiquitination 
of substrates, and it was suggested that RING finger proteins act as E3 ubiquitin ligases 
that mediated the transfer of ubiquitin onto target proteins (Joazeiro & Weissman, 2000).  
The RING finger domain of ICP0 was shown to function as an E3 ubiquitin ligase, 
inducing the formation of polyubiquitination chains and the subsequent proteasome-
dependent degradation of selected cellular proteins (Boutell et al., 2002).  The E3 ubiquitin 
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ligase activity of ICP0, its cellular substrates and the ubiquitin pathway are discussed in 
more detail in section 1.8. 
  
1.6.4 Association with ND10 
At early stages of infection, ICP0 localises to cellular nuclear structures known as nuclear 
domains 10 (ND10, otherwise known as PML nuclear bodies or PML oncogenic domains) 
(Maul et al., 1993), and this requires the C-terminal region of ICP0 (Maul & Everett, 
1994).  ND10 are dynamic, macromolecular structures that appear as distinct punctate foci 
within the nucleus by immunofluorescence. They range from 0.2-1 µm in size, with 
anything from 2-30 present in each cell, depending on the cell type and status (Ascoli & 
Maul, 1991).  ND10 are composed of PML, Sp100, hDaxx and small ubiquitin-like 
modifier 1 protein (SUMO-1), as well as several other regulatory proteins (reviewed in 
Tavalai & Stamminger, 2008).  PML can be covalently modified with the SUMO family of 
proteins, and this SUMO-modification is required for ND10 formation, in which  PML acts 
as a scaffold protein and recruits other proteins to ND10 (Ishov et al., 1999; Zhong et al., 
2000).   
 
As the infection progresses, ICP0 causes the disruption of ND10 (Maul et al., 1993), and 
the RING finger of ICP0 is essential for this disruption (Everett & Maul, 1994).  ICP0 
induces the proteasome-mediated degradation of PML and Sp100, particularly their 
SUMO-modified isoforms (Chelbi-Alix & de The, 1999; Everett et al., 1998a; Parkinson 
& Everett, 2000), and this process also requires the RING finger of ICP0 (Everett et al., 
1998a) due to its E3 ligase ability (discussed in section 1.8).  The degradation of PML and 
Sp100 leads to the dispersal of other ND10 proteins. 
 
Additionally, after the HSV-1 genome enters the nucleus, ND10 proteins including PML, 
Sp100, hDaxx and ATRX become associated with the viral genomes and early replication 
compartments (Everett & Murray, 2005).  This recruitment of ND10 proteins to viral 
genomes occurs very rapidly (Everett & Chelbi-Alix, 2007), but, due to ICP0 inhibiting the 
recruitment, it is difficult to detect in wt infections (Everett & Murray, 2005).  This 
recruitment can be visualised in ICP0-null mutant infected cells at the edges of developing 
plaques, as ICP4 is recruited to replicating viral genomes at the early stages of infection 
and forms discrete foci, most of which become associated with ND10 proteins (Everett et 
al., 2003).  Unlike the formation of ND10, the recruitment of ND10 proteins to viral 
genomes is not dependent on PML (Everett et al., 2007; Everett et al., 2008; Everett et al., 
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2006), but the recruitment of ATRX is dependent on hDaxx (Lukashchuk & Everett, 
2010).  The recruitment of ND10 proteins to incoming viral genomes is involved in the 
host response to HSV-1.  PML and Sp100 are IFN-stimulated genes (ISGs), and so are 
upregulated in response to IFN (Grotzinger et al., 1996; Guldner et al., 1992; Lavau et al., 
1995) and play a role in the cellular restriction of viral infection, as explained in section 
1.7.3.   
 
1.6.5 Association and interaction of ICP0 with other cellular 
proteins 
As well as its association with ND10, ICP0 has been implicated in many diverse cellular 
pathways, including the DNA damage response, transcriptional regulation, influencing 
chromatin assembly and modification, and immune signalling pathways.  Therefore, ICP0 
associates or interacts with many diverse cellular proteins involved in these pathways, 
some of which will be described below.  The interactions of ICP0 with components of the 
innate immune response (particularly the IFN response) will be discussed in section 1.7.1.   
 
1.6.5.1 ICP0 and interactions with chromatin assembly and modification 
components 
Within cells, free DNA normally becomes associated with histones to form chromatin.  
During lytic infection, HSV-1 DNA is not extensively associated with histones, and viral 
proteins may play a role in preventing the addition of histones to viral DNA.  In latently 
infected cells however, the viral DNA is in a heterochromatin structure tightly associated 
with histones leading to the silencing of viral gene expression.  A potential way that ICP0 
may promote gene expression and influence the switch from lytic to latent infections is 
through association with chromatin and its related modifying complexes (reviewed in 
Knipe & Cliffe, 2008).   
 
The structure of chromatin plays a role in gene regulation, and can be influenced by post-
translational modification of the core histones, including acetylation, methylation, 
ubiquitination and phosphorylation.  Acetylation of histones by histone acetyltransferases 
forms less condensed active euchromatin, which is associated with active gene expression 
(reviewed in Knipe & Cliffe, 2008).  The removal of the acetyl group from the lysine of 
the acetylated histone protein by histone deacetylases (HDACs) forms highly condensed 
heterochromatin that is transcriptionally inactive and is associated with repression of gene 
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expression (reviewed in de Ruijter et al., 2003).  In transfected cells, ICP0 interacts with 
class II HDACs 4, 5 and 7 and leads to the redistribution of HDAC 4 to colocalise with 
ICP0 (Lomonte et al., 2004).  HDAC inhibitors can induce gene expression in trigeminal 
ganglia latently infected with ICP0-null mutants (Arthur et al., 2001; Terry-Allison et al., 
2007).  However, inhibitors of HDACs cannot complement the defects of an ICP0-null 
mutant virus in restrictive cell lines (Everett et al., 2008).   
 
ICP0 has also been shown to displace HDAC1 from the REST/CoREST/HDAC 
transcriptional repressor complex, which has a role in chromatin modification.  ICP0 
achieves this by binding to CoREST, a corepressor for the cellular protein REST (Gu et al., 
2005), through residues (671 and 673) located in the C-terminal third of ICP0 (Gu et al., 
2005; Gu & Roizman, 2009).  Therefore, the presence of ICP0 and its displacement of 
HDAC1 from this complex may have a role in reactivation/derepression of viral gene 
expression (Gu & Roizman, 2007).  However, depletion of CoREST did not improve the 
PFE or replication efficiency of an ICP0-null mutant virus (Everett, 2010).   
 
1.6.5.2 ICP0 interactions with components of the DNA damage response 
HSV-1 infection activates the DNA damage response (Lilley et al., 2005; Mohni et al., 
2010; Weller, 2010; Wilkinson & Weller, 2006), and ICP0 interacts with some 
components of this response.  The DNA damage response pathway consists of a variety of 
cellular proteins and signalling pathways for sensing and repairing DNA damage within 
cells.  DNA damage sensor proteins detect DNA damage and activate protein kinases, 
including ATM kinase and DNA-dependent protein kinase (DNA-PK), which are involved 
in responses to double-stranded DNA breaks, and ATR kinase, which responds to single 
strand DNA damage.  These protein kinases activate downstream signalling components to 
mediate repair of the damaged site (reviewed in Ciccia & Elledge, 2010).   
 
ICP0 induces the degradation of components of the DNA damage response, including 
DNA-PK and the cellular ubiquitin ligase RNF8 (Chaurushiya et al., 2012; Lilley et al., 
2010; Parkinson et al., 1999; Wilkinson & Weller, 2006).  DNA-PK is composed of a large 
catalytic subunit and DNA-binding protein Ku, which targets DNA-PK to DNA.   DNA-
PK is involved in DNA double-strand break repair and V(D)J recombination (reviewed in 
Lees-Miller, 1996).  The RING finger of ICP0 induces the degradation of the catalytic 
subunit of DNA-PK in a proteasome-dependent manner (Parkinson et al., 1999). 
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RNF8 is also degraded by ICP0 (Lilley et al., 2010).  RNF8 is recruited to double-strand 
breaks by binding to phosphorylated Mdc1, and ubiquitinates histones H2A and H2AX 
(Huen et al., 2007; Mailand et al., 2007).  RNF168 binds to ubiquitinated histone H2A and 
acts to further ubiquitinate histones to enhance the recruitment of repair proteins involved 
in the damage response, including 53BP1 and BRCA1 (Doil et al., 2009; Stewart et al., 
2009).  ICP0 is phosphorylated by the cellular kinase CK1 at residue T67, which mimics 
phosphorylated Mdc1, allowing ICP0 to bind to RNF8 and induce its degradation 
(Chaurushiya et al., 2012).  By inducing the degradation of this cellular ligase, ICP0 
prevents histone ubiquitination and the recruitment of cellular repair factors to sites of 
DNA damage. 
 
ICP0 additionally affects the DNA damage response by disrupting the ATR signalling 
pathway.  ICP0 causes the redistribution of the ATR recruitment protein ATRIP, 
preventing the colocalisation with ATR and the recruitment of ATR to sites of DNA 
damage (Wilkinson & Weller, 2006).  Therefore, ICP0 has multiple mechanisms to disrupt 
the DNA damage response by targeting proteins for degradation and preventing 
downstream signalling events involved in DNA repair.   
 
1.6.6 ICP0 in reactivation from latency 
Although ICP0 is not essential for HSV-1 replication, the virus is more likely to enter a 
non-productive infection and enter a quiescent state in cells infected at a low MOI if ICP0 
is not present (Everett et al., 2004a; Stow & Stow, 1989).  However the requirement of 
ICP0 initiating reactivation from latency or quiescent infections and during reactivation 
remains controversial.  ICP0-null mutant viruses reactivate inefficiently from latency 
following explant of infected mouse trigeminal ganglion cells, indicating ICP0 may induce 
efficient reactivation (Cai et al., 1993; Halford & Schaffer, 2001).  Additionally, ICP0 has 
been shown to have the ability to reactivate gene expression in quiescently infected non-
neuronal in vitro models (Everett et al., 2009; Harris et al., 1989; Samaniego et al., 1998), 
and this was dependent on the RING finger region of ICP0 (Everett et al., 2009; Ferenczy 
et al., 2011; Harris et al., 1989).  Furthermore, the expression of ICP0 in latently infected 
mouse trigeminal ganglion cells resulted in active replication of viral genomes (Halford & 
Schaffer, 2001; Terry-Allison et al., 2007). 
 
Reactivation of gene expression and viral replication in quiescently infected non-neuronal 
cells, however, can also be induced, albeit to a less marked degree, by cellular stress in the 
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absence of ICP0 (Preston & Nicholl, 2008).  In vivo mouse studies using hyperthermic 
stress found that ICP0 was not required for the initiation of reactivation.  However, ICP0 
was important for productive replication and gene expression following the exit from 
latency (Thompson & Sawtell, 2006).  Other viral proteins, such as VP16, may 
additionally play a role in initiating reactivation (Thompson et al., 2009).  Therefore, 
despite extensive research into the requirements for reactivation from latency, whether 
ICP0 plays a role still remains unclear.  Other viral or cellular factors may also be 
important and play a role, and the conclusions gained may depend on the experimental 
system used.       
 
1.7 Host defences against viruses 
The host response to viral infection and viral evasion strategies determine the outcome of 
the infection.  The immune response has traditionally been divided into two groups, the 
innate and the adaptive immune responses.  However, a recently emerged third aspect of 
the immune response, termed intrinsic antiviral resistance, acts immediately against 
invading viruses and involves pre-existing cellular proteins.  Each aspect of the immune 
response and the effects on HSV-1, and the interactions of viral and cellular immune 
response proteins, are discussed below.      
 
1.7.1 Innate immunity to HSV-1 
The innate immune response is a non-specific response that aims to resist microbial 
infection.  The consequences of activated innate immunity include the induction cell lysis, 
the priming of neighbouring cells to induce an antiviral state, and also the shaping of the 
adaptive immune response.  Natural killer cells, the complement system and IFN-mediated 
defences are all components of the innate immune response. 
 
Pattern recognition receptors such as Toll-like receptors detect ‘pathogen-associated 
molecular patterns’, which activate a signalling cascade leading to the activation of IRF3 
and NF-κB transcription factors.  These proteins enter the nucleus and activate the 
transcription of chemokine and cytokine genes including those of type I IFNs (IFN α/β).  
Type I IFNs bind to cellular receptors, leading to the activation of Janus kinase (JAK) and 
phosphorylation of signal transducer and activator of transcription (STAT) molecules 
(STAT1 and STAT2), initiating the JAK/STAT signalling pathways. Phosphorylated of 
STAT1 and STAT2 allows the formation of a heterodimer that is then translocated into the 
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nucleus, where it binds to IFN-stimulated response elements (ISRE) within the promoters 
of IFN stimulated genes (ISGs) in order to activate their transcription.  The activation of 
type I IFNs induces an antiviral state in both the initially stimulated and neighbouring 
cells, thereby limiting viral replication and spread, and it leads to the transcription of 
further ISGs.  ISGs include dsRNA-dependent protein kinase R (PKR) and 2’-5’ 
oligoadenylate synthetase (OAS), which both recognise double-stranded RNA.  PKR is 
activated after binding double-stranded RNA, and phosphorylates eukaryotic initiation 
factor 2α (eIF-2α), which inhibits protein synthesis.  OAS binding of double-stranded RNA 
activates RNase L, which leads to the degradation of viral (as well as cellular) mRNA 
within the cell (reviewed in Randall & Goodbourn, 2008). 
 
HSV-1 is sensitive to both type 1 IFN (IFN-α/-β) and type II IFN (IFNγ), which together 
inhibit virus replication both in vivo and in vitro (Halford et al., 2005; Leib et al., 1999; 
Mittnacht et al., 1988; Sainz & Halford, 2002).  Three Toll-like receptors (TLR) have been 
shown to recognise HSV; TLR2, which recognises extracellular ligands (Kurt-Jones et al., 
2004), TLR3, which binds to double-stranded RNA (Zhang et al., 2007), and TLR9, which 
recognises unmethylated CpG motifs (Lund et al., 2003).  However, HSV-1 proteins have 
been shown to act on multiple levels to evade and inhibit the innate immune response 
(reviewed in Paladino & Mossman, 2009; Vandevenne et al., 2010).  Some of the 
strategies used by the different viral proteins are described below.      
 
ICP0 inhibits the TLR2 activation of NF-κB in a RING-dependent manner, possibly 
through the degradation of TLR adaptor proteins, therefore blocking the production of 
inflammatory chemokines and cytokines (van Lint et al., 2010).  ICP0 also acts to prevent 
TLR signalling and NF-κB activation through its association with USP7, which de-
ubiquitinates key components in this signalling pathway (Daubeuf et al., 2009).  ICP0 has 
also been shown to block ISG expression by inhibiting transcriptional activator IRF3 (Lin 
et al., 2004; Melroe et al., 2004).  ICP0 interferes with the activation of STAT-1 (Halford 
et al., 2006) and also induces the degradation of key ISGs including PML and Sp100 (see 
section 1.7.3).   
 
Other viral proteins also play a role in evading the immune response including the IE 
protein ICP27 and several late proteins.  In addition to the roles described in section 1.5.2,  
ICP27 causes a decrease in cytokine production in infected cells, probably through down 
regulating IRF3 activation (Melchjorsen et al., 2006), and also decreases STAT-1 
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phosphorylation, thereby preventing the accumulation of STAT-1 in the nucleus and 
inhibiting the JAK/STAT pathway (Johnson et al., 2008).  Late viral protein ICP34.5 
blocks the inhibition of protein synthesis mediated by PKR, by inducing the 
desphosphorylation of eIF-2α (He et al., 1997) and inhibiting the activation of IRF3, 
thereby preventing induction of IFN and ISGs in infected cells (Verpooten et al., 2009).  
US11 protein also inhibits PKR activation by binding to PKR, therefore preventing the 
phosphorylation of eIF-2α (Cassady et al., 1998), and also blocks 2’-5’ OAS activation 
(Sànchez & Mohr, 2007).  The late proteins US3 and vhs have also been implicated in 
antagonising the innate immune response (reviewed in Paladino & Mossman, 2009). 
 
HSV-1 has evolved multiple mechanisms to prevent IRF3 and NF-κB signalling, therefore 
inhibiting IFN production.  However, a study found that depletion of IRF3 or STAT-1 in 
HFs did not improve the PFE of an ICP0-null mutant virus (Everett et al., 2008).  ICP0-
null mutant viruses though were sensitive to IFN pre-treatment of cells both at high and 
low MOIs, indicating that the phenotype of an ICP0-null mutant virus is not due to 
repression through IFN pathways alone (Everett et al., 2008).   
 
HSV-1 also evades the complement component of the innate immune response.  Viral 
glycoprotein gC binds to complement protein C3b, therefore inhibiting the complement 
pathway and preventing neutralisation and cell lysis (Friedman et al., 1984; Harris et al., 
1990).  Therefore, HSV-1 encodes multiple proteins that can antagonise the host innate 
immune response at different points in multiple pathways.   
 
1.7.2 Adaptive immunity to HSV-1 
The adaptive or acquired immune response is pathogen-specific and exhibits memory 
against re-infecting pathogens.  The key components of the adaptive immune system are B 
lymphocytes, which are involved in the humoral response and the production of antibodies, 
and T lymphocytes, which initiate the cell mediated response.  B lymphocytes recognise 
viral antigens via their B-cell receptors, which leads to the production of antibodies 
directed against the invading virus.  T lymphocytes are able to recognise infected cells 
through MHC complexes presenting viral peptides, and act either to destroy the infected 
cell or to assist B-cells with antibody production.  T lymphocytes are divided into two 
classes: CD4+ and CD8+ cells.  CD4+ cells recognise peptides presented on MHC class II, 
and their role is to activate other effector cells and provide co-stimulation to B 
lymphocytes to enable them to produce antibodies.  Cytotoxic CD8+ cells recognise 
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peptides presented via MHC class I and, when activated, kill virus-infected cells (Janeway, 
2001).     
 
The adaptive immune response is important for the control of HSV infections.  Individuals 
with a compromised immune system, such as those with HIV and transplant recipients, are 
more likely to suffer many episodes of reactivation, and primary infection in newborns 
whose immune system is yet to develop is associated with more severe disease (reviewed 
in Whitley et al., 2007).   
 
Infection with HSV-1 leads to the production of antibodies directed against a number of 
viral proteins, including glycoproteins and a nucleocapsid protein (Zweerink & Stanton, 
1981).  However, HSV-1 employs multiple mechanisms to evade recognition by the 
adaptive immune response by inhibiting antigen presentation.  As described in section 
1.5.4, ICP47 disrupts antigen presentation by MHC class I by binding to TAP, enabling the 
virus to prevent cell lysis by cytotoxic T lymphocytes (Fruh et al., 1995; Hill et al., 1995).  
Glycoprotein gB targets the MHC class II pathway by interacting with HLA-DR (MHC 
class II cell surface receptor), preventing its cell surface expression and causing release of 
HLA-DR into the exosome pathway (Neumann et al., 2003; Temme et al., 2010).  HSV 
infection of B lymphocytes has additionally been shown to inhibit their ability to activate 
CD4+ T cells (Barcy & Corey, 2001).     
 
Furthermore, viral glycoproteins gE and gI play a role in evading the immunoglobulin G 
(IgG)-mediated response, which act to neutralises viruses, targeting them for phagocytosis 
and activating the complement system.  gE and gI form a heterodimeric transmembrane 
complex gE-gI that binds the Fc domain of IgG (Johnson et al., 1988).  The antigen-
binding fragment of the IgG can still bind viral antigens, but the activation of downstream 
signalling pathways is prevented, and these are then targeted for degradation within 
lysosomes (Ndjamen et al., 2014). 
 
1.7.3 Intrinsic antiviral resistance 
Intrinsic antiviral resistance is a relatively recently discovered part of the immune 
response, and is mediated by pre-existing cellular factors that are constitutively expressed.  
Intrinsic resistance is the first line of defence against virus infection, acting on a cellular 
level to suppress or prevent viral infections.  Unlike innate immunity, proteins involved in 
intrinsic resistance are not upregulated in response to infection and do not require 
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intracellular signalling, but some of these factors can further be induced by IFN during 
viral infection (reviewed in Bieniasz, 2004).   
 
Intrinsic resistance was first recognised as a response to retroviruses, with cellular proteins 
TRIM5α and APOBEC3G.  TRIM5α, which is present in the cytoplasm, recognises and 
binds to incoming HIV capsids, and although the mechanisms of restriction are not fully 
understood, it occurs in a species specific manner (Stremlau et al., 2004).   APOBEC3G is 
a cytidine deaminase that catalyses the hydrolysis of cytidines to uridines.  APOBEC3G 
affects HIV replication, leading to guanine to adenine hypermutation on the positive-sense 
DNA, which therefore may lead to the encoding of defective viral proteins (Mangeat et al., 
2003).  Tetherin also restricts HIV-1 infection by binding to and retaining retrovirus 
particles on the cell surface, therefore inhibiting their release (Neil et al., 2008). 
 
In many instances, viruses express regulatory proteins that counteract the effects of 
intrinsic resistance factors. Therefore, proteins involved in intrinsic resistance are most 
easily studied in the context of infections with mutant viruses that fail to express these 
regulatory proteins, as the restriction effect can then be observed.   For example, tetherin is 
counteracted by the HIV protein vpu, which facilitates virus spread (Neil et al., 2008), and 
the HIV viral infectivity factor (vif), which binds to APOBEC3G, promoting its 
polyubiquitination and degradation by the proteasome (Sheehy et al., 2003). Intrinsic 
resistance also has the potential to be overcome by the infecting virus, especially when 
present in large amounts, thereby swamping the inhibitory effects.     
 
The proteins within ND10, including PML, Sp100 and hDaxx, are involved in intrinsic 
resistance to virus infection.  Therefore, different herpesviruses have evolved ways to 
target these ND10 components to prevent viral gene repression and promote viral 
replication.  These include ICP0 (Everett & Maul, 1994), IE1 protein of HCMV (Ahn & 
Hayward, 1997), EBV proteins BLZF1 and BNRF1 (Adamson & Kenney, 2001; Tsai et 
al., 2011) and KSHV proteins LANA2 and ORF75 (Full et al., 2014; Marcos-Villar et al., 
2009).  The restrictive effects of some of the individual components of ND10 (PML, 
Sp100, hDaxx and ATRX) and their intrinsic resistance to herpesviruses are explored in 
more detail below, focussing on HSV-1.     
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1.7.3.1 PML 
PML is a major component of ND10, and is required for ND10 assembly (Ishov et al., 
1999; Zhong et al., 2000).  There are six major isoforms of PML produced by alternative 
splicing.  These isoforms differ in their C-terminal region, but the N-terminal region 
composed of a RING finger, two B-boxes and a coiled-coil domain is conserved and forms 
the tri-partite motif (TRIM) that is found in a large family of proteins (Jensen et al., 2001).  
PML is covalently modified by members of the SUMO family of small ubiquitin-like 
proteins (Sternsdorf et al., 1997) at one of three SUMO modification sites at lysine 65 
within the RING finger domain, at residue 160 located in the B1-box and one within the 
nuclear localisation signal at residue 490 (Kamitani et al., 1998).   
 
PML plays a role in restricting the replication of ICP0-null mutant HSV-1.  In HFs 
depleted of PML by shRNA, ICP0-null mutant virus PFE was increased by five- to ten-
fold and gene expression also increased, but no effect was seen with the wt virus.  The 
increase in PFE of an ICP0-null mutant virus, however, did not restore it to wt levels 
(Everett et al., 2008; Everett et al., 2006).  The depletion of PML in HFs also increased the 
replication and PFE of wt HCMV at low MOIs, and increased the IE gene expression of 
IE1 deletion HCMV mutant in both low and high MOI infections (Tavalai et al., 2006).  
PML depletion furthermore improved the replication of VZV (Kyratsous & Silverstein, 
2009).  Additionally, in differentiated human neural and skin cells infected with VZV in 
vivo, PML isoform IV (PML.IV) sequestered newly synthesised VZV nucleocapsids in the 
nucleus. This is thought to occur by PML.IV binding to VZV capsid surface protein 
ORF23, preventing nuclear egress and the formation of infectious particles (Reichelt et al., 
2011).  
 
1.7.3.2 Sp100 
Sp100 is another permanent ND10-associated protein, and, like PML, undergoes 
alternative splicing to produce different isoforms designated Sp100-A, Sp100-B, Sp100-C 
and Sp100-HMG (Guldner et al., 1999).  Sp100-B, Sp100-C and Sp100–HMG all contain 
a SAND domain required for DNA binding in other proteins (Bottomley et al., 2001).  
Sp100 can be covalently modified by SUMO family members (Sternsdorf et al., 1997), and 
during infection ICP0 induces the degradation of SUMO-modified but not unmodified 
forms of Sp100 (Parkinson & Everett, 2000; Sternsdorf et al., 1997).  SUMO modification 
of Sp100 is not required for its localisation to ND10 (Sternsdorf et al., 1997), but this 
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localisation is dependent on PML (Ishov et al., 1999).  However, in the absence of PML, 
Sp100 and hDaxx are still recruited to HSV-1 genomes (Everett et al., 2008), and therefore 
these proteins as well as PML are likely to play a role in viral restriction.  Depletion of 
Sp100 in HFs increased ICP0-null mutant gene expression by about five-fold, and 
simultaneous depletion of PML and Sp100 gave an 15-fold rise in PFE of an ICP0-null 
mutant in HFs (Everett et al., 2008).   
 
1.7.3.3 ATRX and hDaxx 
The Swi/SNF protein ATRX and the transcriptional repressor protein hDaxx, which that 
plays a role in chromatin remodelling, are constitutive components of ND10.  hDaxx is 
recruited to ND10 by a SUMO interaction motif located at its C-terminal domain binding 
to SUMO-modified PML (Ishov et al., 1999; Li et al., 2000), whereas ATRX localisation 
at ND10 is dependent on interaction with the PAH1 domain of hDaxx located near its N-
terminus (Ishov et al., 2004; Lukashchuk & Everett, 2010).  hDaxx functions as a 
transcriptional repressor by interactions with chromatin-related proteins, including HDACs 
(Hollenbach et al., 2002).  ATRX and hDaxx are recruited to viral genomes, but the 
recruitment of ATRX, as in the case of ND10 recruitment, requires hDaxx (Lukashchuk & 
Everett, 2010). 
 
Overexpression of hDaxx repressed HCMV IE gene expression, but this restriction was 
multiplicity-dependent (Cantrell & Bresnahan, 2006; Woodhall et al., 2006).  In cells 
depleted of hDaxx by siRNA, HCMV showed an increase in IE protein expression 
(Woodhall et al., 2006), and this was also seen in pp71-null HCMV mutant infected cells 
(Cantrell & Bresnahan, 2006; Preston & Nicholl, 2006).  Transcriptional activator pp71 of 
HCMV lifts the restriction mediated by ATRX by interacting with hDaxx, leading to the 
displacement of ATRX from the complex and its relocation from ND10 to the 
nucleoplasm.  Cells depleted of ATRX showed an increase in IE gene expression and viral 
replication of an pp71-null HCMV mutant (Lukashchuk et al., 2008).  In cells depleted of 
hDaxx or ATRX, an ICP0-null mutant virus has been shown to have an increase in PFE 
and gene expression, but no effect was observed with the wt virus (Lukashchuk & Everett, 
2010).   
 
Depletion of PML, Sp100 and hDaxx simultaneously increased the PFE of an ICP0-null 
mutant virus by around 50-fold, which was greater than the increase achieved by the 
addition of individual protein depletions (Glass & Everett, 2013).  However, depletion of 
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these ND10 factors did not restore the phenotype of ICP0-null mutant virus to wt, and 
therefore other restriction factors must play a role in the intrinsic immunity against HSV-1 
infection that are antagonised by ICP0 (Glass & Everett, 2013).     
 
1.8 E3 ligase activity of ICP0 and its interactions with the 
ubiquitin pathway 
The RING finger domain of ICP0 functions as an E3 ubiquitin ligase, inducing the 
formation of polyubiquitin chains and the subsequent proteasome-dependent degradation 
of a range of cellular proteins (see section 1.8.5) (Boutell et al., 2002).  Ubiquitin, a small, 
highly conserved 76 amino acid protein is attached to protein substrates by an enzymatic 
cascade involving an E1 ubiquitin activating enzyme, an E2 ubiquitin-conjugating enzyme 
and one of many substrate specific E3 ubiquitin ligase enzymes, in a process known as 
ubiquitination.  Ubiquitination of proteins controls a variety of cellular processes, 
including the DNA damage response, apoptosis, cell cycle progression and differentiation, 
and is involved in protein degradation, signal transduction and cellular localisation  
(reviewed in Deshaies & Joazeiro, 2009).   
 
1.8.1 Overview of the ubiquitin pathway 
The ubiquitin pathway consists of the sequential activities of an E1 activating enzyme, an 
E2 ubiquitin-conjugating enzyme and an E3 ubiquitin ligase, and is summarised in Figure 
1.6.  The E1 enzyme activates ubiquitin, using ATP to adenylate the C-terminal carboxyl 
group of ubiquitin.  The E1 enzyme binds to adenylated ubiquitin through its cysteine 
active-site, forming a covalent thioester bond between the E1 enzyme and ubiquitin.  The 
ubiquitin is then transferred from the E1 enzyme to the cysteine active-site of an E2 
ubiquitin-conjugating enzyme. The C-terminus of ubiquitin is then conjugated to the ε-
amino group of a lysine in the substrate protein through a covalent isopeptide bond, using 
an E3 ubiquitin ligase, which provides the substrate specificity.  Subsequently, further 
ubiquitin molecules can be conjugated to the first via an analogous process that involves 
lysine residues within ubiquitin. Multiple rounds of ubiquitination lead to the formation of 
a polyubiquitin chain, which can regulate cellular processes such as DNA repair, 
proteasome mediated degradation, cell cycle regulation and inflammation (reviewed in 
Deshaies & Joazeiro, 2009).     
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Figure 1.6 Overview of the ubiquitin pathway.   
Ubiquitination of a given substrate requires an E1 ubiquitin activating enzyme, an E2 
ubiquitin-conjugating enzyme and one of many substrate-specific E3 ubiquitin ligases.  
The E1 enzyme activates ubiquitin (ub), and the adenylated ubiquitin forms a covalent 
thioester bond with the cysteine active-site residue of the E1 enzyme.  Ubiquitin is 
transferred to the active site of the E2 ubiquitin-conjugating enzyme.  The E3 ubiquitin 
ligase binds to the E2-ubiquitin and the substrate protein to mediate the transfer of 
ubiquitin onto the target protein.  These steps can occur multiple times to create a 
polypeptide chain that acts as a proteosomal degradation marker if the chain contains at 
least four ubiquitin molecules linked via K48 residues.  The ubiquitin molecules are 
removed by the action of deubiquitinating enzymes (DUBs), so the ubiquitin can be used 
in subsequent ubiquitination reactions (adapted from Deshaies & Joazeiro, 2009).   
 
 
 
1.8.2 Components of the ubiquitin pathway and processes 
The main components of the ubiquitin pathway are E1 ubiquitin activating enzymes, E2 
ubiquitin-conjugating enzymes and the E3 ubiquitin ligases.  There are two known E1 
ubiquitin activating enzymes in humans, UBA1 and UBA6, that activate and form thioester 
bonds with ubiquitin (Jin et al., 2007; Pelzer et al., 2007).  There are at least 32 E2 
ubiquitin-conjugating enzymes in humans, which all contain a highly conserved ubiquitin 
conjugating domain of about 150 residues composed of the catalytic cysteine residue, anti-
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parallel beta-sheet and four alpha-helices (Huang et al., 1999; VanDemark et al., 2001; 
Zheng et al., 2000).     
 
The E3 ubiquitin ligases, of which there are hundreds, are the determinants of substrate 
specificity.  E3 ligases can be classed into two main groups, those that contain a RING 
domain and those that contain a HECT domain.  The RING finger E3 ubiquitin ligases, of 
which ICP0 is one, bind to the E2 enzyme-ubiquitin and the target protein simultaneously 
(sometimes with the aid of adaptor proteins).  This simultaneous binding enables close 
proximity between the substrate and ubiquitin, allowing the direct transfer of ubiquitin 
from the E2 enzyme to the substrate protein.  With HECT E3 ligases, the transfer of 
ubiquitin from the E2 ubiquitin conjugating enzyme to the substrate is a two-step process.  
The ubiquitin is first transferred from the E2 enzyme to an active site cysteine within the 
HECT domain, and the ubiquitin is then transferred to the substrate protein (reviewed in 
Kerscher et al., 2006).     
 
Ubiquitinated proteins containing a chain of at least four ubiquitin molecules linked by 
Lys48 residues are targeted for degradation via the 26S proteasome (Thrower et al., 2000).  
The proteasome is composed of two 19S regulatory subunits and a 20S catalytic core 
subunit.  Ubiquitinated substrates bind to ubiquitin receptors located on the 19S complex, 
and the substrate is then unfolded, translocated to the catalytic core, and degraded into 
small peptide fragments in a process that is dependent upon ATP (reviewed in Finley, 
2009).  The ubiquitin molecules do not get degraded and are removed by the action of 
deubiquitinating enzymes (DUBs), so the ubiquitin is recycled and can be used in 
subsequent ubiquitination reactions.       
 
1.8.3 Chain linkage 
The addition of one ubiquitin protein to a substrate protein is termed monoubiquitination.  
This mainly functions for signalling and transcriptional regulatory control, and does not 
function as a degradation signal.  Ubiquitin contains seven lysine residues; Lys6, Lys11, 
Lys27, Lys29, Lys33, Lys48 and Lys63.  These lysine residues can act as acceptor sites for 
further rounds of ubiquitin addition, leading to the formation of a chain of ubiquitin 
molecules on the substrate protein, termed polyubiquitination.  The linkage between 
ubiquitin molecules can determine their signal and function.  Polyubiquitin chains linked 
through Lys48 residues act to target substrates for degradation via the 26S proteasome 
(Chau et al., 1989; Finley et al., 1994; Thrower et al., 2000), whereas Lys63 polyubiquitin 
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chains are involved in the DNA damage response (Hoege et al., 2002; Hofmann & Pickart, 
1999; Spence et al., 1995) and NF-κB signalling (Deng et al., 2000).  Lys11-linked 
polyubiquitin chains may also play a role in proteasomal degradation of proteins involved 
in cell cycle control (Jin et al., 2008; Matsumoto et al., 2010).  The functions of the other 
chain linkages remains poorly characterised and understood.  Polyubiquitin chains can also 
contain mixed lysine linkages to form branched chains, although the functions of these are 
not clear. 
 
1.8.4 ICP0 and its interactions with components of the ubiquitin 
pathway 
The RING finger domain of ICP0 has been shown to interact with the highly homologous 
E2 ubiquitin-conjugating enzymes UBE2D1 and UBE2E1, and can catalyse the formation 
of unanchored polyubiquitin chains in vitro (Boutell et al., 2002; Vanni et al., 2012).  The 
alpha-helix and loop regions of the RING finger domain of ICP0 are important for the 
interaction with UBE2D1 (Vanni et al., 2012).  ICP0 has also been shown to interact with 
UBE2R1 (cdc34) via its RING finger domain (Van Sant et al., 2001).  However, this 
interaction was not verified in a yeast-two-hybrid study that detected an interaction with 
UBE2D1 and UBE2E1 (Vanni et al., 2012), and ICP0 does not produce polyubiquitin 
chains in the presence of UBE2R1 in vitro (Boutell et al., 2002).   
 
ICP0 undergoes auto-ubiquitination in vitro in the presence of UBE2D1 and UBE2E1, 
therefore targeting itself for degradation (Boutell et al., 2002; Canning et al., 2004; Vanni 
et al., 2012).  To prevent its own degradation, ICP0 interacts with a deubiquitylating 
enzyme (USP7) through a motif located in the C-terminal third of ICP0 (Everett et al., 
1997; Meredith et al., 1995; Meredith et al., 1994).  This interaction with USP7 increases 
the stability of ICP0 by the removal of ubiquitin molecules from ICP0, thereby preventing 
its degradation (Boutell et al., 2005; Canning et al., 2004).  Mutations of residues within 
the USP7-binding motif of ICP0 caused the protein to be highly unstable during viral 
infection and resulted in significantly reduced viral replication and ability to stimulate gene 
expression (Everett et al., 1999b; Everett et al., 1997).  It is likely that the cellular function 
of USP7 is to prevent degradation of cellular proteins that are still required by the cell.  
However, USP7 binding contributes to the ability of ICP0 to transactivate gene expression 
and stimulate viral lytic infection (Canning et al., 2004).  ICP0 also induces the 
ubiquitination and degradation of USP7, which is surprising given that the interaction with 
USP7 stabilises ICP0.  The significance of these two opposing functions is not fully 
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understood, but it is thought that the stabilisation of ICP0 by USP7 is more relevant in 
vivo, especially when there are low levels of ICP0 (Boutell et al., 2005).    
 
It has been shown that E3 ubiquitin ligases have the ability to interact with other E3 ligases 
(Weissman et al., 2011).  This is also the case for ICP0, which interacts with cellular RING 
finger E3 ubiquitin ligases RNF8 (see section 1.6.5.2) and SIAH-1 (Chaurushiya et al., 
2012; Lilley et al., 2010; Nagel et al., 2011).  SIAH-1 is involved in the cellular stress 
response, cell signalling pathways and the degradation of a number of substrates (reviewed 
in Qi et al., 2013), including PML (Fanelli et al., 2004).  Most substrates of SIAH-1 
contain a PXAXVXP motif for interaction with a conserved substrate-binding domain 
within SIAH-1 (House et al., 2003).  ICP0 contains the PXAXVXP interaction motif at 
residues 401-407, and was shown to interact with SIAH-1 and be targeted for proteasomal 
degradation (Nagel et al., 2011).  Overexpression of ICP0 resulted in the stabilisation of 
SIAH-1, whereas silencing of SIAH-1 increased ICP0 stability during infection (Nagel et 
al., 2011).  Therefore, it is possible that SIAH-1 and ICP0 act together to regulate their 
functions. 
 
1.8.5 Cellular proteins targeted for proteasome-mediated 
degradation by ICP0 in a RING finger-dependent manner 
The RING finger domain of ICP0 possesses E3 ubiquitin ligase activity and induces the 
proteasome-mediated degradation of a range of cellular proteins.  A screen for SUMO-
conjugated proteins that were destabilised during HSV-1 infection identified over 100 
proteins that showed a three-fold or greater decrease in levels of their sumoylated species, 
some of which have later been identified as potential substrates of ICP0 (E. Sloan 
unpublished data). 
 
The catalytic subunit of DNA-PK, RNF8 (section 1.6.5.2), and USP7 (section 1.8.4), are 
substrates of ICP0 that are degraded in a RING finger and proteasome-dependent manner 
(Boutell et al., 2005; Canning et al., 2004; Chaurushiya et al., 2012; Lilley et al., 2010; 
Parkinson et al., 1999).  Substrates of ICP0 also include high molecular weight SUMO-1 
and SUMO-2/3 conjugated proteins (Boutell et al., 2011; Everett et al., 1998a), and 
SUMO-modified isoforms of PML and Sp100 (Chelbi-Alix & de The, 1999; Everett et al., 
1998a; Muller & Dejean, 1999).  The ability of ICP0 to degrade proteins conjugated to 
SUMO is influenced by its SUMO interaction motif-like sequences (SLS), especially SLS4 
(Boutell et al., 2011; Everett et al., 2014). The E2 ubiquitin conjugating enzyme UBE2D1 
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and its association with ICP0 have also been shown to be important for the degradation of 
PML and Sp100 (Gu & Roizman, 2003).  ICP0 also degrades PML.I, which is not 
modified by SUMO in a SUMO-independent manner, and this occurs more rapidly than 
the degradation of the majority of proteins conjugated to SUMO (Boutell et al., 2011; 
Cuchet-Lourenço et al., 2012).  The N-terminal third of ICP0 and the C-terminal region of 
PML.I are important for the interaction between ICP0 and PML.I (Cuchet-Lourenço et al., 
2012).   
 
At early stages of infection, ICP0 associates with centromeres of condensed chromosomes 
in cells in mitosis and also during interphase, which is dependent on the RING finger 
domain of ICP0 (Everett et al., 1999a).  ICP0 induces the proteasome-dependent 
degradation of the centromeric proteins A (CENP-A), CENP-B, CENP-C, CENP-H, 
CENP-I and CENP-N, which are involved in centromere assembly.  The degradation of 
these proteins results in the stalling or arrest of mitosis and defects in chromosomal 
alignment with condensed chromosomes in a prometaphase alignment (Everett et al., 
1999a; Gross et al., 2012; Lomonte & Everett, 1999; Lomonte & Morency, 2007; Lomonte 
et al., 2001). 
 
The transcription factor E2FBP1 is also a substrate of ICP0.  During HSV-1 infection, high 
expression levels of E2FBP1 caused a decrease in ICP0 transcripts.  Therefore, ICP0 may 
induce the ubiquitination of E2FBP1 to lift the restrictive effect of this protein on viral 
transcription and promote replication (Fukuyo et al., 2011).  Another substrate of ICP0 is 
IκBα.  IκBα binds to the NF-κB transcription factor in the cytoplasm, preventing its 
translocation into the nucleus until the pathway is activated, and IκBα is ubiquitinated and 
degraded.  ICP0 interacts with IκBα and induces its ubiquitination, causing the activation 
of NF-κB leading to relocation to the nucleus and the transcription of its target genes.  The 
significance of ICP0 targeting IκBα for degradation is unknown (Diao et al., 2005).  
 
1.9 Aims and objectives of this study 
ICP0 is a multifunctional protein that is involved in interactions with a number of diverse 
cellular pathways, and plays a role in regulating the balance between lytic and latent 
infections.  The N-terminal third of ICP0 contains a RING finger domain, which acts as an 
E3 ubiquitin ligase targeting cellular proteins for degradation, including PML and Sp100, 
which are involved in intrinsic immunity.  
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This study was separated into two distinct parts.  Part I investigated the RING finger alpha-
helix of ICP0, and part II investigated regions of ICP0 that have high similarity to related 
proteins of other alphaherpesviruses or contained motifs that were believed to interact with 
cellular proteins but whose functions had not, in most cases, been investigated in detail.    
 
1.9.1 Investigations of the RING finger alpha-helix of ICP0 
This section of the study was stimulated by an observation in Vanni et al. (2012) that a 
mutation in the alpha-helix region of the RING finger of ICP0 (N151D) had differential 
effects on complementation of an ICP0 null mutant virus and reactivation of quiescent 
HSV-1 in experiments using an inducible ICP0 expression system.  This raised the 
possibility that complementation and reactivation involve differential activities of ICP0.   
 
Therefore, one of the aims of this section of the study was to investigate in greater detail 
the N151D mutation.  The nearby mutation K144E was also included in the study, as it is 
located in the alpha-helix along with N151, and has previously been analysed in limited 
transfection and virus-based assays and had phenotypes similar to the N151D mutation.  
These alpha-helix mutants were initially characterised using the inducible ICP0 expression 
system to further investigate the findings of Vanni et al. (2012).  The mutations were then 
analysed in the context of viral infection to investigate if these mutations differentially 
affect the stimulation of lytic infection and reactivation from quiescence.   
 
Vanni et al. (2012) additionally showed that the alpha-helix of the RING finger region of 
ICP0 is involved in interactions with E2 ubiquitin-conjugating enzyme UBE2D1, and that 
ICP0 has the potential to interact with different E2 enzymes.  As the N151 and K144 
residues are located in the charged side chains that are exposed on the surface of the alpha-
helix, they may play a role in the interactions of ICP0 with cellular components, including 
E2 ubiquitin-conjugating enzymes.  Therefore, these mutants were also analysed for their 
ability to interact with components of the ubiquitin pathway, particularly focusing on 
interactions with E2 ubiquitin-conjugating enzymes, to investigate if interactions with E2 
ubiquitin-conjugating enzymes affect the stimulation of lytic infection and reactivation 
from quiescence.   
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1.9.2 Regions of ICP0 that have high sequence similarity between 
alphaherpesviruses or contained motifs that were believed 
to interact with cellular proteins 
The second part of this study investigated regions throughout ICP0 that contain sequences 
with similarity to other alphaherpesviruses (other than the RING finger).  Furthermore, 
sequences or motifs within ICP0 that are related to those present within other viral 
proteins, and which are thought to interact with cellular proteins and have not previously 
been studied in detail, were also characterised. 
 
1.9.2.1 High sequence similarity downstream of the RING finger domain 
Areas of high sequence similarity between alphaherpesvirus proteins have been shown to 
have conserved functions.  One of the highest regions of similarity within the ICP0 family 
of proteins is the RING finger domain, which acts as an E3 ligase (Boutell et al., 2002), 
and deletion of this region causes a defect as severe as deletion of the whole ICP0 gene 
(Everett, 1989; Everett et al., 2004a; Lium & Silverstein, 1997).  When examining other 
regions of high sequence conservation between alphaherpesvirueses HSV-1, HSV-2 and 
herpesvirus B of macaque monkeys (HVB), the C-terminal third shows sections of high 
sequence similarity. This region contains the USP7 binding motif, SLS 5/6/7, the ND10 
localisation domain and the nuclear localisation sequence (Everett et al., 2014).   
 
A region that additionally shows high sequence similarity is downstream of the RING 
finger domain.  The effect of deletion of the region immediately downstream of the RING 
finger domain (Δ162-188) has been investigated, and has been shown to render ICP0 E3 
ligase negative (Boutell et al., 2002).  Further downstream from this region there is an 
additional region (residues 193-224) that also shows high sequence similarity, but has not 
been studied in detailed (Figure 1.7).  Although this region (Δ197-222) is not required for 
E3 ligase activity in vitro, its deletion causes ICP0 to be defective in the ability to form 
intracellular conjugated ubiquitin chains (Everett, 2000).  Therefore, this region may affect 
either the E3 ligase function of ICP0 or its ability to interact with E2 ubiquitin-conjugating 
enzymes.     
 
This region located downstream of the RING finger and E3 ligase negative region was 
investigated by constructing viruses containing deletions within the area of sequence 
similarity from amino acids 188-224.  Two separate deletion mutants were constructed 
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from residues 197-211 and 211-222.  These deletions were studied in the context of viral 
infection to investigate if these sequences play a role in HSV-1 infection and whether they 
affect the E3 ligase ability of ICP0.   
 
 
 
 
Figure 1.7 The region downstream of the RING finger domain shows high sequence 
similarity in HSV-1, HSV-2 and herpesvirus B (HVB).  
The asterisks denote completely conserved residues from the three alphaherpesviruses.  
Labelled are the deletion mutants ICP0Δ197-211 and ICP0Δ211-222 that were analysed in 
this study. 
 
 
 
1.9.2.2 Sequences within ICP0 that are reported to interact with cellular 
proteins, including E3 ubiquitin ligases  
Region of ICP0 that has been implicated in binding to CoREST 
A region within the C-terminal third of ICP0 contains a sequence of amino acids (537-613 
aa) that show some sequence homology to the N-terminal part of the cellular protein 
CoREST (Gu et al., 2005).  Outside of this region, two residues of ICP0 (aa 671 and 673), 
have been reported to be required for the binding of ICP0 to CoREST (Gu & Roizman, 
2009), and that this binding leads to the displacement of HDAC1 from the 
REST/CoREST/HDAC transcriptional repressor complex (Gu et al., 2005).  In cells 
infected with virus containing mutations in the CoREST-binding region (R8507-
D671A/E673A), PML was not fully degraded and viral replication was delayed (Gu & 
Roizman, 2009).  It has been suggested that the REST/CoREST/HDAC complex may 
repress viral gene expression in the absence of ICP0, and therefore may have a role in the 
reactivation/derepression of viral gene expression (Gu & Roizman, 2009).  The role of 
these residues on derepression of viral gene expression from quiescent genomes was 
investigated using the ICP0 inducible cell line system.    
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1.9.2.3 A residue that has been shown to be required for binding to RNF8 
Residue T67 of ICP0 is involved in interacting with and inducing the degradation of 
cellular E3 ubiquitin ligase RNF8.  RNF8 is involved in the DNA damage response, 
leading to the loss of ubiquitinated forms of histones H2A and H2AX (Chaurushiya et al., 
2012; Lilley et al., 2010).  The T67 RNF8-binding residue within ICP0 was investigated to 
analyse whether ICP0 promotes transcription and prevents histone mediated transcriptional 
repression by inducing the degradation of RNF8.  As stimuli such as UV light can induce 
both the DNA damage response and HSV-1 reactivation, it is possible that these two 
pathways are linked through the T67 residue.  The effect of this residue on the ability of 
ICP0 to reactivate quiescent HSV-1 to initiate gene expression was also investigated.    
 
1.9.2.4 The PPEYPTAP motif  
The sequence PPEYPTAP is present within ICP0 at residues 717-724.  The sequence is 
highly related to PTAP and PPXY motifs present in other viral proteins, including 
retroviral Gag proteins that have been shown to be involved in interactions with cellular E3 
ubiquitin ligases, including HECT and Nedd4.  These motifs play a role in retroviral 
budding (reviewed in Bieniasz, 2006; Freed, 2002).  This PPEYPTAP motif was 
investigated within ICP0, to analyse if it played a role during HSV-1 infection.   
 
1.9.2.5 SIAH-1 binding motif 
ICP0 contains the cellular E3 ubiquitin ligase SIAH-1 interaction motif PXAXVXP at 
residues 401-407, and was shown to interact with SIAH-1 and be targeted for proteasomal 
degradation (Nagel et al., 2011).  The SIAH-1 interaction motif within ICP0 was mutated 
and studied within the context of the inducible cell line system and virus infection. 
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2 Materials and Methods 
2.1 Bacterial and nucleic acid techniques 
2.1.1 Solutions and buffers 
STET  8% sucrose (Sigma-Aldrich), 5% Triton-X 100 (Sigma-
Aldrich), 50 mM EDTA (VWR International Ltd), 50 mM 
Tris-HCl (VWR International Ltd) pH 8.0 
 
40x TAE buffer  96.8 g Tris (Roche), 8.2 g sodium acetate (Sigma-Aldrich), 
7.4 g EDTA, pH to 7.6 with glacial acetic acid (VWR 
International Ltd), dH2O added to 500 ml   
 
1x TE 1 mM EDTA, 10 mM Tris-HCl pH 8.0 
 
2.1.2 Transformation 
Transformation of bacteria with plasmid DNA was carried out using 50 µl aliquots of 
competent Escherichia coli DH5α cells (Invitrogen).  Transformation after ligation used 5 
µl of the precipitated ligation mixture (section 2.1.7), and re-transformation of a plasmid 
was carried out using 100 ng DNA.  The DNA was added to the competent cells and mixed 
gently, after which the cells were incubated on ice for 30 minutes.  The cells were heat-
shocked for 40 seconds at 42 °C and incubated on ice for 2 minutes to recover, after which 
300 µl pre-warmed Luria-Bertani medium (LB broth) (E&O Laboratories Ltd) was added 
to the cells, which were then placed at 37 °C for 30 minutes with constant agitation.  The 
cells were plated onto agar (E&O laboratories Ltd) plates with the appropriate antibiotic 
selection, usually ampicillin (Amp) (Melford laboratories Ltd), and incubated at 37 °C 
overnight for colonies to grow.  Amp was added to liquid media and molten agar (once 
cooled to 50 °C) at a concentration of 100 µg/ml, but this was increased to 150 µg/ml for 
lentiviral vector plasmids in order to prevent satellite colonies.                    
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2.1.3 Plasmid DNA extractions  
2.1.3.1 Small scale (miniprep) plasmid DNA extraction 
A single colony selected from freshly transformed bacteria on an agar plate was grown 
overnight at 37 °C in 5 ml LB broth with horizontal agitation.  The following day, 1.3 ml 
of the culture was transferred to an Eppendorf tube and centrifuged at 13000 rpm for 20 
seconds in a bench top centrifuge (MSE Micro Centaur).  The bacterial pellet was 
resuspended in 200 µl STET buffer, and the bacteria were lysed by adding 5 µl 10 mg/ml 
lysozyme (Sigma-Aldrich) and boiled in a boiling water bath for 50 seconds.  To remove 
the cellular debris, the lysed bacterial cells were centrifuged at 13000 rpm for 30 minutes, 
and 180 µl of supernatant was transferred to a fresh Eppendorf tube.  The supernatant was 
vortexed with 165 µl isopropanol (VWR International Ltd) and centrifuged at 13000 rpm 
for 2 minutes to pellet the DNA.  The supernatant was discarded, and 200 µl 80% EtOH 
(Fisher Scientific UK Ltd) was added to wash the pellet and was removed after a short 
13000 rpm spin.  The pellet containing the DNA was air dried at room temperature and 
resuspended in 30 µl dH2O.    
 
2.1.3.2 Large scale (midiprep) plasmid DNA extraction    
A single colony was selected from freshly transformed bacteria on an agar plate, which 
was grown for 8 hours in 10 ml LB broth with the appropriate antibiotic selection at 37 °C 
with horizontal agitation.  The culture was transferred into 350 ml LB broth with antibiotic 
selection and grown overnight at 37 °C with horizontal agitation.  The following day the 
DNA was extracted using the NucleoBond® Xtra Midi kit (Macherey-Nagel), following 
the NucleoBond Xtra plasmid purification, high-copy plasmid purification (midi) protocol 
as described by the manufacturer.   
 
2.1.4 Restriction endonuclease digestions 
All restriction endonucleases and associated buffers were sourced from New England 
Biolabs.  Standard restriction digest reactions were carried out in a total volume of 20 µl.  
The reaction consisted of 2 µl of the appropriate 10x buffer supplied with the enzymes, 
plasmid DNA (10 µg for fragment preparations, 0.5 µg for analytical digestions) and 10 
units (1 µl) of restriction enzymes and dH2O to make up the final volume to 20 µl.  
Reactions were incubated at 37 °C for 2 hours.  Digestions were analysed by agarose gel 
electrophoresis and, when necessary, fragments were purified as described in section 2.1.6.   
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2.1.5 Annealing and cloning of complementary oligonucleotides 
Oligonucleotides were dissolved in the recommended volume of dH2O to give 
concentrations of 100 µM.  A reaction mix containing 50 µl of each oligonucleotide, 2 µl 
50x TE and 1 µl 5 M NaCl (10 mM Tris-HCl pH 8.0, 50 mM NaCl) was prepared.  
Reactions were incubated in a PCR thermal cycler (Techne Endurance TC-312) with the 
following temperature change conditions: 
 
Heated lid   105 °C 
Initial denaturation step 95 °C     2 minutes 
Oligonucleotide annealing 72 °C      2 minutes 30 seconds 
    65 °C      2 minutes 30 seconds  
    60 °C      2 minutes 30 seconds    
    Sequential 5 °C decreases,      each   2 minutes 30 seconds  
    15 °C      2 minutes 30 seconds  
Hold    4 °C      ∞ 
 
 
The annealed oligonucleotide mix was diluted 1 in 100, and 5 µl of this diluted annealed 
mix was used per ligation (section 2.1.7). 
 
2.1.6 Gel electrophoresis 
1.5% agarose (Sigma-Aldrich) gels prepared in 1x TAE buffer were used for DNA 
restriction digest analysis and DNA fragment purification on the basis of fragment size.  
The gels were run in 1x TAE buffer at 100 volts, with samples mixed with 5 µl of 6x 
loading dye (Thermo Scientific) and run alongside 1 kb and 100 bp marker ladders 
(Thermo Scientific) of known fragment sizes.  The gels were stained with 1 µg/ml 
ethidium bromide (Sigma-Aldrich) in 1x TAE buffer for 15 minutes with constant 
agitation, and washed in dH2O, and the DNA bands were visualised on a UV 
transilluminator (long wave for fragment isolations, short wave for analytical gels).  DNA 
fragments requiring purification were excised from the agarose gel using a scalpel and 
purified using the Biomega-Dundee Cell Products Gel Purification kit, according to the 
manufacturer’s instructions.  The purified fragments were eluted from the purification 
columns in 30 µl of the elution buffer provided. 
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2.1.7 Ligation of DNA fragments 
Ligation of DNA fragments extracted and purified from agarose gels or from PCR was 
carried out using 5 µl of each purified DNA fragment, 2.5 µl 10x T4 DNA ligase buffer 
(New England Biolabs) and 1 µl T4 DNA ligase (New England Biolabs) in a total reaction 
volume of 20 µl.  Reactions were incubated at room temperature overnight.  The ligated 
DNA was precipitated by the addition of 10 µl 3 M sodium acetate (Merck Millipore), 65 
µl of 1x TE, 1-2 µl pellet paint (Merck Millipore) to allow visualisation of the pellet, and 
250 µl 100% EtOH. After incubation at -20 °C for 10 minutes, the sample was centrifuged 
at 13000 rpm (MSE Micro Centaur) for 5 minutes to pellet the DNA. The supernatant was 
removed and the visible pellet was washed in 80% EtOH and resuspended in 20 µl dH2O.  
The DNA was then transformed into DH5α cells using 5 µl of precipitated DNA (Section 
2.1.2).            
 
2.1.8 DNA sequencing 
The overall structure of newly constructed plasmids was confirmed by the appropriate 
restriction enzyme digestions prior to DNA sequencing.  Selected plasmid DNA prepared 
on a small scale (Section 2.1.3) were purified by removing RNA by digestion with 1 µg/µl 
RNase A for 30 minutes at 37°C, and then purifying the DNA using the Biomega- Dundee 
Cell Products Gel Purification kit, as outlined above (Section 2.1.6).  The sequencing 
reactions containing 500 ng DNA in 30 µl dH2O and 2 µl primer at 3.2 µM were submitted 
to the DNA sequencing service at the University of Dundee.  Sequencing data was 
analysed using VectorNTI (Life Technologies) software.    
 
2.2 Specific cloning strategies used in this study 
2.2.1 Plasmids 
The plasmids used in the study are described in Table 2.1, with their main characteristics 
described.  The cloning strategies for the construction of all other plasmids containing 
mutations generated throughout this study are described in section 2.2.3.  All plasmids 
used throughout this study were Amp resistant unless otherwise stated.   
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Table 2.1 Plasmids provided for use in this study 
 
 
 
 
2.2.2 Oligonucleotides 
All oligonucleotides used in this study were synthesised by Sigma-Aldrich.  The 
oligonucleotides were dissolved in dH2O to a final concentration of 100 µM by adding the 
volume specified by the manufacturer.  The sequences of the oligonucleotides and their 
purpose of use are described in Table 2.2 below.  The positions of the oligonucleotides 
within the ICP0 cDNA sequence are illustrated in Figure 2.1.     
 
 
 
 
 
Plasmid Characteristics  Source 
pUCDT.cICP0 The ICP0 cDNA coding region linked to a 
truncated HCMV promoter/enhancer under 
tetracycline inducible control in pUC9 
R.D. Everett, 
unpublished. 
pLKO.DCMV.TetO.
cICP0  
(pLDT.cICP0) 
Expresses ICP0 from a tetracycline inducible 
promoter in a lentiviral vector plasmid 
Everett et al., 
2009 
p110 Expresses ICP0 under the control of the 
genomic IE1 transcription unit 
Perry et al., 1986 
p111 Same as p110 but elimination of the EcoRI site 
in the pUC9 multi-cloning sequence. 
Everett, 1987 
p110 JA1 (K144E) Contains the ICP0 K144E mutation   
Barlow et al., 
1994 
p110 JD (N151D) Contains the ICP0 N151D mutation  
p110 JE (KE/ND) Contains the ICP0 K144E/N151D double 
mutation 
T67A Contains the ICP0 T67A mutation  Chaurushiya et 
al., 2012 
p110-E32-1 12-mer EcoRI linker 5'-CCCGAATTCGGG-3' 
inserted in codon 222 of ICP0 in plasmid p111 
 
 
Everett, 1987 p110 R3 12-mer EcoRI linker 5'-CCCGAATTCGGG-3' 
inserted in codon 212 of ICP0 in plasmid p111 
p110 E13 12-mer EcoRI linker 5'-CCCGAATTCGGG-3' 
inserted in codon 197 of ICP0 in plasmid p111 
p110 D13/32 In-frame deletion of codons 197-222 of ICP0 in 
plasmid p111 
Everett, 1988 
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Table 2.2 Oligonucleotides used in this study 
 
 
 
 
 
 
 
 
Name Sequence 5’-3’ Purpose of use 
PTAP1 F GTAACCACGTGATGGCCGCCGAGTACG
CGACGGCCGCCGCGTCGGAGTGGAACA 
 
 
 
 
 
 
 
Mutation of the 
PPEYPTAP motif of 
ICP0 to AAEYATAA 
PTAP2 F GCCTCTGGATGACCCCCGTGGGGAACAT
GCTGTTCGACCAGGGCACCCTAGTGGGC
GCC 
PTAP3 F CTGGACTTCCGCAGCCTGCGGTCTCGGC
ACCCGTGGTCCGGGGAGCAGGGGGCG 
PTAP4 R GTGCACTACCGGCGGCTCATGCGCTGCC
GGCGGCGCAGCCTCACCTTGTCGGAGA
CCTACTG 
PTAP2 R GGGGCACCCCTTGTACGACGGGCTGGTC
CCGTGGGATCACCCGCGGGACCTGAAG
GCGTCG 
PTAP3 R GACGCCAGAGCCGTGGGCACCAGGCCC
CTCGTCCCCCGCAGCT 
R8507  F CTGCCCATCCTGGCCATGGCCACGGGGA
ACATC 
Mutation of the 
LPILDMETGNI motif 
of ICP0 to 
LPILAMATGNI 
R8507 R GATGTTCCCCGTGGCCATGGCCAGGATG
GGCAG 
SIAH F CGTGCAGCAGGTGCCGGATGCGTACGA
GCGCCGCCTCCG 
Mutation of the SIAH1 
binding motif of ICP0 
RPRAAVAPCVR to 
RPRAAGAGCVR 
SIAH R TCCGGCACCTGCTGCACGTGGGCGCGCG
GGTCCCGA 
110seq2 R CTTGTTCACGTAAGGCGACAG Used as PCR and 
sequencing primers in 
SIAH mutagenesis 
ICP0-24 F GCCCCCCTTGCAAACAACAG 
ICP0-4 R GACACGGATTGGCTGGTGTA Used as PCR and 
sequencing primers in 
PTAP and R8507 
mutagenesis 
ICP0-15 F GTCGGGCCAGGAAAACCCCT 
ICP0-17 F CGTGTGCACGGATGAGATCG Sequencing of viral 
DNA ICP0-18 R CTGCTGCAAGAGACAACGGG 
X110 F CTCGAGAGGACGGGGGGA Sequencing of the 
RING finger region of 
ICP0 
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Figure 2.1 The position of the mutations, restriction sites and primer binding 
locations used in this study relative to the ICP0 cDNA. 
The locations of the mutations within ICP0 investigated in this study are illustrated.  The 
primer binding positions and restriction sites used in the cloning strategies and construction 
of these mutants described within this section are also annotated.     
 
 
2.2.3 Construction of lentiviral vector plasmids expressing ICP0 
mutants  
The overall cloning strategy was to transfer fragments containing existing plasmid 
mutations to, or create novel mutations within, the simple vector plasmid pUCDT.cICP0 
prior to transfer of the required complete ICP0 cDNA sequence into the plasmid 
pLKO.DCMV.TetO.cICP0 (Figure 2.2) (Everett et al., 2009).  Lentiviral vector plasmid 
pLKO.DCMV.TetO.cICP0 expresses ICP0 from a tetracycline-inducible promoter and was 
used for the production of lentiviruses to generate inducible cell lines that expressed wt or 
mutant ICP0.  The production of the mutants used in this study and the strategies used to 
sub-clone the mutants into the pUCDT.cICP0 and then into the pLKO.DCMV.TetO.cICP0 
vector plasmid are detailed below.  All intermediates in the pUCDT.cICP0 plasmid 
backbone and pLKO.DCMV.TetO.cICP0 derivate plasmids were confirmed by DNA 
sequencing (University of Dundee).   
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Figure 2.2 Map of the pLKO.DCMV.TetO.cICP0 (pLDT.cICP0) plasmid vector.   
The lentivirus vector contains an HCMV promoter/enhancer (DCMVp) with a tetracycline- 
dependent operator (TetO) located downstream.  This system is tetracycline-inducible to 
induce the expression of ICP0.  The vector encodes puromycin resistance (Puro r), which 
was used for selection of cell lines.  This ICP0 inducible cell line system induces ICP0 
expression in the majority of induced cells to levels that are comparable to the very early 
stages of HSV-1 infection.  This system is advantageous as long term ICP0 expression is 
detrimental for long-term cell survival (Everett et al., 2009). 
 
 
 
 
 
2.2.3.1 ICP0 RING finger mutants N151D and K144E 
Plasmids p110-JA1, p110-JD and p110-JE containing the K144E, N151D and 
K144E/N151D (KE/ND) mutations respectively were digested with XhoI and KpnI and the 
320 bp fragment isolated.  The pUCDT.cICP0 plasmid was digested with KpnI and BstEII 
and the 1.5 kb fragment isolated, and pUCDT.cICP0 was also digested with XhoI and 
BstEII and the 4 kb fragment isolated.  The 320 bp fragment containing the alpha-helix 
mutations was ligated together with pUCT.cICP0 1.5 kb KpnI-BstEII fragment and 4 kb 
pUCDT.cICP0 XhoI-BstEII.    
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2.2.3.2 PCR-driven overlap extension for site-directed mutagenesis of the 
PPEYPTAP, R8507 and SIAH-1 interaction motif sequences 
Site-directed mutagenesis was carried out using PCR-driven overlap extension and 
splicing, in order to create the desired mutations R8507 and those within the PPEYPTAP 
and SIAH-1 interaction motifs.  This technique, described in Heckman & Pease, 2007 and 
summarised in Figure 2.3, uses mutagenic primers and flanking primers to amplify 
selected regions creating overlapping fragments of the sequence containing the mutations.  
These overlapping fragments act as the template for the amplification of the whole DNA 
fragment with the desired mutations using the flanking primers.  The DNA fragment was 
inserted into vector plasmids by restriction digestion using sites present in the flanking 
primers, or that exist within the whole amplified fragment.      
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Figure 2.3 PCR splicing strategy for site-directed mutagenesis.   
Flanking primers a and d amplify the sequence of interest, and mutagenic primers b and c 
contain the mutation of interest (denoted by +).  During the first rounds of PCR (PCR#1 
and #2), the flanking primers (a/d) and mutagenic primers (b/c) amplify selected regions, 
producing PCR fragments that overlap in the region containing the mutation(s).  The PCR 
products from PCR#1 (AB) and PCR#2 (CD) are annealed in PCR#3 in a reaction that 
contains no primers.  The amplification of the whole DNA fragment containing the 
mutation is carried out in PCR#4 in a reaction containing the flanking primers.  The DNA 
fragment can be inserted into vector plasmids by restriction digests (Heckman & Pease, 
2007). 
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For site-directed mutagenesis to generate the PPEYPTAP, R8507 and SIAH-1 interaction 
motif mutations, the initial PCR reaction consisted of 50 ng template DNA, 10x Pfu buffer, 
10 mM dNTPs, 10 µM forward primer, 10 µM reverse primer, 1 µl Pfu phusion enzyme 
and dH2O to 50 µl.  The PCR cycling conditions (Techne Endurance TC-312) are detailed 
below: 
 
PCR cycling conditions 
98 °C 30 seconds 
98 °C 30 seconds 
60 °C 30 seconds  x 35 cycles 
72 °C 30 seconds 
72 °C 5 minutes 
4 °C Hold 
 
The PCR products from the initial reactions were separated on a 1.5% agarose gel and the 
DNA products purified (section 2.1.6).  The two overlapping PCR fragments were 
annealed together by a second round of PCR performed using 2 µl of each of the PCR 
products, 10 x Pfu buffer, 10 mM dNTPs, 1 µl Pfu phusion enzyme and dH2O to 50 µl.  
The PCR cycling conditions were the same as above but carried out for 5 cycles and 
without primers to allow the fragments to anneal.  After 5 cycles, 10 µM of each of the 
outside flanking primers were added to the reaction and the PCR continued for another 30 
cycles.  The PCR product was run on an agarose gel and the DNA extracted and purified.  
The extracted PCR product was digested with the relevant restriction enzymes and could 
then be ligated into the pUCDT.cICP0 plasmid.     
 
Plasmid p111, which expresses wt ICP0, was used a template for site-directed mutagenesis 
by PCR splicing for construction of the PPEYPTAP and R8507 mutants.  The wt 
PPEYPTAP motif was mutated to AAEYATAA using mutagenic primers PTAP-4 and 
PTAP-1.  Substitution mutations in the R8507 sequence mutated the wt amino acid 
sequence from LPILDMETGNI to LPILAMATGNI using mutagenic primers R8507-F and 
R8507-R.  The flanking primers for both mutants PPEYPTAP and R8507 were ICP0-4 and 
ICP0-15, and the resulting PCR fragments were digested with MluI and SalI and ligated 
individually with the 4.8 kb MluI-SalI pUCDT.cICP0 fragment.      
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Plasmid pUCDT.cICP0 was used as a template for site-directed mutagenesis by PCR 
splicing using mutagenic primers SIAH1-F and SIAH1-R, and flanking primers 110seq2 
and ICP0-24 to change the wt SIAH-1 interaction motif sequence from RPRAAVAPCVR 
to RPRAAGAGCVR.  The PCR products were spliced together by a second round of PCR 
using flanking primers ICP0-24 and 110seq2.  The NotI-MluI PCR fragment was then 
ligated with the 4.5 kb NotI-SalI and 0.7 kb MluI-SalI fragments of pUCDT.cICP0.   
 
2.2.3.3 Transfer of ICP0 mutations from pUCT.cICP0 intermediate plasmids 
into the pLKO.DCMV.TetO.cICP0 lentiviral vector plasmids 
The pUCDT-based intermediate vectors were restriction digested with NdeI/SalI/ScaI and 
the 2.7 kb band containing the promoter, the tetracycline operator sequences and all but the 
last 7 codons of the ICP0 cDNA sequence was isolated (the other bands were 2.2 kb and 
0.7 kb).  Plasmid pLKO.DCMV.TetO.cICP0 was restriction digested with NdeI and SalI 
and the 7.1 kb vector band isolated (this includes the last 7 codons of the ICP0 cDNA 
sequence).  The 2.7 kb band from the pUCDT-intermediate and the 7.1 kb vector band 
from pLKO.DCMV.TetO.cICP0 were ligated together.  Once all the mutations were in the 
pLKO.DCMV.TetO.cICP0 plasmids, restriction digests were carried out to check the 
overall structures of the plasmids, and the desired mutations were confirmed by DNA 
sequencing. 
 
2.2.4 Construction of deletion mutants downstream of the RING 
finger (197-222) in the p110 backbone to enable construction 
of viral deletion mutants 
Plasmids containing deletions of regions downstream of the RING finger domain 
ICP0Δ197-211 and ICP0Δ211-222 were constructed using plasmids that are derivates of 
p111 backbone.  These plasmids were used for the construction of viruses containing these 
deletions (section 2.6).   
 
2.2.4.1 Deletion mutant ICP0Δ197-211  
Plasmid p110-E13 was digested with EcoRI and SalI and the 5.4 kb fragment isolated.  
Plasmid p110-R3 was also digested with EcoRI and SalI and the 1.8 kb fragment isolated.  
These 5.4 kb and 1.8 kb fragments were then ligated together to produce the ICP0Δ197-
211 plasmid, which contains a deletion of codons 197-211 of ICP0.   
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2.2.4.2 Deletion ICP0Δ211-222 
The 5.4 kb fragment isolated from the digestion of p110-R3 with EcoRI and SalI was 
ligated together with the 1.8 kb fragment isolated from the EcoRI and SalI digestion of 
p110-E32-1.  This produced the ICP0Δ211-222 plasmid, which contains a deletion of 
codons 211-222 of ICP0.   
 
2.3 Protein methods 
2.3.1 Antibodies 
Primary and secondary antibodies used throughout this study are listed in Tables 2.3 and 
2.4, respectively. The tables detail their dilutions used for Western blot (WB) and 
immunofluorescence (IF), and the suppliers.   
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Table 2.3 Primary antibodies used in this study 
 
Antibody Type Target Dilution 
in WB 
Dilution 
in IF 
Source 
AC-40 Mouse 
monoclonal 
Actin 1/10000 N/A Sigma-Aldrich 
Z378A Mouse 
monoclonal 
β-galactosidase N/A 1/500 Promega 
M2 Mouse 
monoclonal 
FLAG tag N/A 1/1000 Stratagene 
27-4577-
01 
Goat polyclonal GST 1/2000 N/A Amersham 
Pharmacia Biotech 
07-471 Rabbit 
polyclonal 
hDaxx N/A 1/200 Upstate 
11060 Mouse 
monoclonal 
ICP0 1/2000 1/1000 Everett et al., 1993b 
R190 Rabbit 
polyclonal 
ICP0 N/A 1/200 Everett et al., 1998b 
58S Mouse 
monoclonal 
ICP4 1/1000 1/500 Showalter et al., 
1981 
ABD-030 Rabbit 
polyclonal 
PML N/A 1/2000 Jena Bioscience 
5E10 Mouse 
monoclonal 
PML 1/100 1/20 Stuurman et al., 1992 
SpGH Rabbit serum Sp100 1/2000 1/2000 Sternsdorf et al., 
1995 
T4026 Mouse 
monoclonal 
Tubulin 1/5000 N/A Sigma-Aldrich 
P4D1 Mouse 
monoclonal 
Ubiquitin 1/1000 N/A Santa Cruz 
FK2 Mouse 
monoclonal 
Mono- and poly-
conjugated 
ubiquitin 
N/A 1/2000 International 
Bioscience Inc 
ZIF11 Mouse 
monoclonal 
UL42 1/1000 N/A Schenck et al., 1988 
DM165 Mouse 
monoclonal 
VP5 1/1000 N/A McClelland et al., 
2002 
A303-
257A 
Rabbit 
polyclonal 
ZBTB10 1/2000 N/A Bethyl Laboratories 
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Table 2.4 Secondary antibodies used in this study 
 
 Antibody Raised in Dilution Source 
Anti-mouse Anti-mouse IgG 
horseradish 
peroxidase 
conjugate  
Sheep 1/1000 Sigma-Aldrich 
A4416 
Anti-mouse IgG-
FITC 
Sheep  1/100 Sigma-Aldrich 
F3008 
Alexa Fluor 555 Donkey 1/5000 Invitrogen 
Molecular 
Probes A31570 
Anti-rabbit Anti-rabbit IgG 
horseradish 
peroxidase 
conjugate 
Sheep 1/20000 Sigma-Aldrich 
A4914 
Alexa Fluor 555 Donkey 1/5000 Invitrogen 
Molecular 
Probes A31570 
Alexa Fluor 633 Goat 1/1000 Invitrogen 
Molecular 
Probes A21071 
Anti-goat Anti-goat IgG 
horseradish 
peroxidase 
conjugate 
Rabbit 1/80000 Sigma-Aldrich 
A5420 
 
 
2.3.2 Western blot solutions and buffers 
Resolving gel buffer (RGB)  1.5 M Tris-HCl (Roche), 0.4% sodium dodecyl 
sulphate (SDS) (VWR International Ltd) pH 8.8 
 
Stacking gel buffer (SGB)   0.5 M Tris-HCl, 0.4% SDS pH 6.8 
 
3x sample boiling mix 1 ml SGB, 1 ml 20% SDS, 1 ml glycerol (VWR 
International Ltd), 0.5 ml β-mercaptoethanol (VWR 
International Ltd), bromophenol blue (Sigma-
Aldrich) 
 
Resolving gel (7.5% gels) 5 ml dH2O, 2.5 ml RGB, 2.5 ml 30% acrylamide/bis-
acrylamide (30:1) (National Diagnostics), 80 µl 10% 
ammonium persulphate (APS, Biorad), 8 µl TEMED 
(Sigma-Aldrich)  
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Stacking gel  1.4 ml dH2O, 0.6 ml SGB, 0.4 ml 30% 
acrylamide/bis-acrylamide (30:1), 20 µl 10% APS, 3 
µl TEMED  
 
Running buffer  0.05 M Tris-base, 0.05 M glycine (VWR 
International Ltd), 0.1% SDS 
 
Towbin buffer  25 mM Tris-base, 192 mM glycine, 20% methanol 
(VWR International Ltd) 
 
PBST  1x PBS (Sigma-Aldrich, made from 10% stock 
solution), 0.05% Tween-20 (VWR International Ltd) 
 
Blocking buffer    5% dried milk powder (Marvel) in PBST 
 
Stripping buffer 2% SDS, 62.5 mM Tris-HCl, 100 mM β-
mercaptoethanol pH 6.7 
 
 
2.3.3 Western blotting for the detection of protein expression  
Cells were seeded at 1 x 10
5
 in 24 well plates (section 2.5.3) and infected or induced as 
required.  The cells were incubated at 37 °C for the required length of time and harvested 
in 70 µl of 1x boiling mix, boiled for 2 minutes, and placed immediately on ice. The 
samples were stored at -20 °C until ready for analysis by Western blot.  Samples were 
resolved on 7.5% polyacrylamide gels consisting of a lower resolving gel and upper 
stacking gel.  Polymerisation of the gels was initiated by the addition of TEMED and APS 
immediately prior to pouring.  The samples were boiled for 2 minutes prior to loading 25-
30 µl per well, and were analysed alongside 10 µl of Spectra
TM
 Multicolor broad range 
protein ladder (Thermo Scientific) in running buffer and run at 100 volts until the dye front 
reached the bottom of the gel. 
 
2.3.4 Transfer of proteins to a nitrocellulose membrane 
Resolved proteins were transferred to a Hybond-ECL nitrocellulose membrane (Amersham 
Biosciences) in a cassette submerged in Towbin buffer and consisting of a fibre pad, a 3 
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mm filter paper, the polyacrylamide gel, a nitrocellulose membrane, a second layer of filter 
paper and another fibre pad.  The cassette was orientated to allow the transfer of proteins 
from the gel to the membrane.  An ice pack was added to the gel tank, which was filled 
with Towbin buffer, and the transfer occurred at 250 mA for 2.5 hours at room 
temperature.  Membranes were incubated in blocking buffer for 10 minutes with constant 
agitation, and stored in the blocking buffer at 4 °C overnight. 
 
2.3.5 Immunodetection of proteins 
Primary antibodies (Table 2.3) were diluted in blocking buffer and incubated with the 
membrane for 2 hours at room temperature with constant agitation.  After incubation with 
the primary antibody, the membrane was washed six times in PBST with each wash lasting 
5 minutes.  Secondary antibodies (Table 2.4) were diluted in 1% dried milk powder/PBST 
and the membrane incubated for 2 hours at room temperature with constant agitation.  
Following this the membrane was washed six times as described before.  The secondary 
antibody was conjugated to horse radish peroxidase, which could be detected using 
Western Lightning ECL reagent (Perkin Elmer Inc), or in the case of the 5E10 antibody, 
Amersham
TM
 ECL Prime Western Blotting Detection Reagent (GE Healthcare) was used 
due to increased sensitivity.  The membrane was incubated for 3 minutes in equal volumes 
of ECL reagent one and reagent two and then exposed to UV X-Omat film (Kodak) for 
variable lengths of time as determined by protein band intensity. The film sheets were 
developed using a Konica Minolta SRX-101-A film processor. 
 
2.3.6 Stripping of nitrocellulose membranes 
To allow sequential re-probing to detect proteins with different antibodies, the 
nitrocellulose membranes were incubated in stripping buffer (with the β-mercaptoethanol 
added just before use) for 45 minutes at 50 °C with occasional agitation.  The membranes 
were washed three times for 5 minutes in PBST, and incubated for 1 hour in blocking 
buffer at room temperature with constant agitation.  The membranes were then ready for 
re-probing with antibody dilutions as described above.  
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2.4 Production of GST-tagged proteins from bacteria 
2.4.1 Solutions and buffers for purification of GST-tagged 
proteins from bacteria 
Buffer A  50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5% glycerol, 
0.1% NP40, 1 mM DTT, 2.5 mM MgCl2 (VWR International 
Ltd), protease inhibitor (Roche, 1 pellet for every 200 ml of 
buffer) 
 
Buffer B 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2.5 mM MgCl2, 1 
mM DTT, 2.5% glycerol. 
 
 
2.4.2 Transformation of plasmid DNA for protein purification 
The transformation of pGEX GST fusion protein expression plasmids into BL21(DE3) 
pLysS bacterial cells (Merck) was performed using a similar method to transformation into 
DH5α cells described in section 2.1.2, using 50 µl of the BL21 cells and 100 ng of plasmid 
DNA.  The only difference was that 250 µl S.O.C medium (Invitrogen) was added to the 
cells instead of LB broth.     
 
2.4.3 Growth of bacterial cultures for protein purification 
Individual colonies were picked from the agar plates and added to 10 ml LB broth 
containing the appropriate antibiotic selection and incubated at 37 °C with horizontal 
agitation overnight.  The following day, 4 ml overnight starter culture was added to 200 ml 
of pre-warmed LB broth (with antibiotic selection) and incubated for 3 hours at 37 °C with 
horizontal agitation until the culture was in mid-log phase.  Protein expression was induced 
by addition of IPTG (Sigma-Aldrich) (final concentration 0.1 mM) to the culture, which 
was then incubated at 37 °C with horizontal agitation for 4 hours.  The culture was 
harvested and centrifuged at 4000 rpm (Sorvall Evolution RC, FIBERLite F10S rotor) for 
20 minutes at room temperature.  The bacterial pellets were frozen on dry ice and stored at 
-20 °C.    
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2.4.4 Purification of GST-tagged proteins from bacterial extracts 
Bacterial pellets were resuspended in 30 ml buffer A and probe sonicated to lyse the cells.  
The cellular debris was removed by centrifugation at 13000 rpm (Sorvall Evolution RC, 
FIBERLite F10S rotor) for 15 minutes.  Approximately 50-100 µl of glutathione agarose 
beads (Sigma-Aldrich) were hydrated in 5 ml PBS, tumbling end-over-end at room 
temperature for 1 hour.  The beads were spin washed in 10 ml PBS and then washed three 
further times in 1 ml PBS.  The glutathione agarose beads were finally resuspended in 400 
µl PBS (giving an approximate 50% v/v mixture).  The bacterial supernatant was incubated 
with the beads for 90 minutes to allow protein binding, tumbling end-over-end at room 
temperature.  The beads were centrifuged at 1000 rpm (MSE Micro Centaur) for 5 minutes 
to remove any unbound proteins and then spin washed in 10 ml buffer A.  The beads were 
washed a further three times in 1 ml buffer A and then in 100 µl buffer A to remove any 
non-specifically bound proteins.  The GST-tagged fusion proteins were eluted from the 
beads by incubation three sequential times with 350 µl 50 mM reduced glutathione in 
buffer A.  20 µl of each elution fraction and the remaining beads were analysed by SDS-
PAGE (using a 10% polyacrylamide gel) and stained with Coomassie brilliant blue 
(National Diagnostics) to visualise the proteins.   
 
The following day, the eluted fractions were combined and dialysed using Millipore mini-
dialysis tubes in buffer B for 2-3 hours at room temperature.  The dialysed samples were 
run on a 10% SDS-PAGE gel alongside BSA standards, and the gel stained with 
Coomassie brilliant blue to quantify the relative protein concentrations.   
 
2.5 Cell culture methods 
2.5.1 Cells 
The cell lines used throughout this study and their growth media are detailed in Table 2.5.  
The purpose of use of the cell lines are described throughout this section.   All reagents and 
media used in cell culture were sourced from Invitrogen unless otherwise stated.  
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Table 2.5 Cell lines and their growth media 
 
Cells Characteristics Growth medium Reference 
HEK-
293T 
Human embryonic 
kidney cells 
 
Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% 
fetal calf (bovine) serum (FBS) 
and 0.1% 
penicillin/streptomycin 
Provided by 
Anne Orr, CVR 
U2OS Human osteosarcoma 
cells 
Provided by 
Anne Orr, CVR 
HF Human fibroblasts  A gift from 
Thomas 
Stamminger 
(Erlangen) 
HepaRG Human hepatocellular 
carcinoma cells 
 
 
William’s medium E with 10% 
FBS Gold (PAA laboratories), 2 
mM glutamine, 0.5 µM 
hydrocortisone (Sigma-Aldrich) 
and 5 μg/ml insulin, 0.1% 
penicillin/streptomycin  
Gripon et al., 
2002 
HA-TetR HepaRG cells 
transduced with 
lentivirus derived from 
pLKOneo.CMV.EGFPn
lsTetR  
Everett et al., 
2009 
HA-
IE1/pp71 
Express HCMV IE1 
and pp71 proteins after 
doxycycline induction 
Everett et al., 
2013 
BHK-21 Baby hamster kidney 
fibroblasts (clone 21) 
Glasgow modified Eagle’s 
medium with 100 units/ml 
penicillin, 100 µg/ml 
streptomycin, 10% new-born 
calf serum (NBCS) and 10% 
tryptose phosphate broth (E&O 
Laboratories Ltd) 
Stoker & 
Macpherson, 
1964 
 
 
 
 
2.5.2 Growth and passaging of cells 
Cells were grown in their respective growth media (Table 2.5) in 75 cm
2
 flasks (Nunc 
Fisher Scientific UK Ltd) at 37 °C in the presence of 5% CO2.  The cells were passaged 
once the cell monolayers were 80-90% confluent.  To passage the cells, the monolayers 
were washed in 5 ml versene in PBS (E&O Laboratories Ltd) and then incubated with 1 ml 
1% trypsin (Sigma-Aldrich) in versene solution for 2-5 minutes.  Disassociated cells were 
resuspended in the appropriate media and a dilution of this was used to seed a new flask, 
with the dilution ranging from 1/3 to 1/10, depending on the cell type.   
 
2.5.3 Cell seeding 
Resuspended cells were counted using a Neubauer haemocytometer to calculate the 
number of cells per ml.  The cells were seeded at the appropriate density in plates or multi-
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well dishes as appropriate (Table 2.6), with the tissue culture plastics all sourced from 
Nunc Fisher Scientific UK Ltd.  
 
 
Table 2.6 Cell seeding densities 
 
 Seeding density 
24 well plate  1 x 10
5
 
12 well plate  2 x 10
5
 
35 mm dish  4 x 10
5
 
60 mm dish  1 x 10
6
 
 
 
 
2.5.4 Freezing and thawing of cell stocks for long term storage 
Confluent cells were washed with versene and then 1% trypsin/versene solution, leaving a 
small volume of the latter on the cells.  After the cells had dissociated, the cells were 
resuspended in 10 ml of culture media.  The cell suspension was transferred to a 15 ml 
Falcon tube and centrifuged at 2000 rpm for 5 minutes in a bench top centrifuge (Thermo 
Scientific Heraeus Megafuge 16R).  The cell pellets were resuspended in 4 ml freezing 
mix, which consisted of the appropriate growth media, with an additional 20% FBS and 
10% DMSO (cryoprotective agent, Sigma-Aldrich).  The resuspended cell pellets were 
aliquoted into 1 ml amounts, distributed into 1.5 ml cryo-vials, then frozen slowly to -70 
°C, and kept there for short term storage or transferred to liquid nitrogen for long term 
storage. 
 
To revive cells from frozen, the cryovials were placed on dry ice and thawed quickly at 37 
°C and pipetted into a flask with the appropriate pre-warmed medium.  Once the cells had 
attached to the tissue culture flask, the medium was replaced to remove residual DMSO.   
 
2.5.5 Lentiviral transduction of cell lines 
The plasmids used and their purposes in the generation of lentiviruses and in the 
transduction of cell lines for the production of the ICP0 inducible cell lines are described in 
Table 2.7.   
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Table 2.7 Plasmids used for generation of cell lines 
 
 
HEK-293T cells were plated at 1.5 x 10
6
 per 60 mm plate in complete DMEM medium. A 
mixture of 8 μl PLUS reagent (Invitrogen)  and 250 μl of serum-free DMEM was added to 
Falcon tubes containing 3 μg pLKO.DCMV.TetO.cICP0 lentivirus plasmid, 3 μg pVSV-G 
(expressing the vesicular stomatitis virus envelope protein G) and 3 μg pCMV-DR.8.91 
(expressing all necessary lentivirus helper functions), and incubated for 15 minutes at room 
temperature. A second mixture of 12 μl lipofectamine (Invitrogen) and 250 μl serum free 
DMEM was dispensed into the DNA-PLUS mixtures and incubated for 15 minutes at room 
temperature. Finally, 900 μl of serum free DMEM was added to the DNA mixture, which 
was added to the serum-free DMEM washed cells. After 3 hours, 4 ml of conditioned 
medium (in which the cells had previously been growing) was added to the cells, which 
were then incubated overnight at 37 °C. The following day, the transfection mix was 
removed and 4 ml DMEM added. The next day, the supernatant was collected and 4 ml 
DMEM and 30% FBS were added to the cells. The supernatant collection was repeated the 
following day and added to the 48 hour supernatant, which was then centrifuged at 1500 
rpm for 5 minutes and filtered through a 0.45 micron filter. HA-TetR cells plated at 6 x 10
5
 
in 60 mm dishes the previous day were infected with 1 ml of the filtered lentiviral 
supernatant and 5 μg/ml polybrene (to aid virus adsorption), and adsorbed for 1 hour. The 
supernatant was removed, and the cells were infected with another 1 ml aliquot of the 
lentiviral supernatant. For the third repeat, 4 ml lentivirus supernatant and 1 μl polybrene 
were added, and the cells were incubated overnight. Puromycin (Sigma-Aldrich) selection 
(1 μg/ml initially, reduced to 0.5 μg/ml for the following days and general cell 
maintenance) was applied to the cells until the cells on the mock infected plate, which 
contained no antibiotic resistant lentivirus, had died. After this, the cells were expanded 
into larger scale cultures for use in the experiments. 
 
Plasmid Purpose Source 
pVSV-G Expression of VSV envelope 
protein for lentivirus production. 
BD Biosciences 
pCMV.DR.8.91 Lentivirus helper vector, providing 
capsid (gag) reverse transcriptase 
polymerase (pol), Rev, and Tat 
helper functions 
A gift from D. Trono 
(http://tronolab.epfl.ch) 
pLKO.DCMV.TetO.cICP0 
based plasmids 
Lentiviral vector plasmids that 
express ICP0 and relevant mutants 
under doxycycline inducible 
control 
Everett et al., 2009, 
this study 
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2.6 Virus construction 
2.6.1 Virus construction buffers and solutions 
Eagles A  0.1495 g CaCl2.2H2O (Sigma-Aldrich), 0.1495 g 
MgSO4.7H2O (Sigma-Aldrich), dH20 to 500 ml. Aliquot 100 
ml into 200 ml bottles.  Autoclave at 15 psi for 15 minutes. 
Store at 4 °C. 
 
Amino acid solution (produced in house, CVR) 
 0.84 g L-Arginine mono-HCl, 0.48 g L-cysteine, 0.384 g L-
histidine mono-HCl, 1.048 g L-isoleucine, 1.048 g leucine, 
1.462 g L-lysine mono-HCl, 0.66 g L-phenylalanine, 0.952 g 
L-threonine, 0.16 g L-tryptophan, 0.724 g L-tyrosine, 0.936 
g L-valine, 0.3 g L-methionine, 0.07 g inositol, 55 g 
NaHCO3, 30 ml phenol red 1%, dH20 to 1000 ml. 
 
Salt solution (produced in house, CVR) 
 102.4 g NaCl, 6.4 g KCl, 2.4 g NaH2PO4.2H2O, 72 g 
glucose, 16 ml ferric nitrate 0.01%, 4.68 g L-glutamine, 16 
ml (1.6 x 10
6
 units) penicillin, 1.6 g steptomycin sulphate, 16 
ml 0.02% antimycotic, dH20 to 1000 ml. 
 
Vitamins solution (produced in house, CVR) 
 0.05 g choline chloride, 0.05 g folic acid, 0.05 g 
nicotinamide, 0.05 g DL-pantothenic acid, CA salt, 0.05 g 
pyridoxal-HCl, 0.05 g thiamine-HCl, 0.005 g riboflavine, 
dH20 to 100 ml.  
 
Eagle’s B (produced in house, CVR) 
 250 ml salt solution, 200 ml amino acid solution, 16 ml 
vitamin solution, dH20 to 500 ml.  Aliquot 20 ml into 
universal bottles. 
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Noble agar  6.4 g Difco Noble agar, dH2O to 200 ml.  Aliquot 30 ml into 
100 ml bottles.  Autoclave at 15 psi for 15 minutes. Store at 
4 °C. 
 
 
2.6.2 Fragments for homologous recombination 
The desired ICP0 mutations or deletions were sub-cloned into the p111 plasmid backbone, 
and 20 µg DNA was digested with SacI and PvuII at 37 °C for 2 hours.  This digestion 
produces a 4.8 kb fragment that included the complete ICP0 genomic region with the 3’ 
flanking sequence and the IE1 promoter, thus enabling insertion into viral DNA by 
homologous recombination. The restriction mix was then heat inactivated at 80 °C for 20 
minutes and ethanol precipitated by increasing the volume of the restriction mix with 1x 
TE to 100 µl, and adding 5 µl NaCl and 250 µl EtOH.  The sample was incubated at -20 °C 
for 10 minutes, and the pellet was spin-washed with 80% EtOH before being resuspended 
in 40 µl 1x TE.  A 1-2 µl aliquot of the fragment sample was run on an agarose gel to 
check that the fragment was the correct size and concentration. 
 
2.6.3 Transfection 
BHK cells (or HA-IE1/pp71 cells in the case of the deletion mutants downstream of the 
RING finger domain ICP0Δ197-222) were seeded at 4 x 105 cells per 35 mm dish.  The 
next day, 2 µl dl1403 purified viral DNA (2 kb deletion within both copies of ICP0 gene) 
(provided by Anne Orr, CVR) and 2 µg precipitated restriction digest mix containing SacI-
PvuII fragment from p111 plasmid backbone (see above) were added to a 15 ml Falcon 
tube.  The DNA was mixed with 4 µl PLUS reagent (used in conjugation with 
lipofectamine to improve transfection efficiencies) and 100 µl serum-free media per 
transfection and incubated at room temperature for 15 minutes.  Then, 4 µl lipofectamine 
and 100 µl serum-free media were added to the DNA/PLUS mix and incubated for a 
further 15 minutes at room temperature.   The cells were washed in serum-free media, and 
the conditioned media in which the cells had been grown in was retained.  An additional 
500 µl serum-free media was added to each reaction mix, and this mixture was added to 
the freshly washed cells.   The cells and transfection mixture were incubated at 37 °C for 3 
hours with gentle agitation every 10 minutes, and at 3 hours post transfection they were 
overlaid with 1.5 ml conditioned medium, and the incubation was continued at 37 °C until 
cytopathic effect (c.p.e) was apparent (after 3-4 days). 
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2.6.4 Plaque purification 
When extensive c.p.e was apparent after transfection, the cells and supernatant were 
harvested and sonicated. After clarification by centrifugation, the virus stocks were 
passaged twice on HFs plated at 1 x 10
6
 cells per 60 mm dishes, using a range of virus 
inputs. Because most ICP0 mutations do not cause a defect as pronounced as the large 
deletion of the gene in dl1403, this step enriches for the desired recombinants. The 
passaged stocks were then plaque purified on 4 x 10
5
 BHK cells in 35 mm dishes at 
dilutions ranging from neat to 10
-5
 and adsorbed for an hour at 37 °C with occasional 
agitation.  The overlay solution was composed of Eagle’s A, Eagle’s B, NBCS and Noble 
agar.  The Eagle’s B solution was warmed at 37 °C until the precipitate had dissolved, and 
20 ml was added to 90 ml Eagle’s A and 5 ml NBCS.  12 ml of the Eagle’s A/B/NBCS 
mixture was aliquoted into a 25 ml glass bottle and warmed to 50 °C.  The Noble agar was 
melted in the microwave and kept in a water bath at 50 °C to prevent it solidifying.  All the 
virus dilutions were removed from the cells so that no liquid remained, 3 ml Noble agar 
was added to the Eagle’s A/B/NBCS mixture, and the cells were overlaid with 2 ml of this 
mixture.  The plates were left to cool at room temperature until the agar had solidified and 
then incubated at 37 °C for 2-3 days until plaques had developed.   
 
Plaques were identified using dark field illumination on a light microscope, and their 
positions were marked on the plastic.  Pipette tips were used to pierce the agar and take up 
a single plaque and the cells associated with it, and these were transferred to an Eppendorf 
tube containing 100 µl BHK medium.  BHK cells were plated the previous day in 24 well 
plates at 1 x 10
5
 cells per well, and 50 µl of the plaque-purified sample was adsorbed onto 
the cells for an hour with occasional agitation at 37 °C.  After adsorption, the cells were 
overlaid with 500 µl BHK medium.  After 2-3 days, when c.p.e was apparent, the 
supernatant was harvested and stored at -70 °C, while the cells were washed in PBS and 
harvested in 70 µl of 1x boiling mix and analysed for the presence of ICP0 by Western 
blotting (Section 2.3.3).  A positive sample identified from the Western blot was used to 
undergo at least another two rounds of plaque purification, and the presence of ICP0 was 
confirmed by Western blotting and immunofluorescence (section 2.8).  When all required 
plaque samples positive for ICP0 expression by Western blot had been identified, one 
positive sample was used to produce small scale virus stocks, which were grown on BHK 
cells in 60 mm plates (section 2.7.2) from the plaque purified supernatant.  
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2.6.5 Sequencing of viral DNA 
To confirm that the isolated viruses contained the desired mutations, the viral DNA was 
sequenced directly.  BHK cells were seeded at 1 x 10
5
 cells per well in 24 well plates and 
infected the following day at an MOI of 1 with the mutant viruses.  The infected cells were 
harvested into the medium after c.p.e was apparent, and the DNA was extracted using the 
DNeasy tissue kit (Qiagen). PCR was performed on the samples with 50 ng of DNA per 
reaction, and the products were separated on a 1.5% agarose gel and the band extracted. 
When necessary, if the yield of the PCR product was insufficient, the PCR was repeated 
with the same primers, using the initial PCR product as the template. The gel extraction 
was repeated and the PCR product was submitted for DNA sequencing (University of 
Dundee) to confirm that the desired mutations were present. 
 
2.7 Virology methods 
2.7.1 Viruses 
Viruses that had been isolated previously and that were used throughout this study are 
listed in Table 2.8. Virus mutants that were constructed during the course of this study are 
described in section 2.2.  All HSV-1 strains were propagated in BHK cells (section 2.7.2) 
and titrated on U2OS cells (section 2.7.3). 
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Table 2.8 Viruses provided for use in this study. 
 
 
2.7.2 Propagation of viral stocks 
Viral stocks were propagated in BHK cells seeded at 1 x 10
6
 in 60 mm dishes.  Cells were 
infected in 1 ml volume at a range of MOIs (0.01 to 0.001), depending on the expected 
viral replication defect, and the virus was adsorbed for 1 hour at 37 °C with agitation every 
10 minutes.  The cells were overlaid with 2 ml of fresh medium and incubated at 37 °C for 
2-3 days until extensive c.p.e was apparent.  The supernatant containing cell-released virus 
was harvested and centrifuged at 3000 rpm (Thermo Scientific Heraeus Megafuge 16R) for 
5 minutes to remove any cellular debris.  Aliquots of the virus were stored short-term at 4 
°C until the viral titre was determined. The aliquots were stored at -70 °C in the long term.   
 
Viruses Characteristics 
wt HSV-1 strain 17 syn+ 
(17+) 
wt HSV-1 syn 17+ strain (Brown et al., 1973) 
HSV-1 ICP0 deletion mutant 
FXE 
Expresses ICP0 with a deletion of amino acid residues 
106-149 within the RING finger domain (Everett, 1989)  
HSV-1 ICP0 substitution 
mutant K144E 
 
 
Derivatives of wt 17+ HSV-1 containing point mutations 
within ICP0 at the position indicated, replacing the 
residue identified by the initial letter (single letter amino 
acid code) with that at the end (Everett et al., 1995). 
HSV-1 ICP0 substitution 
mutant W146A 
HSV-1 ICP0 substitution 
mutant Q148E 
HSV-1 ICP0 substitution 
mutant N151D 
in1374 Defective HSV-1 that cannot enter lytic replication under 
restrictive conditions as it contains a deletion of the ICP0 
gene, a mutation within VP16 so is unable to stimulate IE 
gene expression and a temperature sensitive mutation 
within ICP4 which disrupts its function. It also contains a 
β-galactosidase reporter gene under the control of the 
HCMV IE promoter/enhancer (Preston & Nicholl, 2005)  
dl1403 Contains a 2 kb deletion within both copies of the ICP0 
gene of HSV-1 strain 17 syn+ (Stow & Stow, 1986)  
in1863 Contains a HCMV promoter and lacZ expression cassette 
inserted into the thymidine kinase gene of wt HSV-1 
(provided by C. Preston)  
dl1403/CMVlacZ Contains a HCMV promoter and lacZ expression cassette 
inserted into the thymidine kinase gene of dl1403 
(provided by C. Preston) 
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2.7.3 Titration of viral stocks 
Titration of viral stocks was carried out in U2OS cells, as ICP0 is not required for efficient 
HSV-1 replication in this cell type (Yao & Schaffer, 1995).  Cells were seeded at 2 x 10
5
 
cells per well in 12 well plates and infected with 10
-2
 to 10
-5
 virus dilutions in a total 
volume of 100 µl for 1 hour at 37 °C, with agitation every 10 minutes.  The cells were 
overlaid with complete DMEM media containing 1% human serum (MP Biomedicals) to 
neutralise any cell-released virus and allow the virus to spread from cell to cell to create 
plaques.  The plates were incubated at 37 °C for 48 hours or until plaques had developed.  
The medium was removed and the cell monolayer was stained with Giemsa stain (VWR 
International Ltd) for 5 minutes and then washed with dH2O. The plaques were counted 
under a light microscope.   
 
The viral titres were calculated using the formula below: 
Viral titre or plaque forming units (PFU) per ml  
= number of plaques x dilution factor x 10 (used 100µl inoculum and titre given per ml) 
 
2.7.4 Viral infections 
Cells were seeded at the appropriate density (section 2.5.3, Table 2.6) and the medium 
was removed to leave enough to cover the cells.  The amount of virus added to the cells 
was calculated on the basis of the MOI.  The virus was added to the cells and absorbed for 
1 hour, with gentle agitation every 5-10 minutes.  After 1 hour, the cells were overlaid with 
the appropriate media. 
 
2.7.5 Plaque assays – ‘blue plaque assays’ and standard viral 
plaque assays 
So-called ’blue plaque assays’ were used when the virus in question contained the β-
galactosidase reporter gene. Cells were seeded at 1 x 10
5
 cells per well of a 24-well plate 
and then, when appropriate, treated with 0.1 μg/ml doxycycline to induce ICP0 expression 
the following day. The day following doxycycline induction, the cells were infected with 
sequential ten-fold dilutions of in1863 (wt) or ICP0-null mutant dl1403/CMVlacZ, which 
both contain an inserted LacZ gene coding for β-galactosidase (controlled by the HCMV 
promoter/enhancer and inserted into the tk locus).  After virus adsorption, the cells were 
overlaid with complete WME containing 1% human serum (and 0.1 μg/ml doxycycline if 
88 
 
the cells had been induced). The plates were stained for β-galactosidase 24 hours later by 
washing with PBS and incubating the cells in PBS/1% glutaraldehyde for 40 minutes. The 
cells were washed with PBS and incubated at 37 °C with pre-warmed reagent solution (see 
below) for 30-120 minutes. 
 
Reagent solution In PBS: 5 mM potassium ferricyanide (Sigma-Aldrich), 5 
mM potassium ferrocyanide (Sigma-Aldrich), 2 mM MgCl2 
(VWR International Ltd), 0.01% NP 40, X-gal (Melford 
Laboratories Ltd) in DMSO (40 mg/ml)  added to a final 
concentration of 2.4 mM 
 
When the virus in question did not contain the β-galactosidase reporter gene, cells were 
seeded into 12-well plates at 2 x 10
5
 cells per well and infected with sequential ten-fold 
dilutions of wt/mutant viruses the following day. After virus adsorption for 1 hour at 37 °C 
with agitation every 5-10 minutes, the cells were overlaid with medium containing 1% 
human serum. After 48 hours, the plates were stained using Giemsa stain and the plaques 
counted. 
 
2.7.6 Viral yield assays 
Human fibroblasts (HFs) and HepaRG cells seeded at 2 x 10
5
 cells per well in 12 well 
plates were infected at a range of MOIs (0.1, 0.01 and 0.001). Cells and supernatant were 
harvested at 24 hours post infection, sonicated (to release cell-associated virus) and titrated 
as sequential ten-fold dilutions on U2OS cells (seeded at 2 x 10
5
 cells per well in 12 well 
plates the previous day). The plates were stained 48 hours later using Giemsa stain, and the 
plaques produced were counted. 
 
2.7.7 Viral quiescence assays 
HepaRG cells were seeded at 1 x 10
5
 cells per well in 24 well plates.  The following day, 
the cells were infected with in1374 virus at MOI of 5 and incubated at 38.5 °C overnight. 
The next day, the cells were super-infected with wt/mutant virus at an MOI of 5 at 37 °C.  
After virus adsorption for 1 hour at 37 °C with agitation every 5-10 minutes, the cells were 
overlaid with medium containing 10 μM ACV (a guanosine analogue that prevents viral 
DNA synthesis) and 1% human serum, and incubated at 38.5 °C for 8 hours. The cells 
were then fixed and stained for β-galactosidase activity by washing with PBS and 
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incubating in PBS/1% glutaraldehyde for 40 minutes. The cells were washed with PBS and 
incubated at 37 °C with pre-warmed reagent solution for staining (see section 2.7.5) for 
30-120 minutes. 
 
2.8 Immunofluorescence and confocal microscopy 
2.8.1 Solutions used during immunofluorescence 
Formaldehyde fix solution  1 ml formaldehyde solution (37% w/v, Sigma-
Aldrich), 0.4 g sucrose, 19 ml PBS 
 
Permeablisation solution   2 g sucrose, 1 ml 10% NP40, 19 ml PBS 
 
 
2.8.2 Immunofluorescence protocol 
Cells were seeded onto circular 13 mm glass coverslips in a 24 well plate at a seeding 
density of 1 x 10
5
 cells per well.  After the experimental procedure was carried out, the 
coverslips were transferred to a fresh 24 well plate and washed once in PBS.  The cells 
were fixed by incubation with 0.5 ml formaldehyde fix solution for 5 minutes at room 
temperature.  The coverslips were washed three times in 1 ml PBS, and the cells were 
permeabilised by incubating for 5 minutes at room temperature with 0.5 ml permeabilising 
solution.  The cells were washed three times in PBS containing 2% FBS, and were stored 
at 4 °C in this buffer until required.   
 
Primary antibodies were diluted as appropriate (Table 2.3) in PBS containing 5% FBS, 
and 35 µl of the antibody dilution was placed onto the coverslip with the cell side facing up 
and incubated for 1 hour at room temperature.  The coverslips were washed six times in 
PBS containing 2% FBS and incubated with secondary antibodies (Table 2.4), as 
described above.  After six washes with PBS/2% FBS, the coverslips were rinsed in dH2O 
to remove any salt residue, and air dried before mounting cell side down on Citifluor AF1 
mounting agent, and fixed in place using clear nail varnish.        
 
Confocal microscopy was carried out using a Zeiss LSM 710 confocal microscope with 
488, 561 and 633 nm laser lines, scanning each channel separately under conditions that 
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eliminated channel overlap.  Images were exported as Tif files using Zen browser software, 
edited minimally using Abode Photoshop, and figures compiled in Abode Illustrator.   
 
2.9 In vitro assays 
2.9.1 Polyubiquitination assay 
Polyubiquitination assays were carried out in reactions containing 2.5 µg ubiquitin (Sigma-
Aldrich), 10 ng 6xHis-E1 ubiquitin activating enzyme (provided by the laboratory of Chris 
Boutell), titrated amounts of 6xHis-E2 ubiquitin conjugating enzyme (10, 20, 40 ng) 
(provided by the laboratory of Chris Boutell) and 30 ng wt or ICP0 mutant forms of a 
GST-ICP0 fusion protein encompassing the first 241 residues of ICP0 (GST-241). The 
mixture was incubated at 37 °C for 45 minutes, and then the reaction was stopped by the 
addition of 6 µl 3x boiling ‘super mix’ containing urea (30% SGB, 30% glycerol, 6.5% 
SDS powder, 9 M urea, 100 mM DL-dithiothreitol (DTT), bromophenol blue) and 
incubating at 95 °C for 10 minutes.  The samples were run on a Biochem/Novex 
NuPAGE® pre-poured 4-12% bis-tris gradient protein gel (Invitrogen) run in NuPAGE® 
MOPS SDS running buffer (Invitrogen) at 160 volts.  The proteins in the gel were 
transferred to a nitrocellulose membrane by electroblotting in NuPAGE® transfer buffer 
(Invitrogen) at 30 volts (~200 mA) for 1 hour.  The membrane was blocked for 1 hour in 
blocking buffer, and then ubiquitin chain formation and autoubiquitination were detected 
using a P4D1 mouse monoclonal antibody and a 27-4577-01 anti-GST antibody, 
respectively.   
 
2.10 Yeast-two-hybrid reagents and methods 
Yeast-two-hybrid assays were used to test for protein interactions, and were conducted 
using the Matchmaker
TM
 GAL4 Two-Hybrid System 3 (Clonetech).  An overview of the 
yeast-two-hybrid system is described in Figure 2.4, with the materials and methods for 
each step being detailed throughout this section.   
 
2.10.1 Yeast strains 
The Saccharomyces cerevisiae Y187 and AH109 yeast strains used throughout the yeast 
two hybrid study were obtained from Clonetech.  Their genotypes are described in Table 
2.9. 
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Table 2.9 Yeast strains used in this study. 
 
 
2.10.2 Plasmids used in yeast-two-hybrid assays 
The plasmids used in the yeast-two-hybrid assay are detailed in Table 2.10, with their 
sources, main characteristics and purpose of use described.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Genotype Reporter genes 
Y187  MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-
3, 112, gal4Δ, gal80Δ, met–,  
URA3 : : GAL1UAS-GAL1TATA-lacZ 
MEL1, lacZ 
AH109 MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, 
gal4Δ, gal80Δ, LYS2 : GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2, 
URA3 : MEL1UAS-MEL1TATA-lacZ  
HIS3, ADE2, MEL1, 
lacZ 
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Table 2.10 Plasmids used in yeast-two-hybrid assays 
 
 
 
 
 
 
 
 
Plasmid Purpose 
pGADT7 
(Clonetech) 
Expression of DNA-activating domain fusion proteins 
GAL4 (768-881) AD, LEU2, amp resistance, HA epitope tag 
Selection on –Leu SD (lacking essential aa) medium. 
Negative control. 
pGAD-ICP0 
 
wt ICP0 (1-775 aa) as a fusion protein to the GAL4 activation 
domain (AD). 
Selection on –Leu.  
(Boutell et al., 2011; Vanni et al., 2012) 
pGAD-N151D 
pGAD-K144E 
Mutant version of pGAD-ICP0 with single point mutations in the 
ICP0 RING finger have been previously described (Vanni et al., 
2012) or, in the case of K144E, were provided by the group of Chris 
Boutell.  
Selection on –Leu. 
pGAD-KE/ND Mutant version of pGAD-ICP0 with double point mutation 
K144E/N151D was constructed from the GST-tagged ICP0 RING 
finger construct (section 2.10.6) during the course of this study. 
Selection on –Leu. 
pGAD-ICP0-2C Mutant version of pGAD-ICP0 containing mutations in double 
cysteine zinc-binding residues (C116G/C156A) 
Selection on –Leu.   
(Vanni et al., 2012). 
pGBKT7 
(Clonetech) 
GAL4(1-147) DNA-BD, TRP1, kan resistance, c-myc epitope tag. 
Expression of DNA binding domain fusion proteins. 
Selection on –Trp (-W).   
Negative control. 
BK-USP7 USP7 fused to the GAL4 DNA-binding domain. 
Selection on –Trp (-W).   
Positive control for ICP0 interaction. 
(Vanni et al., 2012) 
BK-UBE2D1 
BK-UBE2E1 
BK-UBE2N 
BK-UBE2V1 
BK-UBE2W 
E2 ubiquitin-conjugating enzymes fused to the GAL4-binding 
domain. 
Selection on –Trp (-W).  
UBE2D1, UBE2E1 (Vanni et al., 2012), others provided by the 
group of Chris Boutell.  
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2.10.3 Yeast reagents and solutions 
10x TE   0.1 M Tris-HCl, 10 mM EDTA pH7.5, autoclaved 
 
10x lithium acetate (LiAC) 1 M LiAc (Sigma-Aldrich) pH 7.5, autoclaved 
 
50% polyethylene glycol (PEG) 
50 g PEG (Sigma-Aldrich) per 100 ml dH2O, autoclaved 
 
1x TE/LiAc solution  1 ml 10x TE, 1 ml 10x LiAc, 8 ml dH2O 
 
TE/LiAc/PEG solution 1 ml 10x TE, 1 ml 10x LiAc, 8 ml 50 % 
PEG 
 
80% glycerol   8 ml glycerol, 2 ml dH2O, autoclaved 
 
0.2% adenine hemisulphate (Sigma-Aldrich) solution   
0.2 g in 100 ml dH2O, autoclaved 
 
3-amino-1,2,4-triazole (3-AT) 
    1 M 3-AT (Sigma-Aldrich). Autoclaved 
 
40% X-gal in N,N-dimethylformamide (DMF) 
0.16 g X-gal powder in 400 µl N,N-dimethylformamide  
(DMF) (Sigma-Aldrich) 
 
K2HPO4 (BDH Chemical Ltd) 
1 M solution, filter sterilised 
 
KH2PO4 (BDH Chemical Ltd) 
    1 M solution, filter sterilised 
 
KPO4 solution   61.5 ml K2HPO4, 38.5 ml KH2PO4 
 
1% agarose in dH2O  1 g agarose per 100 ml dH2O 
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Agarose/X-gal staining solution  
5 ml KPO4 solution, 600 µl DMF (which permeabilises yeast 
cells), 50 µl 20% SDS, 100 µl 40% X-gal solution in DMF 
and 5 ml 1% agarose in dH2O.   
 
 
2.10.4 Yeast media and agar plates 
Yeast strains were cultured in YPD broth, a media base including essential amino acids, or 
minimal SD base (Clonetech), which is a basic (drop out) medium lacking certain essential 
amino acids, e.g. -L to select for LEU2 (leucine biosynthesis) expression, -W to select for 
TRP1 (tryptophan biosynthesis) expression and –L-W to select for both LEU2 and TRP1 
expression.  After autoclaving adenine hemisulfate was added to YPD broth or agar 
(YPDA) to a final concentration of 0.003% to minimise yeast strains harbouring ADE1 and 
ADE2 which produce white colonies, so pink/red colour of colonies without the mutations 
were selected. 
 
2.10.5 Reviving yeast glycerol stocks 
Frozen yeast strains from -70 °C glycerol stocks were streaked onto pre-warmed YPDA 
agar plates or the appropriate drop out agar plates and incubated at 30 °C.  Colonies of the 
yeast strains were then picked and re-streaked onto fresh agar plates after three days or 
once the colony exceeded 2 mm in diameter.   
 
2.10.6 Transforming competent yeast cells using the 
polyethylene glycerol (PEG)/LiAc based method 
Yeast strain AH109 was used for the transformation of the pGADT7-derived plasmids, and 
yeast strain Y187 was used for the transformation of the pGBKT7-derived plasmids.  
Empty vectors pGADT7 and pGBKT7 were transformed as the appropriate negative 
controls.   
 
A culture containing four colonies of the appropriate yeast stain (AH109 or Y187) that had 
been passaged for less than three weeks was added to 3 ml YPDA media and incubated 
overnight at 30 °C with constant horizontal agitation.  The following day, 750 µl of the 
overnight culture was diluted in 15 ml YPDA medium in a 15 ml Falcon tube and 
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incubated for 3.5 hours with horizontal agitation at 30 °C.  The culture was centrifuged at 
3500 rpm (Thermo Scientific Heraeus Megafuge 16R) for 5 minutes, and the pellet was 
resuspended in 2 ml dH2O.  The pellets were spin washed a further two times in dH2O.  
The pellets were then centrifuged as before, resuspended in 2 ml 1xLiAc 0.1M/TE pH 8.0, 
spin-washed a further two times, and resuspended in 1xLiAc 0.1M/TE pH 8.0 buffer.  
After treatment with LiAc, the cells are fragile and cannot be vortexed.  After the final 
spin-wash, the cells were resuspended in 1/200 of the culture volume (75 µl of 1xLiAc / 
TE pH8.0).  After this, the yeast cells were competent for transformation. 
 
The transformation mix contained 50 µl resuspended yeast cells, 25 µg denatured herring 
testes carrier DNA (Invitrogen, boiled for 30 minutes at 100 °C and cooled on ice prior to 
use) and 1-2 µg plasmid DNA (pGAD-KE/ND).  The mixture was incubated at room 
temperature for 15 minutes, 150 µl of PEG 50% LiAc 0.1 M final/ TE pH 8.0 was added, 
and the tubes were inverted gently to mix.  PEG enhances the binding of plasmid DNA to 
yeast cell surfaces during transformation.  The mixture was incubated at 30 °C for 1 hour 
with horizontal agitation and then heat shocked for 20 minutes at 42 °C.  After the heat 
shock, 700 µl dH2O was added to the transformation mix, and the cells were centrifuged 
for 1 minute at 6000 rpm (MSE Micro Centaur).  The pellet was resuspended in 400 µl 
selective medium (–L or –W, determined by the plasmid).  AH109 was used to transform 
pGAD plasmids that allow growth in the absence of leucine (–L), and Y187 was used to 
transform pGBK plasmids that allow growth in the absence of tryptophan (–W).  Aliquots 
(200 µl) of the mixture were plated onto pre-warmed selective agar plates (if the 
transformation efficiency was high, 1/10 or 1/100 dilutions were also plated).  The colonies 
were incubated at 30 °C for 3-4 days until they were about 2-3 mm in diameter.  The 
colonies were then ready for restreaking, and when restreaked a further two times, they 
were then ready to mate.   
 
2.10.7 Mating  
Mating cultures of the AH109 and Y187 yeast strains were set up in 500 µl YPDA.  Five 
colonies approximately 2 mm in diameter from each of the –L and –W plates were placed 
into the YPDA and incubated at 30 °C overnight with horizontal agitation.  The following 
day, the overnight cultures were diluted 1/10 and 100 µl plated onto –L-W plates to select 
for diploids that contained both pGADT7 (selection on –L) and pGBKT7 (selection on –
W) derived plasmids.  The plates were incubated at 30 °C for about four days until the 
colonies reached 2-3 mm in diameter.  
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Figure 2.4 Studying protein-protein interactions using the yeast-two-hybrid system.   
The GAL4 transcription factor is divided into two fragments, the binding domain (BK) in 
pGBK-T7 plasmids and activating domain (AD) in pGAD-T7 plasmids.  Proteins of 
interest are expressed as fusion proteins with the BK and AD domains.  The pGBK 
plasmids are transformed into Y187 yeast strain grown on agar lacking Trp (-W), and the 
pGAD plasmids are transformed into AH109 yeast strain grown on agar lacking Leu (-L).  
After mating, the yeast strains are grown on agar lacking –Leu/-Trp (-L/-W) to select for 
the presence of both proteins.  The BK domain binds to the GAL UAS located upstream of 
the reporter genes, and, if the two tested proteins interact, the BK and AD are brought into 
close proximity and activate transcription of downstream reporter genes HIS3 and LacZ.  
Detection of protein interactions are confirmed by growth on agar plates lacking –Leu/-
Trp/-His (-L/-W/-H), and can be visualised by X-gal staining.    
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2.10.8 Yeast-two-hybrid plating 
Five colonies each 2-3 mm in diameter were picked from the mating plates lacking Leu 
and Trp, put into an Eppendorf tube containing 500 µl of –L-W broth, and incubated 
overnight at 30 °C with constant horizontal agitation.  The following day, the samples were 
vortexed, 7 µl was pipetted onto agar plates (listed below), and the plates were incubated at 
30 °C for 2-3 days.   
a) Lacking Leu and Trp: selects for diploids containing pGADT7 and pGBKT7 based 
plasmids 
b) Lacking Leu, Trp and His: selecting for expression of the downstream reporter 
gene HIS3, indicating an interaction between the two proteins tested.    
c) Lacking Leu, Trp and His plus 1 mM 3-amino-1,2,4-triazole (3-AT): 3-AT is a 
competitive inhibitor of the HIS3 gene product, imidaxoleglycerol phosphate 
dehydratase, and it enables greater selection for positive interactions in yeast-two-
hybrid system and eliminates background growth on –H selection plates. 
d) Lacking Leu, Trp and His plus 5 mM 3-AT: the most stringent selection used for 
positive interactions 
   
2.10.9 X-gal staining 
Colonies growing on the agar plates lacking Leu, Trp and His with 1 or 5 mM 3-AT were 
further analysed for positive protein interactions by X-gal staining to detect β-galactosidase 
expression from the LacZ reporter gene downstream of the HIS3 reporter gene.  The agar 
plates were imaged prior to X-gal staining, and the buffers were pre-warmed to 50 °C prior 
to use to prevent X-gal crystal formation.  The agarose/X-gal staining solution (containing 
DMF which permeabilises yeast cells) was added to the plates, and, once dried, the plates 
were incubated at 37 °C overnight. The following day, the plates were imaged in colour, 
with a blue colour indicating β-galactosidase activity and an interaction between the two 
proteins, whereas colonies that remained white indicated no interaction.   
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3 Results - Analysis of the alpha-helix RING finger 
ICP0 mutants using an inducible cell line system 
3.1 Introduction 
The tertiary structure of the RING finger domain of the equine herpesvirus 1 (EHV-1) 
protein, which is highly related to ICP0, shows that it consists of an amphipathic alpha-
helix that lies between the second and third strands of the triple stranded anti-parallel beta 
sheets (Figure 1.4) (Barlow et al., 1994).   Several polar and charged side chains extend 
off the alpha-helix, and it has been shown by site-directed mutagenesis that some of these 
side chains are required for fully efficient ICP0 activity in gene expression reporter assays 
and also a limited number of virus infection assays (Barlow et al., 1994; Everett et al., 
1995).  These alpha-helix mutations do not appear to reduce in vitro E3 ligase activity of 
ICP0 in combination with E2 ubiquitin-conjugating enzyme UBE2D1 (Boutell et al., 
2002).   
 
This chapter investigates mutations in the alpha-helix of the RING finger domain of ICP0, 
namely N151D and K144E.  These mutations are located in the charged side chains that 
are exposed on the surface of the alpha-helix and which may therefore form an interface 
with ICP0 interaction partners.  Recently, Vanni et al. (2012), using an inducible ICP0 
expression system, found that mutation N151D was defective in inducing reactivation of 
quiescent HSV-1, but was only slightly defective in complementing lytic infection of an 
ICP0-null mutant HSV-1 (Vanni et al., 2012).  This observation raises the possibility that 
complementation and reactivation involve differential activities of ICP0.  This was an 
exciting and potentially extremely important finding that merited confirmation and further 
investigation.  Therefore, based on this observation, one of the aims of the work presented 
in this chapter was to repeat the investigation of the N151D mutation and extend the 
studies to include the nearby K144E mutation which has previously been analysed in 
transfection and virus based assays and had phenotypes similar to the N151D mutation 
(Barlow et al., 1994; Everett et al., 1995).  Therefore, these two mutations were analysed 
in parallel to investigate in more detail their effects on ND10, complementation of an 
ICP0-null mutant virus, and reactivation of quiescent HSV-1. These studies aimed to 
elucidate in greater detail the role of the RING finger alpha-helix in the functions of ICP0.        
 
These mutants were initially studied using an ICP0 inducible expression system, (Figure 
2.2) (Everett et al., 2009), which expresses ICP0 in an inducible manner to levels 
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comparable to the early stages of HSV-1 infection.  This system is advantageous in many 
assays, as it allows direct analysis of ICP0-specific functions in the absence of other viral 
proteins, whereas attempts at long term ICP0 expression would be detrimental for cell 
survival (Everett et al., 2009).  Using the inducible ICP0 cell line avoids problems 
associated with comparing defects of ICP0 mutant HSV-1 that depend on factors such as 
cell type and input MOI, and the limitations of transfection experiments that can expresses 
the protein of interest at very high non-physiological levels.  These complications with 
virus infection and transfection-based systems in certain assays can be minimised by using 
the inducible cell line system. However, studies of the effects of the mutations in the 
context of the viral genome remain important, and these studies will be presented in a later 
chapter.     
 
3.2 Results 
3.2.1 The RING finger alpha-helix mutant proteins colocalise with 
PML but have reduced abilities to induce its dispersal 
At the early stages of infection, ICP0 shows colocalisation with PML, but as the infection 
progresses ND10 are disrupted, with the RING finger domain of ICP0 inducing the 
degradation of PML, particularly its SUMO-modified isoforms (Boutell et al., 2011; 
Everett et al., 1998a; Everett & Maul, 1994; Maul & Everett, 1994; Maul et al., 1993).  
PML is involved in host cell restriction of HSV-1 infection, and this can be counteracted 
by ICP0 inducing the degradation of PML, thereby lifting its repressive effects (Everett et 
al., 2006; Parkinson & Everett, 2000).  The effects of the RING finger mutations K144E 
and N151D on ICP0 localisation and degradation of PML were investigated using the 
inducible ICP0 expression system.   Initially, the RING finger mutants K144E and N151D 
were transferred into the pLKO.DCMV.TetO.cICP0 plasmid (Everett et al., 2009) (section 
2.2.3).  Inducible cell lines were established by transducing HA-TetR cells with lentivirus 
produced from pLKO.DCMV.TetO.cICP0 plasmids expressing wt or K144E and N151D 
mutants.   
 
Cells were treated with 0.1 µg/ml doxycycline for 24 hours to induce ICP0 expression, and 
the localisation of ICP0 and dispersal of PML were analysed by immunofluorescence 
(Figure 3.1).  The control HA-TetR cells showed no ICP0 expression after treatment with 
doxycycline, showing that ICP0 expression was specific to cells transduced with the ICP0 
lentivirus.  In these control cells, the PML remained in distinct foci that were distributed 
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throughout the nucleus.  In cells expressing wt or mutant forms of ICP0, the ICP0 was 
widely expressed in a high proportion of transduced cells and was both dispersed 
throughout the nucleoplasm and present in discrete foci.  In wt ICP0 expressing cells, the 
PML was almost completely dispersed, whereas in K144E and N151D expressing cells, 
although ICP0 was widely expressed at apparently higher levels than seen with wt ICP0, in 
most cells the PML remained in distinct foci that showed a high degree of colocalisation 
with ICP0.   
 
These results show that although the K144E and N151D mutant proteins are expressed at 
high levels and colocalise with PML, they induce its dispersal inefficiently.  These results 
confirm previous results using transfection assays that showed that the N151D and K144E 
mutant forms of ICP0 colocalise with PML at ND10 but fail to disperse PML (Everett et 
al., 1995), and also the more recent analysis of mutant N151D in the inducible cell line 
system (Vanni et al., 2012). 
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Figure 3.1 Analysis of ICP0 expression in wt and mutant HA-ICP0 cells and the 
dispersal of PML. 
HA-TetR, HA-cICP0 or cells expressing the RING finger mutants were treated for 24 
hours with doxycycline to induce ICP0 expression, and the ability of these proteins to 
colocalise with and disperse PML was analysed.  The cells were stained using rabbit anti-
PML polyclonal antibody and the mouse anti-ICP0 monoclonal antibody 11060.  EGFP 
autofluorescence from expression of the EGFP-linked tetracycline repressor protein is 
shown for all cells.  The images are representative of a large number of cells that were 
examined.   
 
 
 
3.2.2 The N151D and K144E RING finger mutant proteins are only 
slightly defective in complementation of the plaque 
formation defect of an ICP0-null mutant virus 
The plaque formation defect of an ICP0-null mutant virus can be complemented by the 
expression of ICP0 (Everett et al., 2004a).  The ICP0 inducible cell line can completely 
complement the plaque formation defect of an ICP0-null mutant virus (dl1403/CMVlacZ) 
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following wt ICP0 induction, whereas the RING finger deletion mutant does not 
complement this defect in PFE (Everett et al., 2009).  The ability of the N151D and K144E 
RING finger mutant protein to complement an ICP0-null mutant virus in comparison to wt 
ICP0 were investigated.   
 
Cells with or without doxycycline treatment to induce expression of wt or mutant ICP0 
were analysed by plaque assay following infection with wt (in1863) or ICP0-null mutant 
(dl1403/CMVlacZ) HSV-1 virus (Table 3.1, Figure 3.2).   Parental HA-TetR cells, which 
do not contain ICP0, were included as a control.  Relative PFEs were calculated in 
comparison to wt ICP0.  The wt virus had similar PFEs in all cell types without ICP0 
induction.  After ICP0 induction, wt ICP0 caused a slight (about 2-fold) increase in wt 
HSV-1 plaque formation, and all the mutants showed slight decreases in plaque numbers 
compared to wt ICP0, but this was always less than a two-fold difference.  Wt and mutant 
ICP0 cells without ICP0 induction showed comparable but very low plaque numbers 
following infection with the ICP0-null mutant virus (Table 3.1).  ICP0-null mutant virus 
plaque numbers increased by about 200-fold after induction of wt ICP0 expression 
compared to HA-TetR control cells.  The RING finger mutants N151D and K144E also 
increased dl1403/CMVlacZ plaque formation to levels about two-fold less efficient than wt 
ICP0 in this system.  In the absence of doxycycline induction, there was little difference in 
ICP0-null mutant virus plaque numbers between HA-TetR and wt ICP0 cells, and this was 
also the case for both ICP0 mutants.  The plaque assay data show that the ICP0 mutants 
analysed here are able to complement ICP0-null mutant HSV-1 plaque formation to levels 
within two-fold of the wt protein. This confirms the previous observation using mutant 
N151D (Vanni et al., 2012) and demonstrates that in this respect the nearby K144E mutant 
has a similar phenotype. 
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Table 3.1 Plaque count data in cells expressing N151D and K144E following infection 
with wt or ICP0-null mutant HSV-1 viruses. 
Cells were treated with doxycycline for 24 hours to induce ICP0 expression or left 
untreated.  The following day the cells were infected with sequential three-fold dilutions 
(dil) of wt (in1863) or ICP0-null mutant (dl1403CMV/lacZ) HSV-1 viruses.  The plaque 
counts at each dilution (tmtc – too many to count), the average plaque counts and the 
relative value of each cell type compared to wt ICP0 (HA-cICP0) are shown from two 
repeat experiments.    
 
A) Wt HSV-1 minus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc 124 59 32 58900000 71.8 90.1 
tmtc tmtc 100 31 86850000 108.4 
cICP0 10
-4
 tmtc 265 101 28 82000000 100.0 100.0 
tmtc tmtc 115 21 80100000 100.0 
cICP0. 
K144E 
10
-4
 tmtc 144 78 0 56700000 69.1 71.9 
tmtc tmtc 61 24 59850000 74.7 
cICP0. 
N151D 
10
-4
 tmtc 241 103 26 78400000 95.6 102.0 
tmtc tmtc 109 28 86850000 108.4 
 
 
 
B) Wt HSV-1 plus doxycycline (0.1 µg/ml) 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc 163 81 19 57700000 37.0 44.3 
tmtc tmtc 84 16 59400000 51.6 
cICP0 10
-4
 tmtc tmtc 179 56 156150000 100.0 100.0 
tmtc tmtc 118 46 115200000 100.0 
cICP0. 
K144E 
10
-4
 tmtc 161 63 0 52500000 33.6 64.1 
tmtc tmtc 116 42 108900000 94.5 
cICP0. 
N151D 
10
-4
 tmtc tmtc 149 31 108900000 69.7 81.0 
tmtc tmtc 119 39 106200000 92.2 
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C) ICP0-null mutant HSV-1 minus doxycycline  
 
Cells  
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 tmtc tmtc 357 22 1903500 89.8 122.5 
tmtc tmtc 176 22 1089000 155.1 
cICP0 10
-2
 tmtc tmtc 312 53 2119500 100.0 100.0 
tmtc tmtc 105 17 702000 100.0 
cICP0. 
K144E 
10
-2
 tmtc tmtc 64 15 490500 23.1 65.7 
tmtc tmtc 133 12 760500 108.3 
cICP0. 
N151D 
10
-2
 tmtc tmtc 236 23 1372500 64.8 96.2 
tmtc tmtc 136 21 895500 127.6 
 
 
D) ICP0-null mutant HSV-1 virus plus doxycycline (0.1 µg/ml) 
 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 tmtc tmtc 93 14 607500 0.5 0.5 
tmtc tmtc 184 25 1165500 0.6 
cICP0 10
-4
 tmtc tmtc 121 50 121950000 100.0 100.0 
tmtc tmtc 204 77 195750000 100.0 
cICP0. 
K144E 
10
-4
 tmtc 131 53 33 58700000 48.1 42.7 
tmtc 191 66 38 73100000 37.3 
cICP0. 
N151D 
10
-4
 tmtc 172 89 18 60100000 49.3 47.8 
tmtc 263 106 36 90500000 46.2 
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Figure 3.2 Plaque formation efficiency of cells expressing N151D and K144E 
following wt HSV-1 and ICP0-null mutant HSV-1 infection.  
The experiments for both the wt HSV-1 (in1863) and ICP0-null mutant (dl1403 
CMV/lacZ) HSV-1 were carried out with or without induction of ICP0 expression using 
doxycycline (0.1 µg/ml) for 24 hours before infection. Cells were infected with sequential 
three-fold dilutions of virus, then stained for β-galactosidase activity 24 hours later.  The 
graph from the data in Table 3.1 shows the average plaque forming abilities from two 
repeat experiments, expressed as a percentage of PFE in HA-cICP0 cells (expressing wt 
ICP0).  The error bars represent the higher and lower percentage values obtained from two 
repeat experiments.            
 
 
3.2.3 RING finger mutants are defective in inducing the 
reactivation of quiescent HSV-1 genomes 
One common characteristic of all herpesviruses is their ability to establish latency from 
which they can periodically reactivate.  ICP0-null mutant viruses that are unable to initiate 
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a lytic infection are maintained in a quiescent or latent state (reviewed in Efstathiou & 
Preston, 2005).  In in vitro quiescence models using non-neuronal cells, ICP0 can reverse 
the silencing of quiescent HSV genomes (Coleman et al., 2008; Ferenczy et al., 2011; 
Harris et al., 1989; Samaniego et al., 1998), and this has been shown to be dependent on 
the RING finger domain of ICP0 (Everett et al., 2009; Ferenczy et al., 2011).  In animal 
models, latent ICP0-null mutant viruses show inefficient reactivation (Cai et al., 1993; 
Halford & Schaffer, 2001).  However, there is some debate whether the defect in 
reactivation efficiency of ICP0-null mutant viruses is due to defects in ability to reactivate 
from latency or due to failure to enter productive lytic infections after reactivation 
(reviewed in Nicoll et al., 2012).   
 
One method to investigate the initiation of viral gene expression from quiescent genomes 
is a cell culture model system using in1374 virus (Preston & Nicholl, 2005).  The in1374 
virus cannot enter lytic replication under restrictive conditions as it contains a deletion of 
the ICP0 gene, a temperature-sensitive mutation within ICP4 and a mutation within VP16 
so that it is unable to stimulate IE gene transcription. Therefore, the in1374 virus 
establishes quiescence very efficiently (Preston & Nicholl, 2005).  The virus also contains 
a marker LacZ gene so that β-galactosidase expression can be analysed to investigate the 
derepression of the LacZ gene within the viral genome.   
 
Cells expressing wt or mutant ICP0 were infected with in1374 at the non-permissive 
temperature so that quiescence could be established, and ICP0 expression was induced by 
the addition of doxycycline the following day (Figure 3.3A).  Following induction with 
doxycycline, a large proportion of wt ICP0 cells expressed β-galactosidase from the LacZ 
gene (indicated by the blue colour), demonstrating reactivated viral gene transcription.  In 
contrast, the control HA-TetR and the HA-cICP0 cells before induction showed little or no 
LacZ gene transcription.  The N151D and K144E RING finger mutant proteins showed a 
substantially reduced proportion of cells expressing β-galactosidase compared to wt ICP0, 
indicating that reactivation of the quiescent genomes was relatively inefficient, particularly 
with K144E.       
 
The plate image data were quantified by taking two random fields of view of each well and 
counting the cells positive and negative for β-galactosidase expression.  The percentage of 
positive cells were calculated and the results presented as a proportion of cells expressing 
β-galactosidase as a percentage of that obtained through wt ICP0 expression (Figure 
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3.3B).  The results showed that there were very few β-galactosidase positive cells in HA-
cICP0 cells that had not been induced and also in the induced HA-TetR control cells, 
indicating that reactivation of gene expression from quiescent HSV-1 is ICP0-dependent.  
The RING finger N151D mutation and particularly the K144E mutation had a considerable 
defect in inducing viral gene expression in quiescently infected cells.  These results are in 
agreement with previous results showing that N151D had a substantial defect in inducing 
gene expression from quiescent viral genomes (Vanni et al., 2012).     
 
The results for the ICP0 mutants T67A and R8507 shown in Figure 3.3 are not relevant to 
the results presented in this chapter, but will be discussed later in chapter 6. It was 
necessary to present them here to avoid cropping the image of the plate. 
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Figure 3.3 Reactivation of viral gene expression by wt and mutant ICP0.   
A) HA-TetR, HA-cICP0 and RING finger mutant ICP0 cells (except the mock infected 
control wells) were infected with in1374 (MOI 5), and 24 hours later ICP0 expression was 
induced with doxycycline (0.1 µg/ml) as indicated.  The cells were stained for β-
galactosidase activity 24 hours later, where a blue colour indicated cells positive for 
reactivated viral gene transcription while negative cells gave a clear background.     
B) Quantification of the reactivation of gene expression by wt and mutant ICP0.  Two 
random fields of view of the cells infected with in1374 and induced with doxycycline were 
imaged from a single plate.  The cells positive and negative for reactivated gene expression 
were counted, and the percentage of positive cells for each cell type calculated which was 
then presented as a percentage of that in the HA-cICP0 cells expressing wt ICP0.  The bars 
show the mean result from the two fields of view, and the error bars represent the higher 
and lower percentages. 
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3.3 Analysis of the double mutant K144E/N151D (KE/ND) 
in the ICP0-inducible cell line 
3.3.1 Introducing both the K144E and N151D mutations into the 
same protein in the inducible cell line system 
The apparent differential effects between complementation of plaque formation of an 
ICP0-null mutant virus and reactivation of gene expression from quiescent viral genomes 
of the N151D and K144E mutants could be because these mutations affect a function that 
is preferentially required for reactivation. For example, stimulation of lytic infection 
involves activities on viral genomes immediately after their entry into the nucleoplasm 
while in an unchromatinised state.  In contrast, reactivation is thought to involve events on 
compacted, repressed chromatin. Thus, different mechanisms could be involved. 
Alternatively, it is possible that the mechanisms involved are similar, but that greater ICP0 
activity is required for reactivation than for complementation, perhaps because of the 
differences in viral chromatin structure.  It is likely that the N151D and K144E mutations 
affect the same ICP0 interface, and therefore the same inherent function.  These two 
mutations may disrupt a binding site of a cofactor that is involved in reactivation of latent 
HSV-1 through altering the surface charge of the alpha-helix.  To further investigate why 
these mutations caused a greater defect in reactivation of quiescent viral genomes 
compared to complementation, the double mutation K144E/N151D (KE/ND) was cloned 
into the pLKO.DCMV.TetO.cICP0 plasmid, and an inducible cell line expressing the 
double mutation KE/ND within ICP0 was created.  If the K144E and N151D mutations 
affect a function that is specific for reactivation, it would be expected that the double 
mutant KE/ND would be defective for this activity, while retaining significant 
complementation activity.  However, if these residues affect a function or binding interface 
that is required for both lytic infection and reactivation, but greater ICP0 activity is 
required for reactivation than complementation, then KE/ND might be expected to have a 
larger defect in the lytic replication assays than the individual mutants.  Therefore, the 
double mutant KE/ND was analysed alongside the single mutants K144E and N151D to 
analyse if the effect of these two mutations were additive.     
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3.3.2 Double mutant KE/ND fails to complement the plaque 
formation defect of an ICP0-null mutant HSV-1 
The ability of the double mutant KE/ND to complement an ICP0-null mutant HSV-1 
(dl1403/CMVlacZ) was analysed by plaque assay (Table 3.2, Figure 3.4).  In parallel, the 
ICP0 single mutant cell lines, as well as the HA-TetR control cells, with or without 
doxycycline induction, were examined as described previously (see section 3.2.2).  ICP0-
null mutant virus plaque numbers were increased by about 600-fold in this series of 
experiments after induction of wt ICP0 expression compared to HA-TetR control cells 
(Table 3.2).  Mutant N151D had a less than two fold decrease compared to wt 
complementation, whereas mutant K144E had more than a three-fold decrease compared to 
wt.  These results are similar to those of the earlier series of experiments (Figure 3.2). The 
double mutant KE/ND, however was highly defective in complementation, with over a 30-
fold decrease in plaque numbers compared to wt. Compared to the HA-TetR cells, the 
double mutant was not entirely negative and was able to increase the ICP0-null mutant 
virus plaque formation by 20-fold.  This is unlike the complete RING finger deletion 
mutant, however, which had no activity at all in this assay (Everett et al., 2009).  
Therefore, introducing both of these mutations within the ICP0 protein produces a major 
defect in complementation of an ICP0-null mutant virus, and a greater defect than the 
single mutations alone.   
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Table 3.2 Plaque count data in cells expressing KE/ND following infection with an 
ICP0-null mutant HSV-1 after induction with doxycycline. 
Cells were treated with doxycycline (0.1 µg/ml) for 24 hours to induce ICP0 expression 
and the following day infected with sequential three-fold dilutions of ICP0-null mutant 
(dl1403CMV/lacZ) HSV-1.  The starting dilution for the HA-TetR cells was 10
-2
, and 10
-4
 
in the other cell types.  The plaque counts at each dilution, the average plaque counts and 
the relative value of each cell type compared to wt ICP0 (HA-cICP0) are shown from three 
repeat experiments.    
 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 81 15 0 1 51000 0.1 0.1 
108 8 4 0 56000 0.2 
61 18 1 0 41333 0.1 
cICP0 10
-4
 324 137 65 18 45150000 100.0 100.0 
229 94 40 5 25150000 100.0 
239 120 52 17 38150000 100.0 
cICP0. 
K144E 
10
-4
 151 70 33 5 19825000 43.9 55.1 
149 53 19 7 16700000 66.4 
223 71 21 8 21025000 55.1 
cICP0. 
N151D 
10
-4
 90 18 6 7 9675000 21.4 29.7 
63 26 7 1 5775000 23.0 
150 61 21 6 17100000 44.8 
cICP0. 
KE/ND 
10
-4
 6 5 1 1 1425000 3.2 2.8 
11 2 1 0 866667 3.4 
7 2 0 0 650000 1.7 
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Figure 3.4 Effect of the RING finger mutations on ICP0-null mutant HSV-1 plaque 
formation.   
The ICP0 inducible cells were treated with 0.1 µg/ml doxycycline to induce ICP0 
expression and 24 hours later infected with sequential three-fold dilutions of ICP0-null 
mutant virus (dl1403/CMVlacZ).  The graph represents the data in Table 3.2, with the 
average plaque forming ability from three repeat experiments, and the PFE in each cell 
type is expressed as a percentage of that in HA-cICP0 cells that express wt ICP0.  The 
error bars represent the standard deviation from the three repeat experiments. 
 
 
 
 
 
3.3.3 Double mutant KE/ND is highly defective in inducing gene 
expression from quiescent viral genomes 
The ability of the double mutant KE/ND to reactivate gene expression from quiescent viral 
genomes was studied using in1374 virus (Figure 3.5), as described previously and using 
the same protocol (section 3.2.3).  As before, the reactivation efficiency was quantified by 
taking three random fields of view of each well of a cell culture plate and calculating the 
percentage of cells positive for reactivation as a proportion of wt ICP0.  The results with 
the single substitution mutants K144E and N151D confirm the results seen in section 
3.2.3, demonstrating that these mutations cause substantial defects in the induction of gene 
expression from quiescent viral genomes. The double mutant KE/ND was even more 
defective, producing only minimal numbers of positive cells that were less than 0.5% of wt 
ICP0 levels.   
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Figure 3.5 Reactivation of gene expression by wt ICP0 and the RING finger mutants. 
HA-TetR, HA-cICP0 and RING finger mutant ICP0 cells were infected with in1374 HSV-
1 mutant virus, and 24 hours later ICP0 expression was induced with doxycycline (0.1 
µg/ml).  The cells were stained for β-galactosidase activity 24 hours later.  Three random 
fields of view of each cell type induced with doxycycline were imaged from a single plate.  
The cells positive and negative for reactivated transcription were counted, and the 
percentage of positive cells for each cell type was calculated and plotted as a percentage of 
that in positive control HA-cICP0 cells.  The bars show the mean results from the three 
fields of view from a single plate, and the error bars represent the standard deviation.   
 
 
3.3.4 The RING finger mutants have a defect in PML degradation 
and express ICP0 to higher levels compared to wt in the 
inducible cell system 
Expression of wt and RING finger mutant ICP0 proteins and their effects on PML were 
analysed by Western blotting (Figure 3.6).  Expression of ICP0 occurred in all induced 
cells except the HA-TetR control cells.  The level of ICP0 expression was greatly 
increased in the RING finger mutants K144E, N151D and KE/ND compared to wt ICP0, 
and this cannot be attributed to loading differences (see actin).  The higher expression 
levels observed in the RING finger mutants were reproducible in a number of Western blot 
experiments.  In the HA-TetR control cells, and uninduced cells including HA-cICP0, 
there was no degradation of any of the PML isoforms.  After induction, all of the PML 
isoforms were degraded in wt ICP0 cells.  All the RING finger mutants showed some 
degradation of the SUMO modified and unmodified forms of PML, but all were less 
efficient than the wt in the degradation of PML, with the double mutant being the least 
efficient.  These results show that, despite the high expression levels of ICP0 and the 
extended time of expression, the RING finger mutants were defective in PML degradation, 
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despite colocalising with PML in ND10 (Figure 3.1). The reduced efficiency of PML 
degradation as detected by Western blot correlates with less effective disruption of ND10 
detected by immunofluorescence analysis of the single mutants (section 3.2.1).   
 
The ICP0 RING finger possesses E3 ligase activity and can induce its own auto-
ubiquitination (Boutell et al., 2002; Canning et al., 2004).  Auto-ubiquitination of ICP0 
makes it less stable, and ICP0 is stabilised by interacting with USP7, a deubiquitinating 
enzyme (Everett et al., 1999b).  It is unlikely that the RING finger mutants affect the 
interaction with USP7, as the USP7 binding motif is located in the C-terminal third of 
ICP0 (Meredith et al., 1995; Meredith et al., 1994)  (within residues 618-634 (Everett et 
al., 1999b)), whereas the RING finger domain is located in the N-terminal third.  The auto-
ubiquitination activity may be disrupted in these RING finger mutants, which could 
explain why they express higher levels of ICP0.  
 
 
Figure 3.6 Western blot analysis of the degradation of different PML and SUMO 
isoforms by wt and mutant forms of ICP0.   
HA-TetR, HA-cICP0 and RING finger mutant ICP0 cells were induced with doxycycline 
(0.1µg/ml) for 24 hours or left untreated.  PML and ICP0 were detected using the mouse 
monoclonal antibodies 5E10 and 11060, respectively.  Actin was used as a loading control 
and was detected using the mouse monoclonal antibody AC-40.   
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3.4 Conclusion and Discussion 
Previous work using the ICP0 inducible expression system showed that mutant N151D had 
a much greater defect in reactivation of quiescent HSV-1 compared to complementation of 
an ICP0-null mutant virus (Vanni et al., 2012).  In addition to N151D, this chapter includes 
analysis of another single mutation within ICP0, K144E, with both these residues located 
in the polar side chains exposed by the alpha-helix.  These single ICP0 mutations were 
analysed in the inducible ICP0 expression system for their ability to complement the 
plaque formation defect of an ICP0-null mutant virus and to induce the reactivation of 
quiescent HSV-1 as well as their effect on the major ND10 protein PML.  The results 
obtained here for the N151D mutant confirmed those seen in Vanni et al. (2012), that 
N151D had less than a two-fold defect when complementing the plaque formation 
efficiency of an ICP0-null mutant virus but had less than 20% of wt levels for reactivation 
of quiescent HSV-1.  The effect with K144E was even more marked, with this mutant 
having only a three-fold decrease in complementation efficiency compared to wt, but less 
than 5% reactivation of quiescent HSV-1 compared to wt ICP0 expressing cells.       
 
The N151D and K144E mutant proteins colocalised with PML, but did not induce ND10 
disruption efficiently (Figure 3.1 and Figure 3.6).  PML is involved in the intrinsic 
resistance to HSV-1 infection, and its expression is enhanced by interferon (Chelbi-Alix et 
al., 1995).  Depletion of PML increases the replication of ICP0-null mutant HSV-1 
(Cuchet et al., 2011; Everett et al., 2006).  Therefore, the inability of the RING finger 
mutants to degrade PML could lead to increased repression of the viral genome and a 
reduced ability to reactivate from latency.   It is known that ICP0 is important for the 
reactivation of quiescent genomes (Leib et al., 1989), but other viral or cellular factors may 
also play a role.  Therefore, these two mutations may disrupt a binding site of a cofactor 
that is involved in the reactivation of latent HSV-1 through altering the surface charge of 
the alpha-helix. 
 
To investigate the differences between the ICP0 mutants with regard to complementation 
and reactivation, ICP0 containing both the K144E and N151D mutations was expressed in 
the inducible cell line system.  The results showed the double mutant had severe defects in 
both complementation and reactivation with levels less than 5% of wt levels for both 
(Figure 3.4 and Figure 3.5). The double mutant was also more defective for PML 
degradation.  Therefore, since the double mutant is defective for both complementation and 
reactivation, the results suggest that these mutations do not affect a function that is specific 
116 
 
for reactivation alone.  These mutations could affect the surface charge, binding site or 
function that is required for ICP0 activity in general, but greater activity from ICP0 is 
required for reactivation rather than complementation during lytic infection.  In this 
hypothesis, the single mutants retain sufficient activity for complementation but this level 
of activity is not enough for efficient reactivation, whereas in the double mutant the 
function of the alpha-helix is reduced to an extent that then produces a more severe 
phenotype in the complementation assays.  
 
The inducible ICP0 expression system used for the experiments in this chapter is a 
valuable tool for studying ICP0 mutants.  However, the system does have some limitations, 
such as the level of expression of ICP0 cannot be tightly controlled, the time course of 
ICP0 expression is different from that during viral infection, and ICP0 does not accumulate 
to the levels seen during a normal infection.  Lowering the concentration of doxycycline 
could reduce ICP0 expression, but this may result in a reduction in the percentage of cells 
expressing ICP0, and increasing the concentration of doxycycline does not lead to higher 
ICP0 expression.  The experiments using the inducible cell line are limited by the cell type, 
as they are all based on HA-TetR cells which are derivatives of HepaRG cells.  HepaRG 
cells are highly restrictive, with ICP0-null mutant viruses having a 500-fold defect 
(Everett, 2010; Everett et al., 2009), but these are not the normal epithelial cells that HSV-
1 would infect.  For the experiments in this study, cells were induced for 24 hours with 
doxycycline to induce ICP0 expression to ensure that over 90% of cells were positive for 
ICP0 expression.  Therefore, the inducible cell line has different kinetics from natural virus 
infection.  For these reasons, it was also valuable to study the effects of these mutations in 
the context of the viral genome, as described in the following chapter. 
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4 Results - Study of ICP0 RING finger alpha-helix 
mutants in the context of the viral genome 
4.1 Introduction  
The results using the inducible ICP0 expression system in Chapter 3 found that mutations 
in the alpha-helix of ICP0’s RING finger domain (N151D and K144E) had two- to three-
fold defects in the complementation efficiency of ICP0-null mutant HSV-1 compared to wt 
ICP0, and had more pronounced defects in reactivation of quiescent HSV-1.  Due to 
certain limitations of the inducible cell line system, described in section 3.4, including 
extended expression times during the experiments, limited cell types and lack of control 
over expression kinetics, it was also important to study the effects of these mutations in the 
context of mutant virus infection.  The inducible cell system allows the properties of ICP0 
to be studied without the complications of virus infection, while virus studies are valuable 
as they are more realistic than the inducible cell line as all viral proteins are present, and 
primary cells such as human fibroblasts (HFs) can be used.   
 
This chapter investigates the phenotype of the RING finger mutants K144E and N151D 
during the context of viral infection.  For these experiments, mutant viruses W146A and 
Q148E were analysed as controls in parallel to the K144E and N151D mutant viruses.  
Like K144E and N151D, mutations W146A and Q148E are also located in the RING 
finger alpha-helix, but these have been previously characterised and found to cause no 
serious defects (Boutell et al., 2002; Everett et al., 1995; Everett, 2000; Vanni et al., 2012).  
Since the time of the original virus infection studies, the assays and available approaches 
for studying ICP0-null mutant viruses have improved and expanded considerably, thus 
justifying a reinvestigation of the RING finger alpha-helix mutant viruses in more detail. 
The deletion mutant FXE was used as the negative control throughout.  FXE contains a 
deletion of amino acid residues 106-149 (Everett, 1989), which includes a large proportion 
of the RING finger domain of ICP0 (amino acid residues 116-156) (Barlow et al., 1994).  
The experiments in this chapter were carried out in HFs and human hepatocellular 
HepaRG cells.  Both cell types require ICP0 for efficient HSV-1 replication, but HFs are 
the more restrictive cell type (Everett, 2010; Everett et al., 2004a; Everett et al., 2009).   
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4.2 Results 
4.2.1 Plaque formation efficiencies of ICP0 mutant viruses 
The defect in plaque formation efficiency of an ICP0 mutant virus is cell type dependent.  
HFs are one of the most restrictive cell types with an ICP0-null mutant virus having a 
1000-fold defect compared to wt HSV-1 (Everett et al., 2004a), whereas in HepaRG cells 
the defect is 500-fold (Everett, 2010; Everett et al., 2009).  However, in the osteosarcoma 
cell line U2OS, an ICP0 null mutant virus replicates as efficiently as wt virus, meaning that 
ICP0 is not required for HSV-1 replication in this cell type (Yao & Schaffer, 1995).  
Therefore, titres in U2OS cells provide a true measure of potentially infectious virus 
without the complication of the ICP0 defect. Therefore in all experiments in this thesis, the 
titres of all virus stocks were determined in U2OS cells, and these values were used to 
calculate input multiplicities for all infected cell types. 
 
Plaque assays were conducted in HepaRG cells and HFs, to take into account the 
differences in restriction of the different cell types.  Cells were infected with sequential 
ten-fold dilutions of wt or ICP0 mutant viruses over a range such that plaques formed and 
could be easily counted. The dilution range was adjusted for each virus according to its 
phenotype.  The cells were overlaid with medium containing human serum that contained 
antibodies to HSV-1, to prevent cell-free virus infecting neighbouring cells and allowing 
plaques to form by cell to cell spread.  Plaques that formed in HepaRG cells and HFs were 
calculated as a ratio of those produced in U2OS cells, and normalised to the percentage of 
plaque forming ratio of the wt virus (Figure 4.1).   
 
The results show that the positive control mutants W146A and Q148E produced more 
plaques than wt virus in HFs but had comparable PFEs to the wt virus in HepaRG cells.  
The N151D virus was about 20% as effective as wt virus, with HFs being the more 
restrictive cell type. Mutant K144E had a 30-fold defect in plaque forming ability 
compared to wt in HepaRG cells, and was almost as defective as the FXE deletion mutant 
in HFs. These results broadly follow the trend of the ICP0 inducible cell lines presented in 
the previous chapter (chapter 3), except that the defects caused by mutations N151D and 
especially K144E were more marked in this lytic replication virus infectivity assay.       
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Figure 4.1 PFEs of ICP0 mutant viruses in HF and HepaRG cells.  
Plaque assays were conducted in cells infected with wt HSV-1 or ICP0 mutant viruses. The 
average PFE of each virus in HF and HepaRG cells were calculated as a ratio of plaques 
formed in U2OS cells and presented as a percentage of the wt value. The error bars 
represent the higher and lower percentages obtained from two repeats. 
 
 
4.2.2 Investigation of the yields of RING finger mutant viruses in 
single step growth experiments in HFs and HepaRG cells 
In addition to cell type, input multiplicity can also influence the apparent phenotype of 
ICP0 mutant viruses.  At low MOI in restrictive cell types, mutant viruses have a high 
probability of entering a latent or quiescent infection, whereas above a certain input 
multiplicity ICP0 null mutant viruses replicate as efficiently as wt HSV-1 (Everett et al., 
2004a).  Therefore, the yields of ICP0 mutant viruses were investigated at a range of input 
multiplicities from 0.1 to 0.001.  HFs and HepaRG cells were infected at input 
multiplicities of 0.1, 0.01 or 0.001, and assayed for the presence of new progeny virus 24 
hours later by titration on U2OS cells (Figure 4.2). Viral yield assays take into account 
any difference in plaque sizes that are not immediately apparent by plaque assays.  
 
At the higher MOI of 0.1, mutants Q148E, W146A and K144E produced similar yields of 
infectious virus in both cell types and were comparable to that of the wt.  Mutants N151D 
and FXE showed a decrease in viral yields compared to wt and the other mutants, but this 
decrease was less than 10-fold.  At MOI 0.01, Q148E and W146A mutant viruses still 
replicated as efficiently as the wt virus, with similar yields of infectious virus produced and 
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this remained the case even at the lower MOI of 0.001.  In N151D infected cells the viral 
yield dropped around 30-fold in the two cell types as the MOI was reduced from 0.1 to 
MOI 0.001. FXE and K144E infected cells showed a two orders of magnitude decrease in 
viral yield in HepaRG cells and three to four order of magnitude decrease in HFs when 
comparing infections at MOI 0.1 and MOI 0.01, and the viral yields at MOI 0.001 were 
very substantially reduced from the wt yields at MOI 0.001.  
 
The results showed that at high viral inputs the mutant viruses replicated as efficiently as 
wt with similar yields of virus produced in both cell types. However at low MOIs the 
effects of the RING finger mutations can be observed, with K144E and FXE giving lowest 
yields of infectious virus.  
 
 
 
 
Figure 4.2 Viral yield assays of ICP0 mutant viruses in HepaRG cells and HFs using a 
range of MOIs.   
Cells were infected using a range of MOIs (0.1, 0.01 and 0.001) and overlaid with medium 
(inoculum not washed off), then 24 hours later the cells and supernatants were harvested, 
sonicated and titrated on U2OS cells as sequential ten-fold dilutions to calculate PFEs. The 
error bars represent the higher and lower values obtained from two repeat experiments. 
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4.2.3 Effects of ICP0 mutant viruses on PML 
Use of the inducible ICP0 expression system demonstrated that N151D and K144E 
colocalised with PML and showed some degradation of the SUMO-modified and 
unmodified forms of PML, but were less active at degrading PML than wt, despite 
expressing ICP0 to greater levels than wt (sections 3.2.1 and 3.3.4).  The ability of the 
RING finger mutants to colocalise with and degrade PML was investigated in the context 
of viral infections.  These experiments were done at high MOI to ensure that all cells were 
infected. 
 
HFs and HepaRG cells were infected with wt or mutant ICP0 viruses at an MOI of 10, and 
the cells were harvested at two, four and six hours post infection (Figure 4.3).  ICP0 was 
expressed at increasing amounts in each virus as the infection progresses, with the levels 
comparable between all viruses. There was no increased expression of the RING finger 
mutant ICP0 proteins relative to wt, in contrast to what was observed in the inducible cell 
line experiments (Figure 3.6).  In the wt infected cells, all PML isoforms were degraded 
by two hours after infection of HepaRG cells, and this was slightly delayed to four hours in 
HFs.  Virus Q148E degraded PML at similar rates to wt, with the majority of PML being 
degraded by two hours post infection.  Mutant N151D had a slight delay in degrading PML 
in HepaRG cells compared to wt, with the majority of PML isoforms being degraded by 
four hours post infection.  In HFs, however, there was only minimal degradation of PML 
by the six hour time-point in N151D infected cells.  Mutant K144E caused slight 
degradation of PML by six hours post infection in HepaRG cells, but there was minimal 
degradation of PML in HFs at this time point.  FXE did not degrade any of the PML 
isoforms by six hours post infection in either of the cell types.    
 
For the immunofluorescence analysis, cells were infected at MOI 5 and stained two or four 
hours post infection (Figure 4.4). The results show that at both two and four hours post 
infection, in cells infected with wt virus the majority of ND10 were disrupted and the 
signal dispersed, and this also occurred in W146A and Q148E infected cells. In contrast, 
mutant viruses K144E, N151D and FXE were unable to disrupt PML, but instead ICP0 and 
PML colocalised in distinct foci under these experimental conditions.  
 
The Western blot and immunofluorescence data confirm the previous results obtained 
using the inducible cell lines (Figure 3.1, Figure 3.6). In HFs infected with mutant viruses 
K144E and N151D, ICP0 colocalised with PML, but did not induce the dispersal or 
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efficient degradation of PML. In HepaRG cells, which are less restrictive, mutant N151D 
induced the degradation of all PML isoforms, but this was slightly delayed compared to wt 
infection. 
 
 
 
 
 
Figure 4.3 Western blot analysis of the degradation of different PML isoforms during 
infection with wt and mutant viruses.  
HFs (A) or HepaRG (B) cells were infected with wt or ICP0 mutant viruses at MOI of 10 
or left uninfected (MI mock infection) and harvested at 2, 4 and 6 hours post infection in 
SDS gel loading buffer. The proteins were resolved on a 7.5% gel and then transferred to a 
nitrocellulose membrane and detected by probing for PML, ICP0 and tubulin.  
 
 
 
 
 
 
 
A 
B 
123 
 
 
Figure 4.4 Analysis of ICP0 expression in wt and ICP0 mutant virus infected HFs and 
the dispersal of PML.  
HFs were infected at MOI 5 with wt and ICP0 mutant virus and at (A) 2 hours and (B) 4 
hours post infection cells were fixed.  The cells were stained using rabbit anti-PML 
polyclonal antibody (red) and the mouse anti-ICP0 monoclonal antibody 11060 (green). 
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4.2.4 Reactivation/derepression of quiescent HSV-1 genomes 
The reactivation (or more properly the derepression) of viral gene expression was 
investigated using the in1374 virus that establishes quiescence very effectively (described 
in detail in section 3.2.3).  HepaRG cells were infected with in1374 (MOI 5) at non-
permissive temperature, followed by infection with wt or ICP0 mutant viruses (MOI 5) the 
next day (Figure 4.5).  In the absence of the second infection, all gene expression from 
in1374 was efficiently repressed. The reactivation of viral gene expression was measured 
by expression of β-galactosidase from the LacZ marker gene.  The plate image in Figure 
4.5A shows that a large proportion of in1374 and wt co-infected cells expressed β-
galactosidase from the lacZ gene, indicating reactivated transcription of the in1374 virus, 
whereas this appeared inefficient in the RING finger mutant co-infections.  This 
experiment was quantified by counting the cells positive for β-galactosidase expression out 
of the total cell population and expressing this as a percentage of the proportion of positive 
wt co-infected cells (Figure 4.5B).  This quantification showed that viruses containing 
mutations N151D and K144E caused significant defects in the efficiency of reactivation, 
with less than 10% of wt levels, however they have higher levels of reactivation than FXE.  
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Figure 4.5 Reactivation of in1374 viral gene expression by ICP0 RING finger 
mutants.   
(A) HepaRG cells (except the mock) were infected with in1374 at MOI 5, and 24 hours 
later super-infected with wt or mutant viruses (MOI 5).  After virus adsorption, the cells 
were overlaid with medium containing 10 µM ACV and 1% human serum.  The cells were 
stained for β-galactosidase activity 24 hours later, where a blue colour indicated cells 
positive for reactivated transcription while negative cells gave a clear background.  
(B) Quantification of the reactivation of gene expression by wt and mutant ICP0 viruses 
shown in A, a single plate was analysed. Three random fields of view of the cells were 
imaged. The cells positive and negative for reactivated transcription were counted, and the 
percentage of positive cells for each virus calculated which was then plotted as a 
percentage of wt virus. The bars show the mean result from the three fields of view and the 
error bars represent the standard deviations. 
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Reactivation of gene expression in quiescent in1374 genomes was also investigated by 
immunofluorescence in parallel to the method described above.  Cells treated as described 
above were stained for β-galactosidase and ICP0 proteins (Figure 4.6).  This approach 
allowed calculation of the proportion of ICP0 positive cells in which β-galactosidase was 
expressed (Figure 4.6B), thus overcoming uncertainties about the proportions of doubly 
infected cells inherent in the assays of Figure 4.5. The results were expressed as a 
percentage of the wt reactivation levels as described above.  The reactivation efficiency of 
FXE compared to wt was 9%, whereas K144E and N151D infected cells had 10% and 17% 
of the reactivation levels seen in wt.  These results gave higher reactivation efficiency for 
the RING finger mutants compared to the results in Figure 4.5b. The immunofluorescence 
method for detecting reactivation appears to be a more sensitive method of detecting cells 
with reactivated gene expression compared to counting cells for β-galactosidase expression 
out of the total cell population, as the reactivated cells are calculated as a percentage of 
cells that are also expressing ICP0.   The differences between the two assays for detecting 
reactivated gene expression highlight the importance of threshold of detection in the two 
different assays.    
 
The fact that some reactivation is detectable in cells super-infected with the FXE mutant is 
initially surprising on the basis of most of the previously published analysis (Harris et al., 
1989; Harris & Preston, 1991; Minaker et al., 2005; Russell et al., 1987). However, when 
examined in great detail, some reactivating cells are detectable even in cells infected with 
an ICP0 deletion mutant (Preston, 2007). The great sensitivity of the immunofluorescence 
staining method may be revealing this ICP0-independent derepression. Nonetheless, the 
results are basically similar to those in Figure 4.5; with the mutant K144E a little more 
active than FXE in this assay, and N151D retaining higher levels of activity. 
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Figure 4.6 Immunofluorescence analysis of the reactivation of in1374 gene expression 
by wt and mutant ICP0 virus.  
(A) Coverslips were treated the same way as the cells in the reactivation experiment 
(Figure 4.5) and fixed and permeabilised 24 hours after infection with wt and mutant ICP0 
virus. The coverslips were stained for ICP0 (red) and β-galactosidase (green), with cells 
positive for β-galactosidase indicating reactivated viral gene expression.   
(B) Quantification of cells on a single coverslip in (A) displaying reactivated gene 
expression compared to those expressing ICP0. Three random fields of view of cells 
infected with in1374 and wt or mutant ICP0 viruses were imaged. The cells expressing β-
galactosidase were counted and calculated as a percentage of those positive for ICP0 
expression, and the results shown as a percentage of the wt super-infected sample. The 
error bars represent the standard deviation obtained from three images. 
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4.3 Analysis of K144E/N151D double mutant virus 
infection  
4.3.1 Construction of a recombinant virus which expresses ICP0 
with both K144E and N151D mutations 
Section 4.2.2 showed that at high input MOIs mutant viruses K144E and N151D replicated 
as efficiently as wt, but that at low MOIs these mutant viruses gave lower yields of 
infectious virus, particularly the K144E mutant, which had only slightly higher yields than 
FXE.  Both mutant ICP0 proteins localised to ND10 but did not induce its dispersal 
efficiently, and K144E in particular showed delays in the rate of degradation of PML 
compared to wt infection.  In addition, mutants K144E and N151D both had substantial 
defects on the efficiency of reactivation of quiescent HSV-1 genomes.   
 
While the results of the previous chapter confirmed and extended those of Vanni et al. 
(Vanni et al., 2012), which suggested that it was possible to separate the activities of ICP0 
during lytic infection and reactivation/derepression, the results using the virus mutants 
showed a greater correlation between relative defects in plaque formation and reactivation. 
As explained in Chapter 3, a cell line expressing ICP0 with both these mutations was 
constructed to test whether the RING finger alpha-helix had a specific function in 
reactivation. The results showed that ICP0 containing both the K144E and N151D 
mutations had severe defects in both complementation of an ICP0-null mutant virus and 
reactivation of quiescent viral genomes, with less than 5% of wt ICP0 activity.  The 
KE/ND results suggest that lytic infection and reactivation from quiescence do not affect 
an ICP0 function specific for reactivation, and the differences observed with the single 
substitution mutants may reflect a requirement for stronger ICP0 activity during 
reactivation.  Therefore, to further analyse how these mutations affect ICP0’s functions, 
and to determine if this was also the case in virus infection when other viral proteins are 
present, a virus containing both mutations was constructed.   
 
The K144E and N151D double mutant (KE/ND) virus was constructed by transfecting 
cells with infectious dl1403 DNA, which contains a large deletion of the ICP0 gene (Stow 
& Stow, 1986), and a fragment of an ICP0 plasmid containing the complete ICP0 gene 
(including promoter, introns and 3’ untranslated region) with both the K144E and N151D 
mutations (section 2.6).  The ICP0 region containing the mutations recombined with the 
dl1403 DNA by homologous recombination.  The virus stock produced from the 
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transfected cells was passaged on HFs to enrich for the presence of ICP0, the resulting 
virus populations were plaque purified, and single plaques were screened for the presence 
of ICP0 by Western blotting.  After three rounds of plaque purification, the viral DNA of 
the final isolate was directly sequenced and was confirmed to have the desired KE/ND 
mutation. The initial passaging of the virus mixtures on HFs enriches for viruses having 
some ICP0 function, an approach which works very efficiently for those with wt activity, 
but which is less effective for mutants with only residual function, as in this case. 
Therefore it was necessary to screen a large number of plaques before the required isolate 
was identified. 
 
The following sections describe the use of this double point mutant virus in the same 
assays used to investigate the single point mutants described previously. For comparison 
purposes, it was necessary to include the single point mutant viruses as controls in these 
experiments. Therefore some of the data below replicate data presented previously, in 
some cases illustrating differences in detail that often occur in the analysis of ICP0 mutant 
viruses due to technical aspects of their phenotype. 
 
 
4.3.2 Mutant K144E and double mutant KE/ND have significant 
defects on plaque forming ability compared to wt HSV-1, 
especially in HFs.  
To analyse the PFE of the double mutant KE/ND virus, plaque assays were conducted in 
HepaRG cells and HFs as described previously in section 4.2.1.  Results were calculated as 
a ratio of plaques formed on U2OS cells and displayed as PFEs as a percentage of the ratio 
observed with wt virus (Figure 4.7).  In this series of experiments, the PFEs of the positive 
control viruses Q148E and W146A viruses were lower than wt, but this was not considered 
significant as it was less than a two-fold reduction.  These results differ slightly from those 
of the earlier series of experiments (Figure 4.1), but not in a way that affects the 
interpretation; differences of this magnitude in plaque assays are within normal 
experimental variation. In this series of experiments, mutant N151D plaque formation was 
reduced by three-fold compared to wt virus, whereas mutant K144E and the double mutant 
KE/ND had reduced plaque forming ability compared to wt by at least three orders of 
magnitude, a defect comparable to that of the RING finger deletion mutant FXE, with HFs 
producing fewer plaques than HepaRG cells.       
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Of note, mutant N151D had a higher PFE in this series of experiments (HepaRG cells 
32%, HFs 25%) compared to the plaque assays in section 4.2.1, in which its plaque 
formation activity was reduced to a greater extent (HepaRG cells 17%, HFs 5%).  These 
differences illustrate some of the difficulties of handling ICP0 mutant virus data, and in 
this case the final percentages depend on four different titration values for each mutant 
(titres of wt and mutant virus in the cells in question and U2OS cells).  Even with replicate 
experiments, the usual variations in plaque assay data could explain the two-fold difference 
in HepaRG cell data between the two series of experiments with mutant N151D.  Plaque 
assay data are even more variable in HFs due to the lack of linearity of plaque numbers 
with respect to dilution of ICP0-defective viruses (Everett et al., 2004a). Therefore 
comparison between the absolute data for a given virus between different series of 
experiments is liable to variation, especially with the more defective viruses. Comparisons 
between different viruses within the same series of experiments are generally more 
reliable, at least in terms of indicating relative defects.  
 
 
 
Figure 4.7 Plaque formation efficiencies of ICP0 mutant viruses in HepaRG cells and 
HFs.   
Cells were infected with sequential ten-fold dilutions of wt or ICP0 mutant HSV-1. After 
adsorption, the cells were overlaid with medium containing human serum.  The average 
PFE of each virus in both cell types was calculated as a ratio of plaques formed in U2OS 
cells and presented as a percentage of wt PFE ratio.  The error bars represent the standard 
deviation obtained from three repeat experiments.   
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4.3.3 Mutants K144E and KE/ND give lower yields of infectious 
virus 
Section 4.2.2, Figure 4.2 showed that the phenotype of the ICP0 alpha-helix mutants was 
most prominent in low multiplicity infections.  Therefore, the yields of RING finger 
mutant viruses were investigated at MOI 0.01 and 0.001, in both HepaRG cells and HFs.  
At the lower MOI of 0.001, KE/ND and FXE failed to produce any infectious virus that 
could be counted on the titration plates, so this MOI was at the limit of detection for some 
of the mutants.  Therefore, viral yield assays were carried out at MOI 0.01 only, infecting 
cells and titrating the virus produced after 24 hours on U2OS cells to calculate PFEs 
(Figure 4.8).  As with the experiments presented at the beginning of this chapter, the 
W146A and Q148E mutant viruses were used as positive controls and were analysed 
alongside the double mutant KE/ND and single point mutants K144E and N151D.    
 
As before, mutant viruses Q148E and W146A replicated as efficiently as wt with similar 
yields of infectious virus in both cell types.  Mutant N151D showed lower viral yields in 
HepaRG cells and HFs compared to wt, but the defect was less than 5-fold (which is again 
a lesser defect than the corresponding results in the previous experiment of Figure 4.2).  
The yields of mutant viruses K144E and KE/ND were reduced by two orders of magnitude 
compared to wt in HepaRG cells.  Within HFs, the reduction with K144E and N151D was 
three to four orders of magnitude, with KE/ND having viral titres only slightly above the 
input virus used for the experiment.   
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Figure 4.8 Viral yield assays of ICP0 mutant viruses in HepaRG cells and HFs at 
MOI 0.01. 
HepaRG cells and HFs were infected at MOI 0.01, then 24 hours later the cells and 
supernatant were harvested, sonicated and titrated on U2OS cells as ten-fold dilutions to 
calculate PFEs.  The error bars represent the standard deviation obtained from three repeat 
experiments (two repeats in the case of KE/ND and FXE, and the lower error bar 
representing the lowest detectable plaque number).  The line on the graph at 10
3
 represents 
the amount of input virus.   
 
 
4.3.4 Virus mutants K144E and KE/ND colocalise with PML but 
have reduced abilities to degrade it   
To investigate the effect of the RING finger mutants on ND10 proteins, the colocalisation 
of these proteins with ND10 protein component PML was investigated, as well as the rate 
of PML degradation.  These experiments were carried out at a high MOI of 5 or 10 to 
ensure that all the cells were infected and therefore that comparisons of rates of protein 
degradation could be properly compared.  The rate of degradation of PML was investigated 
over a time course of infection with samples harvested at 2, 4, 6 and 8 hours (Figure 4.9).  
In HepaRG cells (Figure 4.9A) infected with wt HSV-1, the majority of PML was 
degraded by two hours post infection, with only minimal amounts of unmodified PML 
remaining.  This was also the case for the N151D mutant infected cells.  In mutant K144E 
infected HepaRG cells, the majority of sumoylated PML was degraded by six hours post 
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infection, whereas in KE/ND infected cells there was no detectable PML degradation by 
the eight hour time-point, as was the case with FXE.  The results with the single mutants 
here are consistent with those of Figure 4.3. 
 
The rate of degradation of PML in HFs (Figure 4.9B) was delayed compared to HepaRG 
infected cells.  Mutants K144E and KE/ND showed greatly reduced abilities to degrade 
PML in HFs, giving results that were comparable to the FXE deletion mutant.  PML 
degradation was delayed in N151D infected cells compared to wt infection, with the 
majority of PML isoforms degraded at six hours post infection as opposed to four hours in 
wt infected cells.  The differences observed in the rate of degradation of PML in both cell 
types is not related to the amount of ICP0 expressed, as all of the mutants had similar 
levels of expression of ICP0 as wt at each time-point. There is a clear correlation between 
the efficiencies of plaque formation, replication and the rate of PML degradation in HFs of 
the single and double mutant viruses. 
 
During lytic infection, gene expression proceeds in a temporally regulated cascade that can 
be divided into three phases; IE, early and late.  Gene expression of each class of genes 
was analysed at the same time as PML degradation at MOI 5 (Figure 4.9).  However, at 
such a high MOI the potential deleterious effects of the ICP0 mutations on viral gene 
expression would be at least partially marked.  In HepaRG infected cells (Figure 4.9A), 
the expression of the early protein UL42, a DNA replication accessory protein, showed 
only a slight decrease in expression in the RING finger mutants compared to wt at this 
MOI, but expression in FXE infected cells was delayed.  The late capsid protein VP5 
expression was slightly delayed in N151D and K144E infected cells, with more of a delay 
occurring in KE/ND and FXE infected cells.  In HFs (Figure 4.9B), UL42 expression was 
delayed in the RING finger mutant virus infections, and this was more pronounced in 
K144E and KE/ND infected cells.  Late gene expression was slightly lower in N151D 
infected cells compared to wt, but expression levels showed a considerable delay in K144E 
and KE/ND infected cells and were comparable to FXE.    
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Figure 4.9 The degradation of PML isoforms and viral gene expression during 
infection by wt ICP0 and mutant viruses in HepaRG cells and HFs.  
HepaRG cells (A) and HFs (B) were infected with wt or mutant viruses at MOI of 5 and 
harvested at 2, 4, 6 and 8 hours post infection.  The proteins were resolved on a 7.5% SDS 
gel, transferred to a nitrocellulose membrane and detected by probing for PML, ICP0, 
UL42, and VP5 representing IE, early and late classes of viral proteins.   
 
 
The effects of the alpha-helix mutations on the localisation and dispersal of PML were 
investigated by immunofluorescence (Figure 4.10).  HFs were infected at MOI 10, and the 
localisation of PML was analysed at two and four hours post infection by staining for PML 
and ICP0.  As expected, the results showed that in uninfected cells the PML was in distinct 
nuclear foci, whereas in wt infected cells by two hours post infection the PML had been 
dispersed. In mutant N151D infected cells at two hours post infection the majority of PML 
A 
B 
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had been dispersed but in a minority of cells (about 10%) the PML remained in distinct 
foci that showed colocalisation with ICP0.  By the four hour time-point however, in all 
N151D infected cells the PML had been dispersed.  In K144E and KE/ND infected cells, 
the PML remained in distinct foci that colocalised with ICP0, and these mutants behaved 
like FXE at two and four hours post infection.  These results correlate with the relative 
rates of PML degradation as assayed by western blotting.    
 
The immunofluorescence of cells infected with mutant N151D at MOI 10 showed that in 
the majority of cells the PML is dispersed by two hours post infection and is dispersed in 
all cells by four hours post infection.  This result is different to that of the experiment done 
at MOI 5 (Figure 4.4), which showed by four hours post infection N151D mutant ICP0 
showed colocalisation with PML and did not induce its dispersal. At the higher MOI, 
N151D is more likely to initiate lytic infection more efficiently, thereby producing more 
ICP0 and inducing the degradation of PML more quickly than at the lower MOI.   This is 
consistent with the increased rate of PML degradation induced by the N151D mutant virus 
in these later experiments (compare Figures 4.3 and Figure 4.9). However, it is also true 
that plaque formation and replication of the N151D mutant stock used in these experiments 
were more efficient in these later experiments. These apparent inconsistencies probably 
reflect the inherent difficulties of working with ICP0 mutant viruses, as the results are very 
sensitive to input MOI, which is dependent on accuracy of the stock titres, which in turn 
may vary enough to affect the detail of experimental outcomes due to factors such as the 
relative status of the cells when the titres were determined.   
 
The infection experiments carried out at high MOIs showed that the N151D induced the 
dispersal of PML, whereas, in the inducible cell line experiments (section 3.2.1), ICP0 
showed colocalisation and did not induce PML dispersal after 24 hours of ICP0 expression.  
One possible explanation for the differing results between the two experimental systems is 
the antibodies used.  The inducible cell line immunofluorescence experiments were carried 
out using anti-PML antibody (Bethyl) that was later shown to cross-react with ICP0 when 
expressed at high levels, which is what occurs in these RING finger mutants.  Therefore, a 
different antibody was used for these virus infection studies.    
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Figure 4.10 ICP0 expression and PML dispersal in wt and ICP0 mutant virus 
infected HFs at two and four hours post infection.   
HFs were infected at MOI 10 with the indicated viruses, and at two (A) and four (B) hours 
post infection the cells were fixed and stained for ICP0 (green) and PML (red).   
 
 
 
4.3.5 Degradation of SUMO-modified Sp100 during infection with 
the RING finger mutants 
Sp100 is a permanent ND10-associated protein that exists in several isoforms due to 
alternative splicing and can be modified by SUMO.  SUMO-modification of Sp100 is not 
required for its localisation to ND10, but this is PML-dependent (Muller & Dejean, 1999; 
Sternsdorf et al., 1997).  During HSV-1 infection, the RING finger domain of ICP0 
induces the degradation of SUMO-modified Sp100 (Chelbi-Alix & de The, 1999; Muller 
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& Dejean, 1999). However, depletion of PML in uninfected cells also leads to the 
desumoylation of Sp100 (Everett et al., 2006), and therefore it is possible that ICP0 does 
not target Sp100 directly, and that its desumolyation is an indirect consequence of PML 
degradation.   
 
The rates of Sp100 degradation in HepaRG cells and HFs were investigated (Figure 4.11) 
at MOI 5, over the course of an eight hour infection with the ICP0 alpha-helix mutants.  
The results in HepaRG cells (Figure 4.11A) showed that wt virus caused degradation of 
SUMO-modified Sp100 by two hours post infection, with only unmodified Sp100 being 
detected.  The degradation of SUMO-modified Sp100 was slightly delayed in N151D 
mutant infected cells, to four hours post infection.  In cells infected with mutants K144E 
and KE/ND, the majority of SUMO-modified Sp100 had been degraded by the eight hour 
time-point, and there was also some degradation in FXE infected cells.  The relative loss of 
the sumoylated form of Sp100 in KE/ND and FXE mutant infected cells contrasts with the 
failure of these mutants to degrade PML, which suggests that different mechanisms may be 
operating between the different cellular proteins, PML and Sp100. Within infected HFs 
(Figure 4.11B), there was a two hour delay in the degradation of SUMO-modified Sp100 
by wt HSV-1 and the N151D mutant compared to the rates seen in HepaRG cells.  By eight 
hours post infection, KE/ND and FXE infected cells had levels of SUMO-modified Sp100 
similar to those in the wt infection at two hours, with K144E exhibiting an intermediate 
phenotype. That at least some loss of sumoylated Sp100 occurred, again contrasts with the 
apparent failure of these mutants to affect PML under similar experimental conditions, 
suggesting that loss of SUMO-modified Sp100 is PML-independent under these 
experimental conditions.   
 
Despite differences in detail in their effects on PML and sumoylated Sp100, the overall 
relative activities of the mutants follow a similar pattern in these assays.  Therefore, 
mutants K144E and KE/ND have the most greatly reduced abilities to degrade PML and 
reduce the sumolylated forms of Sp100.  Also, the efficiency of the degradation of the 
ND10 proteins correlates with the efficiency of plaque formation and replication.    
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Figure 4.11 The rate of degradation of sumoylated Sp100 during infection with wt 
and RING finger mutant viruses in HepaRG cells and HFs.   
HepaRG cells (A) and HFs (B) were infected with wt ICP0 or mutant viruses at MOI 5 and 
harvested at two, four, six and eight hours post infection. The proteins were resolved on a 
7.5% SDS gel, transferred to a nitrocellulose membrane and detected by probing for 
Sp100, ICP0 and actin.  
    
 
 
4.3.6 Viral gene expression is delayed in the alpha-helix mutant 
virus infections 
At the high MOI of 5, the rate of viral gene expression was not greatly affected in the 
RING finger mutant infections of HepaRG cells, and was only substantially delayed for 
late protein VP5 in K144E and KE/ND mutant infected HFs (Figure 4.9).  However, the 
effects of the ICP0 mutations on viral gene expression might be concealed due to the high 
MOI.  Therefore, viral gene expression was investigated using a lower MOI (MOI 1) over 
the course of an eight hour infection (Figure 4.12).     
 
In the wt ICP0 and alpha-helix mutant infected HepaRG cells (Figure 4.12A), there was a 
similar level of ICP0 expression, which was slightly delayed in FXE infected cells.  
A 
B 
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Expression of the early protein UL42 was detected in wt infected cells from four hours 
onwards, and this was also the case in N151D infected cells, although the level of 
expression was lower at each time-point.  K144E and KE/ND infected cells exhibited 
substantially delayed UL42 expression compared to wt, with strong expression only 
occurring at the eight hour time-point. VP5 expression was extensively delayed in the 
RING finger mutants, with K144E and KE/ND having the greatest effect on VP5 
expression.  FXE infected cells showed very low expression levels of UL42 at eight hours 
post infection and no detectable expression of the VP5 capsid protein.  In infected HFs 
(Figure 4.12B), ICP0 expression was similar in the RING finger point mutants compared 
to wt, with levels of ICP0 expression delayed in FXE infected cells.  UL42 expression was 
delayed in N151D infected cells, with strong expression occurring at eight hours post 
infection as opposed to six hours in wt infected cells, and this was the same for VP5 
expression.  There was no detectable expression of UL42 or VP5 proteins in K144E and 
KE/ND infected cells throughout the eight hours, and this was the same with FXE infected 
cells.  
 
The differences between the gene expression profiles at MOI 5 (Figure 4.9) and MOI 1 
(Figure 4.12) highlight the substantial effect that choice of MOI has on experimental 
output when analysing ICP0 mutant viruses.  Given inherent variations in determination of 
virus titre stocks, these data suggest that even two-fold differences between true and 
determined virus titres could have substantial experimental consequences.  The viral gene 
expression during virus infection results confirm previous results using transfection assays 
that used different concentrations of plasmid DNA and found that both the N151D and 
K144E mutations had a significant effect on ICP0’s ability to activate gene expression, but 
that K144E had the most substantial defect and was comparable to FXE (Everett et al., 
1995).   
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Figure 4.12 Viral gene expression during infection with RING finger mutants 
compared to wt HSV-1 in HepaRG cells and HFs.   
HepaRG cells (A) and HFs (B) were infected at MOI 1 and harvested at two, four, six and 
eight hours post infection.  Samples were analysed by Western blotting using antibodies 
against ICP0, UL42 and VP5, to represent the IE, early and late classes of genes, 
respectively.  Actin was used as a loading control. 
 
 
4.3.7 Analysis of the abilities of the ICP0 alpha-helix mutant 
viruses to inhibit the recruitment of ND10 proteins to viral 
genomes.  
ICP4 is an IE protein and functions as a transcriptional activator of early and late gene 
transcription by interacting with the transcriptional preinitiation complex (Smith et al., 
1993).  ICP4 binds strongly to viral DNA and is recruited to replicating viral genomes at 
the early stages of infection to form discrete foci, most of which are associated with ND10 
(Everett et al., 2003).  At early stages of viral infection, ICP4 shows an asymmetric arch-
like distribution inside the nucleus of newly infected cells or cells at the edges of a 
developing plaque (Everett & Murray, 2005).  In the absence of ICP0, ND10 components 
including PML and Sp100 are recruited to sites associated with the ICP4 complexes and 
with the viral genomes (Everett & Murray, 2005; Everett et al., 2004b).  This recruitment 
also occurs in wt infected cells, but due to ICP0 disrupting ND10 and inducing the 
A 
B 
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degradation and/or dispersal of PML and other ND10 proteins, this process is transient and 
difficult to detect (Everett & Murray, 2005).  Unlike the formation of ND10 which is 
PML-dependent (Ishov et al., 1999; Zhong et al., 2000), the recruitment of Sp100 and 
hDaxx proteins to viral genomes occurs independently of PML (Everett et al., 2006).              
 
The recruitment of ND10 proteins (PML, Sp100 and hDaxx) was investigated by 
immunofluorescence staining for ICP4 and the ND10 proteins (Figure 4.13).  In wt 
infected HFs, the majority of PML signal was dispersed, and any remaining foci were not 
recruited to sites associated with viral genomes.  PML was also dispersed in the majority of 
N151D infected cells.  However, in less than 5% of N151D infected cells, there was some 
faint recruitment of PML to viral genomes, which occurred in cells that had very low 
amounts of ICP4.  In contrast, there was marked recruitment of PML in cells infected with 
K144E, KE/ND or FXE viruses (Figure 4.13A).  There was also recruitment of Sp100 in 
N151D infected cells when ICP4 levels were low, but no recruitment was detected when 
the ICP4 foci were better developed.  Sp100 (Figure 4.13B) and hDaxx (Figure 4.13C) 
recruitment supported the PML results with K144E and the double mutant KE/ND.  These 
results therefore suggest K144E and KE/ND mutations in ICP0 are defective in their 
ability to inhibit the recruitment of these cellular repressors to viral genome sites through 
their inefficient degradation.  
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Figure 4.13 Immunofluorescence analysis of the recruitment of ND10 proteins to viral 
genomes at the early stages of HSV-1 infection by wt and RING finger mutant 
viruses.  
Cells were infected with wt/mutant viruses at low MOI and stained for ICP4 (green) and 
ND10 proteins (red), PML (A), Sp100 (B) and hDaxx (C) the following day. Cells at the 
edges of plaques showing an asymmetric distribution of ICP4 were selected, as these cells 
represent the early stages of infection, with ICP4 indicating the location of the viral 
genomes. 
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4.3.8 Investigation of the degradation of a further ICP0 substrate  
It is possible that the mutations in the alpha-helix of the RING finger domain affect ICP0’s 
interactions with substrates, components of the ubiquitin conjugation machinery, or both. 
They could therefore cause differential defects in the rate of degradation amongst different 
ICP0 substrates. The effects of the alpha-helix mutations on the degradation of two main 
ICP0 substrates (PML and Sp100) have been presented in section 4.3.4 and section 4.3.5, 
with each substrate having a similar degradation profile. Therefore, the degradation of 
another recently identified ICP0 substrate was investigated.   
 
Protein ZBTB10 (zinc finger and BTB domain protein 10) belongs to a family of proteins 
that has been implicated in transcriptional regulation, particularly repression of 
transcription (reviewed in Lee & Maeda, 2012. The C-terminal end of ZBTB proteins 
contains a zinc finger domain that binds specific DNA sequences, and the N-terminal BTB 
domain mediates interactions with other proteins (reviewed in Lee & Maeda, 2012).  
ZBTB10 was identified as a potential ICP0 substrate in a screen for proteins that were 
destabilized during HSV-1 infection (E. Sloan, unpublished data), and the rate of 
degradation of the ZBTB10 protein was investigated during infection with the RING finger 
mutant viruses. 
 
HepaRG cells were infected at a MOI 5 and the results (Figure 4.14) showed that in wt 
infected cells ZBTB10 was degraded at early time points of infection, with the majority 
being degraded by the four hour time-point.  Mutants N151D and K144E showed a delay 
in degrading ZBTB10, and this delay was more pronounced in K144E infected cells. The 
double mutant KE/ND achieved only slight degradation of ZBTB10 at eight hours post 
infection and was comparable to FXE, showing that the double mutant was defective in 
degrading ZBTB10. The defects in RING finger mutants in degrading ZBTB10 were not 
due to differences in the levels of ICP0 expression, as the levels of ICP0 during infection 
with the mutant viruses were similar to the expression level of the wt virus.  ZBTB10 
degradation followed the same pattern as PML and Sp100 degradation, with the rate of 
degradation by mutants N151D and K144E delayed, with K144E showing the greater 
effect, and only minimal degradation occurring in the double mutant KE/ND infected cells.  
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Figure 4.14 Rate of degradation of ZBTB10 during infection by the RING finger 
mutant viruses.   
HepaRG cells were infected at MOI 5 and harvested at two, four, six and eight hours post 
infection. The arrow indicates the ZBTB10 specific band and the asterisk denotes a non-
specific band.   
 
 
 
4.3.9 Mutants K144E and KE/ND greatly reduce the efficiency of 
reactivation in quiescently infected cells while the N151D 
mutation caused a lesser defect 
 
In a final experiment to analyse the phenotype of the KE/ND double mutant virus, 
reactivation of β-galactosidase expression in HepaRG cells quiescently infected with 
in1374 was analysed by immunofluorescence (Figure 4.15), using the same methodology 
as described for Figure 4.6.  Quantification of the immunofluorescence images showed 
that mutant N151D was 40% as effective as wt in reactivating viral gene expression in 
quiescently infected cells, whereas mutants K144E and KE/ND had significant defects on 
reactivation.  Of note was that infections with wt and mutant viruses were done at MOI 5, 
under conditions in which lytic infection with the RING finger mutants was progressing at 
a similar rate to wt with regard to viral gene expression (see Figure 4.9).   
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Figure 4.15 Immunofluorescence analysis of the reactivation of viral gene expression 
by wt and mutant ICP0 virus.  
(A) Cells on coverslips were infected with in1374 at MOI 5, and 24 hours later 
superinfected with wt or ICP0 mutant viruses at MOI 5. After virus adsorption, the cells 
were overlaid with medium containing 50 μM ACV and 1% human serum. The cells were 
fixed and permeabilised 24 hours later, then stained for ICP0 (red) and β-galactosidase 
protein (green).  Cells positive for β-galactosidase indicate reactivated viral gene 
expression of the in1374 virus.  
(B) Quantification of cells displaying reactivated viral gene expression compared to those 
expressing ICP0 as seen in (A). Three random fields of view of cells were imaged and the 
cells expressing β-galactosidase protein were counted and calculated as a percentage of 
those positive for ICP0 expression. The results are shown as a percentage of the wt ratio. 
The error bars represent the standard deviation obtained from three images. 
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The results from each of the reactivation experiments correlate with those obtained for the 
plaque assays with each of the mutants (Figure 4.1 and Figure 4.7).  However, during the 
reactivation experiment, the infections with the alpha-helix mutant viruses and wt were 
carried out at an MOI 5, at which all the cells should have been productively infected over 
a 24 hour period if ACV was not present.  In HepaRG cells infected at MOI 5 (Figure 4.9), 
the IE and early gene expression in the alpha-helix mutants is comparable to wt expression 
levels, and late gene expression is only slightly delayed in these mutants.  Therefore, the 
defect in reactivation efficiency seen with mutants K144E, KE/ND and FXE occurs under 
conditions in which lytic gene expression should be progressing normally (see Figure 4.9). 
It has previously been thought that failure of ICP0 mutant viruses to reactivate quiescent 
HSV-1 genomes, despite lytic replication of the superinfecting virus, could be due to 
genome competition resulting from the high MOI required to get the mutants replicating. 
However, in the experiments presented here this should have been overcome by the use of 
ACV and MOIs based on titres in U2OS cells, and thus the number of superinfecting viral 
genomes should have been equivalent in all infections.  Therefore, there appears to be a 
differential in the results for reactivation over lytic infection under these experimental 
conditions, which was especially the case for K144E.  However, before this can be 
confirmed the viral gene expression of early and late genes in the reactivated cells should 
be confirmed to show that gene expression has proceeded beyond the IE stage and ICP0 
expression. Nonetheless, based on the gene expression profiles of the mutants at the same 
MOIs (Figure 4.9), this is expected over a 24 hour period.            
 
Reactivation efficiency for N151D in this assay was considerably higher than the previous 
reactivation assay (Figure 4.5 and Figure 4.6), and this was also the case for N151D PFE.  
As discussed previously, the higher activity of N151D observed here could be due to slight 
differences in the viral titres of the stocks used for each set of assays.  
 
 
4.4 Conclusion and Discussion 
The viral infection experiments described in this chapter show that at high input MOIs the 
alpha-helix mutants replicated as efficiently as wt and had no major defects in early and 
late gene expression.  However, mutants K144E and KE/ND had a substantial delay in 
degrading PML compared to wt. At lower MOIs, the phenotypes of the RING finger 
mutants were more noticeable, with K144E and KE/ND giving lower yields of infectious 
virus and the expression of early and late genes by all the RING finger mutants was 
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delayed compared to wt, with the delay more pronounced with VP5 (a typical late protein). 
In all the above assays, the N151D mutant was less defective than the other mutants.  The 
ability of the mutants to reactivate gene expression in quiescently infected cells correlates 
with their relative abilities to degrade PML and their activities in viral yield and plaque 
formation assays. Again, mutant N151D was the least defective, with mutants K144E and 
KE/ND having substantial defects that were comparable to the RING finger deletion 
mutant FXE.   
 
In the later series of assays carried out alongside the double mutant KE/ND, mutant 
N151D had increased activity in assays of PFE, viral yield and reactivation efficiency 
(sections 4.3.2-4.3.9) compared to the assays carried out at the beginning of this chapter 
(sections 4.2.1-4.2.4).  This could be due to slight differences in viral titres as a fresh plate 
stock of virus was produced for each set of assays.  However, both sets of assays show that 
N151D activity was greater than that of the FXE, K144E and KE/ND mutants, and is 
closer to that of wt virus, especially in HepaRG cells.  Mutants K144E and KE/ND were 
highly defective in both sets of assays, with the double mutant tending to be even more 
defective than K144E and quite similar in phenotype to that of the deletion mutant FXE.   
 
It was possible that the mutations in the alpha helix of the RING finger domain affect ICP0 
interactions with substrates and it is likely that the mutations also affected the degradation 
of other ICP0 substrates (other proteins that have repressive effects), in a similar manner to 
that of PML.  This was shown to be the case with the rates of degradation of Sp100 and 
ZBTB10 mirroring those of PML.  Therefore, PML may be a good indicator of ICP0 
activity but not necessarily the only important target (indeed, it is highly likely that there 
are several biologically relevant substrates of ICP0).  
 
The data from the virus infected cell experiments do not fit easily with the original 
hypothesis arising from the work of Vanni et al. (2012) that, as demonstrated by mutant 
N151D, which has a greater defect in reactivation compared to complementation of an 
ICP0 null mutant virus, the activities of ICP0 involved in stimulating lytic infection may 
be separable from those required for reactivation.  This hypothesis suggests that the RING 
finger helix provides an interface that is required mainly for the former function.  The 
results using mutant N151D in the inducible cell line chapter were by and large consistent 
with the work of Vanni et al., and were extended to mutant K144E which showed a similar 
phenotype.  However, as discussed in chapter 3, the results from the double mutant KE/ND 
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(which has substantial defects on both lytic infection and reactivation from quiescence) 
were more consistent with the hypothesis that greater ICP0 activity is required for 
reactivation than for the initial stimulation of lytic infection, and that the RING finger helix 
is required for both functions.  At first sight, the virus infected cell experiments also show 
a good correlation between lytic infection and reactivation from quiescence in terms of the 
relative defects of the mutants examined.  There is one important qualification to this 
conclusion, however.  The viral infection reactivation experiments were performed at an 
MOI at which ICP0 is not essential for lytic viral gene expression (as illustrated by 
expression of UL42 and VP5 in parallel experiments), yet induction of reactivation was 
very inefficient. This suggests that ICP0 is almost essential for reactivation or derepression 
of quiescent HSV-1 genomes in cultured cells, even under conditions in which it is 
dispensable for lytic infection.  
 
The efficiency of reactivation by each of the alpha-helix mutants correlates with PML 
degradation, viral yield and PFE.  The differences in ICP0’s activity in the RING finger 
helix mutants may be due to effects on the efficiency of substrate recognition by ICP0, or 
they may affect its E3 ligase activity by hindering its interactions with the E2 ubiquitin-
conjugating enzymes.  Indeed, it has been previously shown that the alpha-helix and loop 
regions of the RING finger domain of ICP0 are involved in the interactions with E2 
ubiquitin-conjugating enzymes (Vanni et al., 2012).  On the basis of the original results of 
Vanni et al., it seemed possible that ICP0 may utilise different E2 ubiquitin-conjugating 
enzymes for different functions, and hence it is possible that these mutations in the RING 
finger alpha-helix may differentially affect the interactions with E2 ubiquitin conjugating 
enzymes and the stimulation of lytic infection and reactivation from quiescence.  Although 
the results presented so far in this thesis now make this hypothesis less likely to be true, it 
was still of value to assess the biochemical activity of these mutants and their interactions 
with different E2 ubiquitin-conjugating enzymes. These studies are presented in the next 
chapter.  
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5 Results - Interactions of ICP0 alpha-helix 
mutants with components of the ubiquitin 
conjugation pathway 
5.1 ICP0 interactions with the ubiquitin conjugation 
pathway proteins 
ICP0, an E3 ubiquitin ligase, binds to E2 ubiquitin-conjugating enzymes and targets 
proteins to promote their (poly)ubiquitination and degradation via the 26S proteasome.  
The RING finger domains of E3 ubiquitin ligases bind to E2 ubiquitin-conjugating 
enzymes, allowing the E2 enzyme and substrate to come into close proximity, enabling the 
direct transfer of ubiquitin from the E2 ubiquitin-conjugating enzyme to the substrate 
protein (reviewed in Deshaies & Joazeiro, 2009).  RING finger E3 ubiquitin ligases have 
been shown to be able to interact with multiple E2 ubiquitin-conjugating enzymes (van 
Wijk et al., 2009), and therefore it may be possible that ICP0 interacts with multiple E2 
enzymes during infection.  It has previously been established that the RING finger domain 
of ICP0 interacts with the highly homologous E2 ubiquitin-conjugating enzymes UBE2D1 
and UBE2E1 (also known as UbcH5a and UbcH6) and catalyses the formation of 
unanchored polyubiquitin chains in vitro (Boutell et al., 2002).  It has been shown that the 
alpha-helix and loop regions of the RING finger domain of ICP0 are involved in the 
interactions with UBE2D1 (Vanni et al., 2012).   
 
This chapter follows on from and extends the work of Vanni et al. (2012), and was done in 
collaboration with Dr Chris Boutell, investigating the E3 ubiquitin ligase activity of the 
RING finger alpha-helix mutants and the interactions of these mutants with components of 
the ubiquitin conjugation pathway.  Given the results of Vanni et al. (2012) and from the 
virus infected cell studies in chapter 4, the underlying hypothesis was that ICP0 may 
utilise different E2s for its various functions, and hence it was possible that mutations in 
the RING finger alpha-helix may differentially affect the interactions with E2 ubiquitin 
conjugating enzymes and the stimulation of lytic infection and reactivation from 
quiescence.   
 
 
152 
 
5.2 Results 
5.2.1 Characterisation of the effects of RING finger mutations on 
ICP0 interactions with E2 ubiquitin conjugating enzymes 
using yeast-two-hybrid assay 
The alpha-helix and loop regions of the RING finger domain of ICP0 have been shown to 
be important for the interaction of ICP0 with UBE2D1 (Vanni et al., 2012), and therefore 
mutations in the RING finger alpha-helix could affect ICP0’s interactions with E2 
ubiquitin-conjugating enzymes or components of the ubiquitin conjugation reaction.  The 
Vanni et al. (2012) study included ICP0 mutant N151D, but not K144E or the double 
mutant constructed during the course of this thesis. Therefore, to extend the previous 
results, a yeast-two-hybrid experiment was carried out to test the interactions of wt ICP0 
and the RING finger mutants with a panel of E2 ubiquitin-conjugating enzymes (Figure 
5.1).   
 
The wt ICP0 and the RING finger ICP0 mutants were expressed as fusion proteins to the 
GAL4-activating domain (AD), and the E2 ubiquitin-conjugating enzymes were expressed 
as fusion proteins to the GAL4-binding domain (BK).  If the proteins fused to the binding 
domain and activation domain moieties interact, then an active transcription factor is 
assembled which binds to the GAL4-binding sites in the reporter promoter and  
transcription of downstream reporter genes (HIS3 and lacZ) occurs (section 2.10, Figure 
2.4).  USP7 was used as a positive control for ICP0 interaction, as USP7 interacts strongly 
with ICP0 via the interaction motif located in the C-terminal third of ICP0 (614-630 aa) 
(Everett et al., 1997; Meredith et al., 1995; Meredith et al., 1994).  Diploids expressing 
only the AD or BK domains were used as negative controls for protein interaction.   
 
The results from the yeast-two-hybrid assay (Figure 5.1) show that wt ICP0 interacted 
with the E2 ubiquitin conjugating enzymes UBE2D1, UBE2E1, UBE2V1 (albeit relatively 
weakly) and UBE2W, but failed to interact with UBE2N.  The RING finger mutant ICP0-
2C, which lacks two of the RING finger cysteine residues (C116G, C156A) that are 
required for zinc binding (Lium & Silverstein, 1997) and therefore the stability of the 
RING finger, interacted with USP7 but did not interact with any of the E2 enzymes tested, 
showing that the integrity of the RING finger domain is important for the interaction of 
ICP0 with these E2 ubiquitin-conjugating enzymes.  The alpha-helix RING finger mutants 
K144E and the double KE/ND mutant interacted with UBE2D1, UBE2E1, and UBE2W to 
the same extent as wt, but their interactions with UBE2V1 were reduced below detectable 
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levels.  This latter point was also true of N151D, but in these experiments the interactions 
of this mutant with UBE2D1 and UBE2E1 also appeared reduced under the most stringent 
conditions. The double mutant also lost the ability to interact with UBE2W on the most 
stringent selection plate (–Leu-Trp-His + 5 mM 3-AT) but still interacted with UBE2W in 
the presence of 1 mM 3-AT (Figure 5.1). 
 
Using high level expression of a dominant negative mutant, evidence has been presented 
that UBE2D1 is important for the degradation of PML and Sp100 (Gu & Roizman, 2003).  
The functions of the other E2 conjugating enzymes analysed in Figure 5.1 during HSV-1 
infection have not been investigated. UBE2V1 has no ubiquitin ligase activity on its own, 
as it is enzymatically inactive due to the lack of an active site cysteine residue (Sancho et 
al., 1998), and instead it forms a functional heterodimer with the enzymatically active E2 
UBE2N (Hofmann & Pickart, 1999; VanDemark et al., 2001).  In previous studies, the 
UBE2N-UBE2V1 complex was found to catalyse the synthesis of Lys63-linked 
polyubiquitin chains that are not thought to be involved in protein degradation by the 
proteasome, but may play a role in the DNA repair pathway (Hofmann & Pickart, 1999) or 
IKK activation (Deng et al., 2000).  Unlike other E2 ubiquitin-conjugating enzymes, where 
ubiquitin is covalently attached via the C-terminal carboxy group of ubiquitin and the ε-
amino group of a lysine residue on target proteins, UBE2W catalyses the linkages between 
the C-terminus of ubiquitin and the N-terminal α-amino groups of target substrates, and 
this only results in mono-ubiquitination events (Tatham et al., 2013).   
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Figure 5.1 Yeast-two-hybrid testing the interactions of wt ICP0 and RING finger 
mutants with a panel of E2 ubiquitin-conjugating enzymes.   
wt ICP0 and RING finger mutants were linked to the GAL4 DNA-activating domain (AD) 
and tested for interaction with USP7 and a panel of E2 ubiquitin-conjugating enzymes 
(UBE2) linked to the GAL4-binding domain (BK).  Protein interaction was analysed by 
plating diploids containing both AD and BD plasmids onto medium lacking leucine, 
tryptophan and histidine, supplemented with 1 mM or 5 mM 3-AT, and stained with X-gal 
(lower panel plates only). The blue colour indicates β-galactosidase activity and thus an 
interaction between the two proteins.   
 
 
 
5.2.2 ICP0 RING finger mutations affect polyubiquitin chain 
formation by the UBE2N-UBE2V1 complex  
The loss of interaction of the ICP0 RING finger mutants with UBE2V1 may contribute to 
the phenotypes seen with these mutants shown in previous chapters and the reduced ability 
of these mutants to reactivate quiescent HSV-1.  To further investigate the interactions of 
the alpha-helix mutants with the E2 ubiquitin-conjugating enzymes UBE2D1 and UBE2N-
UBE2V1, the first 241 residues of ICP0 and the RING finger mutants were fused to GST.  
These GST constructs were then analysed for their abilities to catalyse the formation of 
polyubiquitin chains in vitro or to undergo auto-ubiquitination in the presence of titrated 
amounts of UBE2D1 and UBE2N-UBE2V1 (Figure 5.2). The reactions also included the 
E1 activation enzyme, ATP and wt ubiquitin.  
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The yeast-two-hybrid results showed that the mutations in the alpha-helix did not affect the 
interaction of ICP0 with UBE2D1, and in the presence of UBE2D1 the RING finger 
mutants could catalyse the formation of polyubiquitin chains to similar levels as seen with 
the wt ICP0 protein.  This confirms previous results that K144E and N151D had no 
significant effect on the in vitro polyubiquitin chain formation with UBE2D1 (Boutell et 
al., 2002; Vanni et al., 2012).  The interaction of UBE2V1 was lost with these RING 
finger mutants in the yeast-two-hybrid experiment.  To test whether the ICP0 mutants 
could catalyse the formation of polyubiquitin chains with UBE2V1, reactions were carried 
out with equal amounts of UBE2N and UBE2V1, as these two ubiquitin conjugating 
enzymes work together as a UBE2N-UBE2V1 heterodimer (Figure 5.2).  The results 
showed that wt ICP0 forms polyubiquitin chains with UBE2N-UBE2V1 and that this 
activity was lost with the negative control mutant ICP0-2C.  The N151D mutant had a 
reduced ability to catalyse the formation of polyubiquitin chains in the presence of 
UBE2N-UBE2V1 compared to wt, and this activity was even less with the K144E mutant.  
The level of polyubiqutin chain formation with the double mutant KE/ND was higher than 
the level seen with the ICP0-2C mutant but was also greatly reduced compared to wt 
levels.   
 
ICP0 can undergo auto-ubiquitination that makes it less stable, and this can be 
counteracted by the interaction of ICP0 with USP7, a deubiquitinating enzyme (Canning et 
al., 2004).  The wt ICP0 and the RING finger mutants (except ICP0-2C) undergo auto-
ubiquitination in the presence of UBE2D1, but no auto-ubiquitination was detected in the 
presence of UBE2N-UBE2V1 with wt ICP0 or the RING finger mutants (Figure 5.2).    
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Figure 5.2 wt ICP0 and RING finger mutants E3 ubiquitin ligase activity in vitro in 
the presence of UBE2D1 and UBE2N-UBE2V1. 
GST-tagged wt ICP0 and RING finger mutants were analysed for their abilities to catalyse 
the formation of polyubiquitin chains in the presence of wt ubiquitin, and to undergo auto-
ubiquitination in the presence of titrated amounts of UBE2D1 (D1) and UBE2N-UBE2V1 
(N/V1) (40, 20, 10 ng).  Polyubiquitin chain formation was detected using P4D1 antibody 
and auto-ubiquitination was detected using anti-GST antibody (labelled by asterisks).  
* 
* 
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5.2.3 Double mutant KE/ND fails to form colocalising conjugated 
ubiquitin foci in infected cells 
The results of the in vitro E3 ubiquitin ligase assays of the ICP0 mutants with E2 ubiquitin-
conjugating enzymes gave some interesting results, which imply at the least that ICP0 may 
utilise a number of different E2 enzymes.  However, it is also important to investigate the 
functional activity of ICP0 and the interactions of ICP0 and the mutants with components 
of the ubiquitin pathway in the context of infection.  The RING finger activity of the ICP0 
mutants in infected cells can be studied by analysing the formation and localisation of 
conjugated ubiquitin by immunofluorescence (Figure 5.3) using monoclonal antibody 
FK2, which recognises ubiquitin-protein conjugates but not free ubiquitin (Fujimuro et al., 
1994).  HFs were infected at MOI 10 with the wt and mutant ICP0 viruses, and stained two 
hours post infection.  The results showed that in non-infected cells the ubiquitin was 
mainly dispersed throughout the nucleus, with a few punctate foci, but in wt infected cells 
the ubiquitin formed discrete foci that showed strong colocalisation with ICP0.  In N151D 
and K144E infected cells, the conjugated ubiquitin also showed a high degree of 
colocalisation with ICP0.  In the RING finger deletion mutant FXE infected cells, there 
were some ubiquitin foci that colocalised with ICP0, but the majority of the ubiquitin 
signal was dispersed throughout the nucleus, as in uninfected cells. This was also the case 
with the double mutant KE/ND infected cells. 
 
These results obtained with the K144E and N151D mutant viruses, showing the formation 
of conjugated ubiquitin colocalising with ICP0, are different from those published 
previously.  Everett (2000) and Vanni et al. (2012) found that HEp-2 cells (human 
epithelial cells originated from a human laryngeal carcinoma) transfected with a plasmid 
containing mutated forms of ICP0 had between 10-20% of wt ability to induce the 
colocalisation of conjugated ubiquitin (Everett, 2000; Vanni et al., 2012).  The 
discrepancies between the sets of results could be due to the different systems used; high 
MOI virus infected HFs stained 2 hours post infection compared to transfected HEp-2 cells 
stained six to 24 hours post transfection. From these infected cell data, it appears that the 
formation of colocalising conjugated ubiquitin by the K144E mutant may reflect 
polyubiquitin chain formation and the auto-ubiquitination seen in vitro in the presence of 
UBE2D1, rather than UBE2N-UBE2V1 catalysed reactions. 
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Figure 5.3 The ability of the RING finger mutants to induce the formation of 
colocalising conjugated ubiquitin.  
HFs were infected at MOI 10 and the virus adsorbed for 1 hour before overlaying cells 
with medium containing 1% human serum.  Cells were fixed, permeablised and stained 
two hours post infection.  ICP0 (red) was detected using rabbit polyclonal R190 antibody 
and ubiquitin (ub, green) was detected using the mouse monoclonal antibody FK2, which 
detects ubiquitin-protein conjugates but not free ubiquitin. The images are representative of 
a large number cells that were examined.   
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5.2.4 E2 ubiquitin-conjugating enzyme localisation in cells 
expressing wt and RING finger mutant ICP0 
The defect in degradation (and by implication ubiquitination) of target proteins such as 
PML by the RING finger mutants, particularly K144E and KE/ND, may be due to effects 
on the RING finger helix interaction interface between ICP0 with the E2 ubiquitin-
conjugating enzyme and target proteins.  The cellular distribution of UBE2D1 and 
UBE2E1 has been previously investigated in cells transfected with plasmids expressing 
tagged E2 ubiquitin conjugating enzymes and ICP0 (Boutell et al., 2002).  In these studies, 
ICP0 and the E2 ubiquitin conjugating enzymes showed nuclear colocalisation but the 
intensity of colocalisation was stronger in some cells than others.  There was no 
recruitment of either of the E2 ubiquitin conjugating enzymes with the RING finger 
deletion mutant FXE (Boutell et al., 2002).   
 
The localisation of UBE2D1 and UBE2V1 was investigated with regards to ICP0 and the 
RING finger mutants by immunofluorescence.  This was achieved by either transfecting 
plasmids expressing ICP0 and the flag-tagged E2 ubiquitin conjugating enzymes into cells 
simultaneously, or by transfecting the flag-tagged E2 plasmids and then infecting the cells 
with wt or mutant viruses 24 hours later.  Different cell types (U2OS and HepaRG cells), 
transfection reagents (GeneJuice®, Lipofectamine® and Lipofectamine® LTX) and 
varying amounts of transfected E2 plasmids (50-1000 ng) were investigated.  Problems 
were experienced in getting enough cells that expressed both the E2 enzyme and ICP0 
simultaneously, especially by the infection method, as the majority of cells expressed only 
the tagged form of the E2 ubiquitin conjugating enzyme or ICP0, and less than 5% of cells 
expressed both.  In cells expressing wt ICP0, there was colocalisation with UBE2D1 or 
UBE2V1, but in cells expressing FXE there were variable results, with some cells showing 
no colocalisation of the E2 enzyme and ICP0 but other cells showing a strong 
colocalisation, as seen with the wt.  These cells were invariably expressing the ICP0 
protein at exceptionally high levels. In general, transfection gave a very wide range of 
expression levels among positive cells in a sample, and the degree of any colocalisation 
with ICP0 was influenced by expression level. While cells could be selected for 
examination in which expression levels appeared closer to physiological levels, this would 
always be subject to observer bias. Therefore, no conclusion could be reached using this 
method as to the relative colocalisation of the various mutant forms of ICP0 with the E2 
ubiquitin conjugating enzymes tested.   
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5.3 Conclusions and Discussion 
The results of the yeast-two-hybrid experiments and the in vitro E3 ubiquitin ligase assays 
show that ICP0 has the potential for functionally relevant interactions with E2 ubiquitin 
conjugating enzymes other than the previously described roles of UBE2D1 and UBE2E1.  
ICP0 formed polyubiquitin chains in vitro in the presence of UBE2N-UBE2V1 and also 
interacted with UBE2V1 and UBE2W in the yeast two hybrid experiments.  The results 
show the RING finger region of ICP0 may influence E2 interactions, as the RING finger 
mutants lost their ability to interact with UBE2V1 in the yeast-two-hybrid and N151D 
exhibited less polyubiquitin chain formation compared to wt, with lower levels still with 
K144E and KE/ND.  The results for the in vitro E3 ubiquitin ligase activity of the ICP0 
mutants in the presence of UBE2N-UBE2V1 are broadly consistent with the results of the 
yeast-two-hybrid experiments, given that the reduced activity in the in vitro ligase assay 
may derive from a residual interaction with the E2 enzyme that is below the level of 
detection in the yeast-two-hybrid assay.  The two assays are consistent in regard to 
interaction and activity of the mutants with UBE2D1.  
 
On the basis of the yeast-two-hybrid experiments and E3 ubiquitin ligase assays, there is 
an implication that UBE2V1 interaction with the RING finger domain may be important 
for ICP0 activity.  From these data, it appears that ICP0’s activity in conjunction with 
UBE2N-UBE2V1 correlates more closely with ICP0 activity in some assays than the 
interaction with UBE2D1.  For example, the levels of polyubiquitin chain formation in 
vitro with UBE2N-UBE2V1 (Figure 5.2) with each of the mutants mirror their activities in 
terms of PML degradation (Figures 4.9, 4.10), viral infectivity (Figures 4.7, 4.8) and  
reactivation induction (Figure 4.15).  This is surprising given the current understanding of 
the differential roles of UBE2D1 and UBE2N-UBE2V1 in protein degradation and 
ubiquitin-mediated signalling.  The lack of formation of colocalising conjugated ubiquitin 
in KE/ND infected cells also correlates with the lack of PML degradation in cells infected 
by this virus, and this again points to the potential role of UBE2N/UBE2V1 in ICP0 
activity, rather than UBE2D1.  On the other hand, the results with K144E fit better with the 
hypothesis that the formation of intracellular co-localising conjugated ubiquitin depends on 
UBE2D1 rather than UBE2N/UBE2V1. Thus, no simple picture emerges from the 
combination of the complete data of all of these assays.  
 
These results should be interpreted with caution, as there is a potential difficulty in 
correlating E3 ligase activity and E2 ubiquitin conjugating enzyme interaction data in vitro 
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with what occurs in vivo.  For example, UBE2D1 has been shown to be important for the 
degradation of PML and Sp100 (Gu & Roizman, 2003), but K144E and KE/ND interacted 
with UBE2D1 in the yeast-two-hybrid and formed polyubiquitin chains in vitro in the 
presence of UBE2D1 to levels comparable to wt, but they do not degrade PML efficiently 
in vivo, at least in infected HFs.  These results therefore raise the question whether the in 
vitro and yeast-two-hybrid results truly reflect ICP0 mediated ubiquitin ligase activity in 
the intracellular environment.  Therefore, more work will be needed to investigate whether 
these residues in the alpha-helix are important for interactions with components of the 
ubiquitin conjugation pathway in infected cells, and the potential roles of different E2 
ubiquitin conjugating enzymes in the HSV-1 life cycle. Future work could therefore 
investigate E2 ubiquitin conjugating enzyme requirements for ICP0 activity by knock-
down or knock-out methodologies.  As yet, there is no clear indication that different E2 
ubiquitin conjugating enzymes are required for lytic infection and reactivation.   
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6 Results - Investigation of motifs within ICP0 that 
show sequence similarity to other viruses or 
that are involved in interactions with cellular 
proteins 
6.1 Introduction  
Among the ICP0-homologue proteins of alphaherpesviruses, the RING finger domain 
shows the highest sequence similarity due to its conserved function as an E3 ubiquitin 
ligase (Boutell & Everett, 2013), and this region has been extensively studied.  There are 
other regions of ICP0 that contain motifs with functions attributed to them, such as the 
nuclear localisation signal, the USP7 binding motif, and a less well defined region required 
for ND10 localisation.  However, there are other regions throughout ICP0 that contain 
motifs or sequences with similarity to those present within other viral proteins, including 
other herpesviruses, which have not previously been studied in detail.  Therefore, the aim 
of this chapter was to investigate motifs and residues that are conserved between 
herpesviruses or that show similarity to motifs in other viral proteins that interact with 
cellular proteins, including E3 ubiquitin ligases.           
 
6.2 Motifs that are reported to interact with cellular E3 
ubiquitin ligases 
There is a growing list of E3 ubiquitin ligases that interact with other E3 ligases, including 
an HECT E3 ligase NEDD4 that interacts with and targets the RING finger E3 ligase 
casitas B-lineage lymphoma (CBL) protein for degradation (reviewed in Weissman et al., 
2011).  Part of this chapter will investigate motifs within ICP0 that show similarity to 
motifs within other viral proteins and/or that interact with cellular E3 ubiquitin ligases, 
including those involved in the DNA damage response (section 6.2.1) and viral budding 
(section 6.2.2).   
 
6.2.1 ICP0 interacts with the cellular E3 ubiquitin ligase RNF8 that 
is involved in the DNA damage response 
The DNA damage response can be activated in response to viral infection, and viruses 
have evolved ways to manipulate this pathway for their own benefit by activating some 
aspects while inhibiting others (reviewed in Weitzman et al., 2010).  HSV-1 has been 
shown to activate the DNA damage response, and interact with or induce the degradation 
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of cellular proteins involved in these pathways to promote viral replication (Lilley et al., 
2005; Mohni et al., 2011; Weller, 2010).  One example of this during HSV-1 infection is 
the ICP0 induced degradation of the DNA-PK catalytic subunit (Lees-Miller et al., 1996; 
Parkinson et al., 1999) that is involved in DNA double-strand break repair and V(D)J 
recombination (reviewed in Lees-Miller, 1996). Other than a requirement for the ICP0 
RING finger, the mechanism of this degradation has not been established.    
 
The DNA damage response pathway consists of a variety of cellular proteins and 
signalling pathways for sensing and repairing DNA damage within cells.  Double-stranded 
DNA breaks are detected by the sensor proteins Mre11, Rad50 and Nbs1 (the MRN 
complex), which then activates protein kinases, including ATM kinase.  Activation of the 
ATM kinase leads to phosphorylation of the histone H2AX, which acts as a marker for the 
site of DNA damage.  The mediator of DNA damage checkpoint protein 1 (Mdc1) binds 
the phosphorylated H2AX, and this leads to further recruitment of proteins involved in the 
DNA damage response (reviewed in Chaurushiya et al., 2012; Weitzman et al., 2010). The 
cellular repair proteins and those involved in chromatin modification are recruited to the 
sites of DNA damage via a process that requires the action of cellular RING finger E3 
ubiquitin ligases RNF8 (Huen et al., 2007; Kolas et al., 2007; Mailand et al., 2007) and 
RNF168 (Doil et al., 2009; Stewart et al., 2009). 
 
ICP0 inhibits the formation of DNA damage repair foci after the stage of H2AX 
phosphorylation by inducing the degradation of the cellular ubiquitin ligase RNF8, which 
is involved in histone ubiquitination and anchoring repair factors at DNA damage sites 
(Lilley et al., 2010).  Later, after the experiments of this thesis were completed, it was 
shown that RNF8 and RNF168 are recruited to incoming HSV-1 genomes and are involved 
in intrinsic restriction of HSV-1 infection (Lilley et al., 2011).  RNF8 binds to the 
phosphorylated TQXF clusters on Mdc1 (Mailand et al., 2007).  ICP0 contains a 
STDTELF motif at residues 64-70, and during HSV-1 infection, the T67 residue is 
phosphorylated by cellular casein kinase 1, thus imitating the phosphorylation sites on 
Mdc1, enabling ICP0 to bind to RNF8. This leads to the proteasome-mediated degradation 
of RNF8, and there is evidence that this enhances viral replication (Chaurushiya et al., 
2012).   
 
ICP0 interacts with the DNA damage response pathway via the phosphorylated T67 
residue binding to RNF8 and targeting it for degradation.  As treatments such as UV light 
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can cause DNA damage and induce reactivation of quiescent genomes, it is possible that 
these two pathways are linked and this may occur via the T67 residue.  As part of a 
collaborative interaction between the Everett and Weitzman laboratories, ICP0 containing 
a threonine to alanine mutation at residue 67 (T67A) was made available. The aim here 
was to study the effects of this mutation on ICP0-null mutant complementation and 
reactivation using the ICP0 inducible cell line system, prior to the later isolation of a 
mutant virus in the Weitzman laboratory. 
                                                                                                                                                                                                                                                                                                                                                
6.2.1.1 Analysis of the effects of the T67A mutation on the ability of ICP0 to 
complement an ICP0-null mutant HSV-1 
The ability of ICP0 mutant T67A that is unable to interact with RNF8 was analysed for its 
ability to complement an ICP0-null mutant virus using the doxycycline inducible ICP0 
expression system (described in chapter 2.2.3, Figure 2.2).  The wt virus infected HA-
TetR control cells and HA-T67A cells gave similar plaque numbers compared to HA-
cICP0 expression cells without ICP0 induction (Table 6.1, Figure 6.1).  After ICP0 
induction, the HA-TetR and HA-T67A cells showed slight decreases in wt virus plaque 
numbers compared to HA-cICP0 cells, but this was by less than two-fold for HA-T67A 
cells.  Cells expressing wt and mutant ICP0 protein without ICP0 induction all showed 
comparable plaque numbers when infected with an ICP0-null mutant dl1403 virus.  When 
complementing the ICP0-null mutant virus, the HA-T67A cells showed a slight decrease in 
plaque formation ability compared to HA-cICP0 after induction, with 75% of wt activity. 
This difference, however, cannot be considered biologically significant in this 
experimental approach.  
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Table 6.1 Plaque count data in cells expressing T67A following infection with wt or 
ICP0-null mutant HSV-1 after 24 hours induction with doxycycline or left untreated. 
Cells were treated with doxycycline (0.1 µg/ml) for 24 hours to induce ICP0 expression or 
left untreated, and the following day infected with sequential three-fold dilutions of wt 
(in1863) or ICP0-null mutant (dl1403CMV/lacZ) HSV-1.  The starting dilutions varied 
between the cell types and viruses.  The plaque counts at each dilution, the average plaque 
counts and the relative value of each cell type compared to wt ICP0 (HA-cICP0) are shown 
from two repeat experiments.    
 
 
A) Wt HSV-1 minus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc 124 59 32 58900000 71.8 90.1 
tmtc tmtc 100 31 86850000 108.4 
cICP0 10
-4
 tmtc 265 101 28 82000000 100.0 100.0 
tmtc tmtc 115 21 80100000 100.0 
cICP0. 
T67A 
10
-4
 tmtc 235 97 22 72400000 88.3 88.5 
tmtc tmtc 92 22 71100000 88.8 
 
 
B) Wt virus plus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc 163 81 19 57700000 37.0 44.3 
tmtc tmtc 84 16 59400000 51.6 
cICP0 10
-4
 tmtc tmtc 179 56 156150000 100.0 100.0 
tmtc tmtc 118 46 115200000 100.0 
cICP0. 
T67A 
10
-4
 tmtc 228 104 26 77400000 49.6 68.3 
tmtc tmtc 109 38 100350000 87.1 
 
 
C) ICP0 null mutant HSV-1 minus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared to 
wt 
Ave 
relative 
values 
TetR 10
-2
 tmtc tmtc 357 22 1903500 89.8 122.5 
tmtc tmtc 176 22 1089000 155.1 
cICP0 10
-2
 tmtc tmtc 312 53 2119500 100.0 100.0 
tmtc tmtc 105 17 702000 100.0 
cICP0. 
T67A 
10
-2
 tmtc tmtc 172 40 1314000 62.0 107.3 
tmtc tmtc 175 21 1071000 152.6 
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D) ICP0 null mutant HSV-1 plus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 tmtc tmtc 93 14 607500 0.5 0.5 
tmtc tmtc 184 25 1165500 0.6 
cICP0 10
-4
 tmtc tmtc 121 50 121950000 100.0 100.0 
tmtc tmtc 204 77 195750000 100.0 
cICP0. 
T67A 
10
-4
 tmtc tmtc 104 45 107550000 88.2 75.4 
tmtc tmtc 128 48 122400000 62.5 
 
 
 
 
 
 
Figure 6.1 Effect of T67A mutation within ICP0 on wt HSV-1 and ICP0-null mutant 
HSV-1 plaque formation efficiency.   
HA-cICP0 and HA-T67A cells were infected with wt HSV-1 (in1863) or ICP0-null mutant 
(dl1403/CMVlacZ) HSV-1, and the following day ICP0 expression was induced with 
doxycycline (0.1 µg/ml) if required.  The plates were stained for β-galactosidase activity 
24 hours later.  The results from the data in Table 6.1 show the average plaque forming 
ability from two repeat experiments and are presented as a percentage of that in HA-cICP0 
cells.  The error bars represent the range between the two repeat experiments. 
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The experiments reported here were intended to provide a relatively rapid test of the role of 
residue T67. That this mutation causes a decrease in the stimulation of plaque formation 
efficiency of the ICP0-null mutant virus of less than two-fold compared to wt ICP0, while 
retaining over a 100-fold improvement of plaque formation compared to the control HA-
TetR cells, implies that any effect on viral replication efficiency of the interaction between 
T67 and RNF8 is not substantial in HepaRG cells.  Later studies, however, showed that 
depletion of RNF8 increases the efficiency of ICP0 null mutant HSV-1 infection in murine 
embryonic fibroblasts (Lilley et al., 2011; Lilley et al., 2010).  A virus carrying the T67A 
mutation had a replication defect on ICP27 gene expression in low MOI infections in 
HepaRG cells compared to wt by around six-fold.  This defect was improved in cells 
expressing a shRNA targeting RNF8 but did not restore replication to wt levels.  Later 
experiments also showed that the T67A virus had around a 10-fold defect in viral yield in 
HFs compared to wt (Chaurushiya et al., 2012).  One factor in the inducible cell line 
approach that could explain the differing results is that ICP0 expression is induced 24 
hours before infection, perhaps allowing time for slight defects in overall ICP0 activity to 
be masked by the extended time of expression.  
 
6.2.1.2 The T67A mutation does not affect ICP0’s ability to degrade ND10 
proteins in the inducible cell line system 
Expression of the T67A mutant ICP0 protein and its effects on PML and Sp100 
degradation was analysed by Western blotting (using the Bethyl Laboratories rabbit anti-
PML antibody) (Figure 6.2).  The results with mutant R8507 shown in this figure is not 
relevant to the results presented in this section, but are discussed in section 6.3.  The figure 
also shows results with mutants K144E and N151D, which were studied in previous 
chapters. These particular results are not presented elsewhere as the PML Bethyl 
Laboratories antibody used for this Western blot was found to cross-react with ICP0 when 
ICP0 is expressed in high amounts, as seen with these mutants, giving the impression that 
unmodified species of PML were not degraded in these cell types.  It was necessary to 
present the results with these mutants here to avoid cropping the Western blot image.   
 
Expression of ICP0 occurred in the cells that were induced with doxycycline except in the 
HA-TetR control cells. The level of ICP0 expression was similar in wt ICP0 and the T67A 
mutant cells.  The T67A mutant after induction showed extensive degradation of all PML 
proteins, with only low levels of PML I/II remaining, and there was also loss of SUMO-
modified Sp100, with only unmodified Sp100 being expressed.  In retrospect, and with 
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reference to the studies which were published after these experiments were conducted, this 
result is not surprising, as while the T67A mutant prevented the degradation of RNF8, 
other substrates of ICP0 including DNA-PK, USP7 and RNF168 were shown to be 
degraded by infection with HSV-1 containing the T67A mutation (Chaurushiya et al., 
2012).  Although PML, Sp100, DNA-PK and USP7 (and also RNF8) are targeted for 
degradation by the RING finger domain of ICP0, these results imply that residue T67 is 
required only for binding to and targeting RNF8, and therefore the other substrates must be 
recognised for degradation using sequences that are different from that used for RNF8.       
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Figure 6.2 Western blot analysis of the degradation of different PML and Sp100 
isoforms by wt and mutant forms of ICP0.   
HA-TetR, HA-ICP0 and mutant ICP0 cells were induced with doxycycline (0.1 µg/ml) for 
24 hours or left untreated.  The proteins were resolved on a 7.5% SDS gel and then 
transferred to a nitrocellulose membrane and detected by probing for PML, ICP0, Sp100 
and tubulin.  The numbers on the right are molecular masses (kilodaltons).  One thing to 
note was that the PML Bethyl antibody showed cross reactivity with ICP0 when ICP0 was 
expressed at very high levels as seen with K144E and N151D.  These mutants are included 
to prevent the need to crop the image. 
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6.2.1.3 The T67A mutation does not have any substantial effects on the 
efficiency of reactivation of quiescent HSV-1 in the inducible cell line 
system 
The DNA damage response pathway and reactivation from quiescence could be linked, as 
stimuli such as UV light causes DNA damage and also induces reactivation.  Therefore, the 
T67A mutation within ICP0, which prevents the degradation of a cellular ligase component 
of the DNA damage response and prevents its downstream effects, may have an effect on 
the reactivation of quiescent HSV-1.  The effect of this mutation on reactivation of 
quiescent HSV-1 was investigated using the in1374 virus, which establishes quiescence 
very effectively (described in Table 2.8).  This reactivation assay was performed using 
HA-cICP0 and HA-T67A cells, which express ICP0 following induction with doxycycline. 
The expression of β-galactosidase indicated reactivation of viral gene expression that could 
be quantified as a percentage of positive cells in the total cell population, which was 
expressed as a proportion of the reactivation observed in HA-cICP0 cells (Figure 6.3).  
The T67A mutation caused a slight defect in reactivation of gene expression from 
quiescent HSV-1, with 67% of the levels seen following induction of wt ICP0, but this was 
less than a two-fold difference and was similar to its ability to complement the plaque 
formation deficiency of an ICP0-null mutant virus.  Therefore, the T67A mutation does not 
appear to have a substantial effect on inducing the reactivation of quiescent HSV-1 in 
cultured cells.  
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Figure 6.3 Quantification of the reactivation of viral gene expression by mutant 
T67A. 
Two random fields of view of the cells infected with in1374 and 24 hours later induced 
with doxycycline (Figure 3.3) were imaged.  The cells positive and negative for 
reactivated gene expression were counted, and the percentage of positive cells for each cell 
type calculated. These were then represented as a percentage of the positive cells in HA-
cICP0 cells expressing wt ICP0.  The bars show the mean result from the two fields of 
view from a single plate, and the error bars represent the higher and lower percentages 
from the two repeat experiments.  HA-TetR (plus doxycycline) and HA-cICP0 (no 
doxycycline) were included as negative controls.       
 
 
 
6.2.1.4 Conclusions and Discussion 
The T67A mutant behaved similarly to wt ICP0 in regards to PML and Sp100 degradation, 
and only had slight defects in complementation of an ICP0-null mutant virus and 
reactivation of gene expression from quiescent HSV-1, showing a less than two fold 
reduction when compared to wt ICP0.  As stimuli such as UV can activate the DNA 
damage response and induce reactivation, it seems unlikely that these two pathways are 
linked, at least via the T67-RNF8 interaction. Later published studies using a T67A mutant 
virus and RNF8 depletion implied that degradation of RNF8 was required to counteract its 
repressive effects on viral transcription. It is possible that these issues are affected by cell 
type or species of origin, as some of the experiments were carried out in murine embryonic 
fibroblasts lacking RNF8, or that the inducible cell line expression system is insufficiently 
sensitive to detect relatively small changes in intrinsic ICP0 activity. 
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6.2.2 The PPEYPTAP motif and SIAH-1 interaction motifs within 
ICP0 that are involved in interactions with cellular E3 
ubiquitin ligases 
HSV-1 ICP0 contains the sequence PPEYPTAP at residues 717-724, which is highly 
related to PTAP and PPXY motifs in other viral proteins that have been shown to be 
involved in interactions with cellular E3 ubiquitin ligases, including HECT and Nedd4 
(reviewed in Bieniasz, 2006).  Retroviral Gag proteins contain conserved motifs termed 
late domains that contain PTAP, PPXY or YXXL motifs that play a role in regulating viral 
budding (reviewed in Freed, 2002).  The PTAP motif within the HIV-1 Gag protein binds 
to Tsg101, an E2 ubiquitin-conjugating enzyme variant protein and a component of the 
endosomal complexes (ESCRT-1) required for transport that regulates viral budding and 
receptor endocytosis (Garrus et al., 2001; Göttlinger et al., 1991; Martin-Serrano et al., 
2001; VerPlank et al., 2001).  The PPXY motif within the gag proteins of retroviruses 
including Rous sarcoma virus (Kikonyogo et al., 2001), human T-cell leukaemia virus 
(Blot et al., 2004; Bouamr et al., 2003; Sakurai et al., 2004) and Pfizer monkey virus 
(Yasuda et al., 2002) play a role in viral budding by interacting with E3 ubiquitin ligases 
including the Nedd4 family.  The matrix (M) proteins of vesicular stomatitis virus and 
rabies virus (Harty et al., 1999), and the Ebola Vp40 protein (Harty et al., 2000; Yasuda et 
al., 2003) also contain the PPXY motifs that play roles in viral budding.  Schreiner et al. 
(2012) reported that the PPXY motif located in protein VI of adenovirus was important for 
capsid transport to the nucleus and efficient viral replication, and that it also mediates 
interaction with Nedd4 ubiquitin ligases.  Protein VI has been shown to localise to ND10, 
and its PPXY motif counteracts the Daxx mediated repression of viral transcription 
(Schreiner et al., 2012). 
 
ICP0 also contains the cellular ubiquitin ligase SIAH-1 binding motif PXAXVXPXXR at 
residues 401-410.  SIAH-1 functions as an E3 ubiquitin ligase of the RING finger class, 
and most substrates of SIAH-1 contain a PXAXVXP motif for interaction (House et al., 
2003). A yeast-two-hybrid experiment showed that SIAH-1 and ICP0 interact and that 
SIAH-1 and ICP0 colocalised in discrete nuclear foci (Nagel et al., 2011).  Overexpression 
of ICP0 resulted in the stabilisation of SIAH-1, whereas silencing SIAH-1 led to increased 
ICP0 stability during infection (Nagel et al., 2011).  Prior to this report, work in this 
laboratory had also detected a possible interaction between ICP0 and SIAH-1 in a yeast-
two-hybrid screen (N. Rauch and R.D. Everett, unpublished results). Therefore, it is 
possible that SIAH-1 and ICP0 act together to regulate their functions.   
173 
 
SIAH-1 has also been shown to interact with KSHV ORF45 in yeast-two-hybrid and co-
immunoprecipitation experiments (Abada et al., 2008).  ORF45 is an IE protein that plays 
a role in the inhibiting the host antiviral response (Zhu et al., 2010) by interacting with 
interferon regulatory factor 7 (IRF-7), thereby preventing the activation of type I IFN 
signalling (Zhu et al., 2002).  ORF45 contains a partially conserved SIAH-1 interaction 
motif (KPVAVVAGRVR) at amino acid residues 140-151.  SIAH-1 promotes the 
ubiquitination of ORF45 and its subsequent degradation via the proteasome through a 
RING finger domain-dependent mechanism (Abada et al., 2008).  
 
One of the objectives of this chapter was to analyse the function of the PPEYPTAP motif 
and SIAH-1 interaction (PXAXVXPXXR) motif within ICP0 in the context of HSV-1.  To 
achieve this objective, mutations were introduced into these motifs, the PPEYPTAP motif 
was mutated to AAEYATAA (termed the PPEYPTAP mutant), and the SIAH-1 interaction 
motif mutated from RPRAAVAPCVR to RPRAAGAGCVR (termed SIAH-IM, which 
changes the central two core conserved amino acids of the consensus motif) (chapter 
2.2.3).  These motifs were initially studied using the ICP0 inducible expression system 
(Everett et al., 2009) (chapter 2..2.3, Figure 2.2), in which doxycycline induces ICP0 
expression, but later these mutations were studied in the context of HSV-1 infection. 
 
6.2.2.1 The PPEYPTAP mutant and SIAH-IM have less than a two-fold defect 
in complementing ICP0-null mutant HSV-1 
The ability of ICP0 proteins with mutations in the PPEYPTAP and SIAH-1 interaction 
motifs to complement HSV-1 wt and ICP0-null mutant virus were analysed using the 
doxycycline inducible ICP0 expression system (Table 6.2, Figure 6.4).  During wt HSV-1 
infection, in the absence of doxycycline induction the HA-PPEYPTAP and HA-SIAH-IM 
cells gave similar PFEs to HA-cICP0 and the control HA-TetR cells.  After induction with 
doxycycline, wt HSV-1 plaque formation decreased slightly in HA-PPEYPTAP and HA-
SIAH-IM infected cells compared to that in HA-cICP0 expressing cells, but this decrease 
was less than two-fold.  Similar results were seen when infecting these cells with the ICP0-
null mutant virus without doxycycline induction.  After induction, the HA-PPEYPTAP 
cells complemented the plaque formation defect of an ICP0-null mutant virus to 66% of wt 
levels and this figure was 53% in the HA-SIAH-IM cells. Therefore, the mutations in the 
PPEYPTAP sequence and SIAH-1 interaction motif do not appear to cause substantial 
defects in complementation of an ICP0-null mutant virus. 
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The two-fold defect in complementation of an ICP0-null mutant virus in HA-SIAH-IM  
cells compared to HA-cICP0 cells is in agreement with previous literature, which showed 
that deletion of the SIAH-1 interaction motif reduced the ability to stimulate plaque 
formation compared to wt ICP0 in cells transfected with ICP0 null mutant DNA and ICP0 
plasmid with a deletion in the SIAH-1 interaction motif (Nagel et al., 2011). 
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Table 6.2 Plaque count data in cells expressing mutations in the PPEYPTAP and 
SIAH-1 interaction motif following infection with wt or ICP0-null mutant HSV-1. 
Cells were treated with doxycycline (0.1 µg/ml) for 24 hours to induce ICP0 expression or 
left untreated, and the following day infected with sequential three-fold dilutions of wt 
(in1863) or ICP0-null mutant (dl1403CMV/lacZ) HSV-1.  The starting dilutions varied 
between the cell types and viruses.  The plaque counts at each dilution, the average plaque 
counts and the relative value of each cell type compared to wt ICP0 (HA-cICP0) are shown 
from three repeat experiments.    
 
A) Wt HSV-1 minus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared to 
wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc tmtc 104 49 112950000 74.3 85.3 
tmtc 321 158 45 120000000 113.9 
tmtc 331 149 40 113800000 67.8 
cICP0 10
-4
 tmtc tmtc 158 60 152100000 100.0 100.0 
tmtc 334 132 36 105400000 100.0 
tmtc 379 199 78 167800000 100.0 
cICP0. 
PTAP 
10
-4
 tmtc 272 103 47 100400000 66.0 89.9 
tmtc 359 178 48 132500000 125.7 
tmtc 409 173 42 130600000 77.8 
cICP0. 
SIAH 
10
-4
 tmtc 255 107 36 90000000 59.2 91.2 
tmtc 474 172 49 143100000 135.8 
tmtc 435 127 56 132000000 78.7 
 
 
B) wt HSV-1 plus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared to 
wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc tmtc 136 39 113850000 72.3 67.5 
tmtc 247 103 37 88900000 51.4 
tmtc 226 110 30 82600000 78.8 
cICP0 10
-4
 tmtc tmtc 134 72 157500000 100.0 100.0 
tmtc tmtc 213 57 172800000 100.0 
tmtc tmtc 137 32 104850000 100.0 
cICP0. 
PTAP 
10
-4
 tmtc 285 116 34 93900000 59.6 88.7 
tmtc 385 182 64 150700000 87.2 
tmtc 314 174 46 125000000 119.2 
cICP0. 
SIAH 
10
-4
 tmtc 236 119 22 79100000 50.2 78.7 
tmtc 472 223 74 180700000 104.6 
tmtc 281 109 27 85100000 81.2 
 
176 
 
C) ICP0 null mutant HSV-1 minus doxycycline  
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 54 12 12 0 60000 15.8 51.3 
157 44 11 3 117250 79.8 
221 41 9 5 140000 58.5 
cICP0 10
-2
 438 127 24 18 380250 100.0 100.0 
225 52 17 2 147000 100.0 
307 88 22 7 239500 100.0 
cICP0. 
PTAP 
10
-2
 67 17 9 4 76750 20.2 67.1 
150 40 12 6 135000 91.8 
269 63 26 6 213500 89.1 
cICP0. 
SIAH 
10
-2
 104 14 9 2 70250 18.5 55.8 
125 32 15 2 102500 69.7 
201 63 23 6 189750 79.2 
 
 
D) ICP0 null mutant HSV-1 plus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 49 11 4 2 43000 0.1 0.3 
151 42 5 3 100750 0.2 
tmtc 72 18 5 171000 0.4 
cICP0 10
-4
 274 84 22 16 28900000 100.0 100.0 
tmtc 148 64 20 52000000 100.0 
276 90 55 18 38175000 100.0 
cICP0. 
PTAP 
10
-4
 159 70 24 10 21375000 74.0 65.6 
281 152 49 8 34850000 67.0 
186 75 19 10 21300000 55.8 
cICP0. 
SIAH 
10
-4
 173 45 17 3 13550000 46.9 52.8 
267 112 53 10 33750000 64.9 
185 70 14 7 17750000 46.5 
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Figure 6.4 Effect of PPEYPTAP motif and SIAH-1 interaction motif mutations within 
ICP0 on wt HSV-1 and ICP0-null mutant HSV-1 plaque formation efficiency. 
The experiments for each virus were carried out using HA-cICP0, HA-PPEYPTAP and 
HA-SIAH-IM cells, with or without doxycycline induction (0.1 µg/ml), 24 hours before 
staining for β-galactosidase activity.  The graphs from data in Table 6.2 show the average 
PFE from three replicate experiments as a percentage of HA-cICP0 cells. The error bars 
represent the standard deviation from three repeat experiments.           
 
 
 
6.2.2.2 Construction of PPEYPTAP and SIAH-IM mutant viruses 
The PPEYPTAP motif and SIAH-1 interaction motif are involved in interactions with 
cellular E3 ubiquitin ligases, so it is conceivable that they are involved with phenotypes 
that are more easily studied in the context of a mutant virus infection.  Viruses containing 
the same mutations in these motifs as those in the inducible cell line (section 6.2.2.1) and 
described in chapter 2.2.3 were constructed by homologous recombination with dl1403 
infectious DNA and plaque purified, as described in chapter 2.6. 
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6.2.2.3 Plaque formation efficiency of PPEYPTAP and SIAH-IM mutant 
viruses during infection of HFs and HepaRG cells  
Plaque assays were conducted in HepaRG cells and the more restrictive HFs.  Since ICP0 
is not required for efficient HSV-1 replication in U2OS cells, the results were presented as 
a ratio of plaques formed on these cells, and presented as a percentage of those formed in 
wt infected cells (Figure 6.5).  The SIAH-IM virus had comparable plaque formation 
efficiency to wt virus in HepaRG cells, and this was almost 50% higher in HFs, which was 
surprising as this is a more restrictive cell type. The reasons for this are unknown, but it 
may simply reflect inherent variation in plaque formation assays.  The PPEYPTAP mutant 
virus had greatly increased PFE compared to wt in HepaRG cells with around 1.7-fold 
increase, but showed around a two-fold defect in HFs in relation to wt.   
 
Mutations in the SIAH-1 interaction motif did not seem to reduce the ability of the virus to 
form plaques.  This was somewhat surprising, based on results from the inducible cell line 
(section 6.2.2.1) that showed SIAH-IM had a two-fold defect compared to wt ICP0, and 
previous results showing transfected ICP0 lacking the SIAH-1 interaction motif had 
reduced plaque forming ability in cells co-transfected with ICP0-null mutant virus DNA  
(Nagel et al., 2011).  The previous results were based on a deletion of the whole SIAH-1 
interaction motif from residues 410-420 in HSV-2 ICP0, whereas in this study mutations 
were created in two residues of the SIAH-1 interaction motif mutating from 
RPRAAVAPCVR to RPRAAGAGCVR.  Therefore, the mutations in SIAH-IM may not 
have been sufficient to completely abolish the interaction with SIAH-1. However, it could 
not be confirmed if the mutant still interacted with SIAH-1 (see section 6.2.2.5). 
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Figure 6.5 Plaque formation efficiencies of PPEYPTAP mutant and SIAH-IM viruses 
in HFs and HepaRG cells.  
Plaque assays were conducted in cells infected with sequential ten-fold dilutions of wt or 
mutant viruses.  The average plaque formation efficiency from each virus in HFs and 
HepaRG cells were calculated as a ratio of plaques formed in U2OS cells and presented as 
a percentage of the wt value.  The error bars represent the higher and lower percentages 
obtained from two repeat experiments.  
 
 
6.2.2.4 PPEYPTAP mutant and SIAH-IM viruses efficiently induce the 
dispersal of PML in infected cells, but the PPEYPTAP mutation 
affects ICP0’s translocation to the cytoplasm at late times of 
infection. 
The PPXY motif of protein VI of adenovirus has been reported to displace hDaxx from 
ND10 (Schreiner et al., 2012).  SIAH-1 is able to bind to and induce the proteasome-
mediated degradation of PML (Fanelli et al., 2004), and it has been reported that ICP0 
lacking the SIAH-1 interaction motif was more efficient at inducing the degradation of 
PML (Nagel et al., 2011).  The effects of the PPEYPTAP and SIAH-1 interaction motif 
mutations on PML, one of the main ND10 proteins, and the localisation of ICP0 were 
investigated by immunofluorescence in HFs during infection at MOI 10 (Figure 6.6) at 
two and eight hours post infection.   
 
At two hours post infection, the majority of PML had been dispersed in cells infected with 
mutant PPEYPTAP and SIAH-IM virus, which was comparable to the wt virus.  The PML 
had been dispersed in SIAH-IM infected cells, even in cells expressing a low amount of 
ICP0.  This agrees with previous literature that found PML was degraded efficiently in 
cells transfected with ICP0 lacking the SIAH-1 interaction motif (Nagel et al., 2011).  At 
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two hours post infection, ICP0 showed a nuclear distribution, whereas at eight hours post 
infection, in wt and SIAH-IM infected cells, the ICP0 was cytoplasmic.  This is expected, 
as at later times of infection ICP0 relocalises to the cytoplasm (Kawaguchi et al., 1997).  
However, in PPEYPTAP infected cells at later times of infection, there was a small 
percentage of cytoplasmic ICP0, though the majority remained in distinct foci in the 
nucleus.  Previous work with virus D14, which contains a deletion of ICP0 residues 680-
720 that overlaps with the PPEYPTAP mutation, ICP0 was retained in the nucleus at later 
times of infection and did not relocate to the cytoplasm (Everett & Maul, 1994).  Mutations 
in multiple SLS located in the C-terminal region of ICP0 also affect the intracellular 
localisation of ICP0 by causing retention of ICP0 in the nucleus at later times of infection 
(Everett et al., 2014), although none of these SLS motifs overlap with the PPEYPTAP 
motif.  Therefore, the mutations in the PPEYPTAP motif most likely affect a more 
extensive region of ICP0 that includes the SLS motifs and that is likely to play a role in the 
redistribution of ICP0 from the nucleus to the cytoplasm at later times of infection.   
    
Figure 6.6 Analysis of ICP0 and PML expression in PPEYPTAP mutant and SIAH-
IM virus infected HFs.  
HFs on coverslips were infected at an MOI of 10 with wt or mutant virus, and at 2 hours 
(A) and 8 hours (B) post infection cells were fixed and permeablised.  The cells were 
analysed by immunofluorescence staining for ICP0 (green) and PML (red).  (A) is an 
image of the cell’s nucleus whereas (B) is a wide-field image of a number of cells, as in 
some cells ICP0 was cytoplasmic at this time-point.   
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6.2.2.5 Colocalisation between ICP0 and SIAH-1 in infected cells could not 
be detected 
SIAH-1 and ICP0 have been reported to colocalise in discrete nuclear foci in HSV-1 
infected cells (Nagel et al., 2011).  Immunofluorescence was carried out to investigate 
whether ICP0 containing mutations in the SIAH-1 interaction motif would still show 
localisation with ICP0.  HFs were infected with wt or SIAH-IM virus at MOI 2 and fixed 
and stained for ICP0 and SIAH-1 at two and four hours post-infection.  In wt infected cells, 
no colocalisation between SIAH-1 and ICP0 could be detected, and SIAH-1 showed a 
diffuse nuclear staining and no colocalisation with the ICP0 foci.  The fact that no 
colocalisation between SIAH-1 and ICP0 was observed may be due to antibody specificity, 
and due to time constraints and reagent availability, no other antibodies against SIAH-1 
could be tested.  Therefore, it could not be confirmed if the mutations in the SIAH-1 
interaction motif abolished the interaction with SIAH-1 completely, or indeed if the 
published interaction between SIAH-1 and ICP0 could be verified independently by this 
method.     
     
6.2.2.6 Conclusion and Discussion 
While mutations in the SIAH-1 interaction motif caused a two-fold defect in plaque 
forming ability when complementing an ICP0-null mutant virus in the inducible cell line 
system, mutations in this motif in the context of the HSV-1 genome did not affect plaque 
forming ability in either HepaRG cells or HFs, and did not affect the dispersal of PML 
within infected cells at early times of infection, which was comparable to wt virus.  This is 
surprising based on previous transfection results that showed deletion in the SIAH-1 
interaction motif reduced plaque forming ability (Nagel et al., 2011).  Therefore, the 
results may show that abolishing the interaction with SIAH-1 does not affect ICP0 
functions within the context of viral infection to any substantial degree, or that the function 
of SIAH-1 is redundant and other cellular proteins can play the role of SIAH-1.  However, 
it could not be confirmed if the interaction with SIAH-1 was abolished in SIAH-IM virus, 
as no interaction could be detected between wt ICP0 and the SIAH-1 protein (at least in 
terms of co-localisation).  Therefore, the mutations introduced into the SIAH-1 interaction 
motif may not have abolished the interaction with SIAH-1 completely (although they do 
affect known important residues), and it is conceivable that the protein could still bind and 
therefore behave as wt ICP0 and give similar results to wt infection.  To investigate this in 
more detail, different antibodies to the SIAH-1 protein should be analysed to investigate 
the interaction between SIAH-1 and ICP0, and to test if this is lost in the SIAH-IM virus.  
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It may be necessary to mutate the whole SIAH-1 interaction motif before it can be 
concluded that this motif does not have an effect during HSV-1 infection.   
 
The PPEYPTAP motif in retroviral gag proteins is involved in interactions with E3 
ubiquitin ligases and is important for regulating viral budding.  HSV-1 ICP0 containing 
mutations in this motif had a slightly reduced PFE in HFs, but this was not the case in the 
less restrictive HepaRG cells (indeed the mutant virus appeared to have an enhanced 
plaque forming ability in these cells) (Figure 6.5).  The mutant virus dispersed PML as 
rapidly as wt virus, but at late times of infection ICP0 remained nuclear and did not 
relocate into the cytoplasm.  Different parts of the C-terminal region of ICP0 have been 
shown to be important for the redistribution of ICP0 from the nucleus to the cytoplasm at 
later times of infection.  Therefore, mutations in this motif are likely to contribute to this 
mechanism rather than being fully responsible for this effect. They may affect the protein 
folding or binding of ICP0 to the cell’s transport machinery.   
 
As PPEYPTAP motifs in retroviral gag proteins have been shown to interact with cellular 
E3 ubiquitin ligases, a yeast-two-hybrid screen could be carried out to analyse whether this 
motif within ICP0 interacts with different E3 ligases of the NEDD4 family.  Co-
immunoprecipitation experiments could be used to confirm any interactions found.  As 
PPEYPTAP motifs are involved in viral budding in retroviruses, the effects of this motif 
on HSV-1 egress could be investigated by immunofluorescence, staining for proteins of the 
nuclear egress complex and investigating if virus containing mutations in the PPEYPTAP 
motif behave in a similar manner to wt virus.   
 
6.3 The role of the sequence within ICP0 implicated in the 
binding to CoREST 
ICP0 contains a region of amino acids (resides 537 to 613) that shows some homology to a 
sequence in the N-terminal part of the cellular protein CoREST (Gu et al., 2005).  CoREST 
is a corepressor for the cellular protein REST, that along with HDAC1 and HDAC2, forms 
a transcriptional repressor complex and has a role in chromatin modification (You et al., 
2001).  In non-neuronal cells, ICP0 has been shown to bind to CoREST during infection 
with HSV-1, leading to the displacement of HDAC1 from the REST/CoREST/HDAC 
complex (Gu et al., 2005).  Subsequent studies showed that the ICP0 residues 671 (aspartic 
acid) and 673 (glutamic acid) are required for ICP0 binding to CoREST (Gu & Roizman, 
2009).  It was shown that PML was largely but not fully degraded in cells infected with the 
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double point mutant R8507 (D671A/E673A) in the CoREST binding region and viral 
replication was delayed (Gu & Roizman, 2009).  This region is within the D14 deletion 
mutation which showed decreased ICP0 activity in the presence of ICP4 (Everett, 1988).    
 
Roizman and Gu (2009) suggested that the REST/CoREST/HDAC complex may repress 
viral gene expression in the absence of ICP0, and therefore may have a role in the 
reactivation/derepression of viral gene expression.  However, Ferenczy et al. (2011) found 
that R8507 and wt virus activated quiescent genomes to an equivalent extent in a cell-
based system that quantified GFP expression from a reporter gene in a mutant virus that 
readily establishes quiescent infections in cell culture. This conclusion was based on the 
proportion of cells that became GFP positive after superinfection with R8507 or wt HSV-1, 
although GFP mRNA was reduced compared to wt (Ferenczy et al., 2011).  Therefore, the 
aim of this section (which was initiated before publication of the Ferenczy et al. study) was 
to investigate the double point mutant R8507 (D671A/E673A) to determine if it plays any 
role in the reactivation/derepression of viral gene expression from quiescent genomes 
using the inducible ICP0 expression system.    
 
 
6.3.1 Ability of R8507 mutant ICP0 to complement an ICP0 null 
mutant HSV-1 virus using the inducible ICP0 expression 
system 
The mutations defined as R8507 in the original publications from the Roizman laboratory 
were independently introduced into the HSV-1 strain 17 ICP0 sequence. For simplicity, the 
mutant ICP0 protein produced here was also termed R8507. The ability of the R8507 
mutant to complement ICP0-null mutant (dl1403/CMVLacZ) and wt HSV-1 (in1863) 
infection was analysed by plaque assay with or without doxycycline to induce ICP0 
expression (Table 6.3, Figure 6.7).  HA-TetR control cells, HA-cICP0 and HA-R8507 
cells infected with the wt virus all had similar plaque numbers without ICP0 induction.  
After ICP0 induction of wt infected HA-R8507 cells, there was a slight decrease in plaque 
numbers compared to HA-cICP0 wt infected cells, though this was less than two-fold.  In 
cells infected with an ICP0-null mutant (dl1403) virus and in the absence of induction, 
there was no difference in plaque numbers between HA-TetR cells and HA-cICP0 cells, 
with HA-R8507 cells showing a slight decrease.  ICP0-null mutant virus plaque numbers 
were increased by about 200-fold after induction of wt ICP0 expression compared to HA-
TetR control cells.  The ICP0-null mutant virus infected HA-R8507 cells induced with 
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doxycycline were 50% as effective as HA-cICP0, and therefore had only a slight defect in 
the complementation of ICP0-null mutant virus. 
 
Table 6.3 Plaque count data in cells expressing R8507 following infection with wt or 
ICP0-null mutant HSV-1. 
Cells were treated with doxycycline (0.1 µg/ml) for 24 hours to induce ICP0 expression or 
left untreated, and the following day infected with sequential three-fold dilutions of wt 
(in1863) or ICP0-null mutant (dl1403CMV/lacZ) HSV-1.  The starting dilutions varied 
between the cell types and viruses.  The plaque counts at each dilution, the average plaque 
counts and the relative value of each cell type compared to wt ICP0 (HA-cICP0) are shown 
from three repeat experiments.    
   
A) Wt HSV-1 minus doxycycline  
Cells 
HA- 
Dil 1  1/3   1/9  1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc 124 59 32 58900000 71.8 90.1 
tmtc tmtc 100 31 86850000 108.4 
cICP0 10
-4
 tmtc 265 101 28 82000000 100.0 100.0 
tmtc tmtc 115 21 80100000 100.0 
cICP0. 
R8507 
10
-4
 tmtc 308 133 38 104900000 127.9 113.1 
tmtc tmtc 97 26 78750000 98.3 
 
 
 
B) Wt HSV-1 plus doxycycline 
Cells 
HA- 
Dil 1  1/3   1/9    
1/27 
Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-4
 tmtc 163 81 19 57700000 37.0 44.3 
tmtc tmtc 84 16 59400000 51.6 
cICP0 10
-4
 tmtc tmtc 179 56 156150000 100.0 100.0 
tmtc tmtc 118 46 115200000 100.0 
cICP0. 
R8507 
10
-4
 tmtc tmtc 106 40 101700000 65.1 60.1 
tmtc tmtc 72 23 63450000 55.0 
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C) ICP0 null mutant HSV-1 minus doxycycline  
Cells 
HA- 
Dil 1  1/3   1/9    
1/27 
Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 tmtc tmtc 357 22 1903500 89.8 122.5 
tmtc tmtc 176 22 1089000 155.1 
cICP0 10
-2
 tmtc tmtc 312 53 2119500 100.0 100.0 
tmtc tmtc 105 17 702000 100.0 
cICP0. 
R8507 
10
-2
 tmtc tmtc 132 23 904500 42.7 59.8 
tmtc tmtc 78 14 540000 76.9 
 
 
 
D) ICP0 null mutant HSV-1 plus doxycycline  
 
Cells 
HA- 
Dil 1  1/3   1/9   1/27 Average Relative % 
compared 
to wt 
Ave 
relative 
values 
TetR 10
-2
 tmtc tmtc 93 14 607500 0.5 0.5 
tmtc tmtc 184 25 1165500 0.6 
cICP0 10
-4
 tmtc tmtc 121 50 121950000 100.0 100.0 
tmtc tmtc 204 77 195750000 100.0 
cICP0. 
R8507 
10
-4
 tmtc 139 68 21 53200000 43.6 50.2 
tmtc 278 143 45 111200000 56.8 
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Figure 6.7 PFE of cells expressing R8507 following wt HSV-1 and ICP0-null mutant 
HSV-1 infection.   
HA-TetR, HA-cICP0 and HA-R8507 cells were infected with wt HSV-1 (in1864) or ICP0-
null mutant virus (dl1403) and either induced with doxycycline (0.1 µg/ml) or left 
untreated.  The following day the cells were stained for β-galactosidase activity to visualise 
plaque formation.  The graphs from the data in Table 6.3 show the average plaque forming 
ability of HA-TetR and HA-R8507 as a percentage of plaques formed in HA-cICP0 cells.  
The error bars represent the range between two repeat experiments.     
 
 
6.3.2 The R8507 mutation affects the rate of degradation of ND10 
proteins 
R8507 is located within the C-terminal quarter of ICP0, which is required for efficient 
localisation to ND10 (Maul & Everett, 1994), and Gu and Roizman found that PML 
degradation was delayed in R8507 infected cells (Gu & Roizman, 2009).  Therefore, the 
effects of the R8507 mutation on PML and Sp100 degradation in the ICP0 inducible 
expression system were investigated by Western blotting (Figure 6.2).  After doxycycline 
induction, wt ICP0 (HA-cICP0) caused extensive degradation of all PML proteins and 
SUMO-modified Sp100, with only unmodified Sp100 remaining.  HA-R8507 cells after 
induction showed degradation of the different PML isoforms, with only low levels of PML 
I/II remaining.  The R8507 mutant did not degrade SUMO modified Sp100 as efficiently 
as wt ICP0, with some SUMO modified Sp100 remaining, but this was at lower levels than 
in the HA-TetR control cells.   
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6.3.3 R8507 had a two-fold reduction in reactivating viral gene 
expression compared to wt ICP0. 
It has been suggested that the REST/CoREST/HDAC complex may play a role in 
reactivation/derepression of viral gene expression in the absence of ICP0 (Gu & Roizman, 
2009).  The ICP0 residues required for binding to CoREST (D671A/E673A), leading to 
displacement of HDAC1 from the complex, were investigated for their role in the 
reactivation/derepression of viral gene expression from quiescent genomes in the inducible 
ICP0 expression system.   
 
HA-cICP0 and HA-R8507 cells were infected with in1374 virus, and the following day 
ICP0 expression was induced by the addition of doxycycline.  The percentage of cells 
positive for β-galactosidase expression were calculated and presented as a percentage 
expression of HA-cICP0 cells (Figure 6.8).  The results showed that R8507 mutant has 
slight defects in reactivating gene expression, with 50% of wt levels.  The reactivation 
efficiency of mutant R8507 correlates with the complementation ability of an ICP0-null 
mutant virus, with both showing a two-fold reduction compared to wt.    
 
 
 
Figure 6.8 Quantification of reactivated viral gene expression by ICP0 mutant R8507.  
HA-cICP0 and HA-R8507 cells infected with in1374 virus and ICP0 expression induced 
by doxycycline (except where indicated) the next day were stained 24 hours later to detect 
β-galactosidase activity (Figure 3.3).  The cells from a single plate were imaged, and the 
proportion of cells expressing β galactosidase for each cell type was represented as a 
percentage of HA-cICP0 reactivation efficiency. The error bars represent the higher and 
lower percentages obtained from two images. 
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6.3.4 Conclusion and Discussion 
Using the inducible ICP0 expression system, it was found that cells expressing R8507 
mutant ICP0 had a two-fold reduction compared to wt ICP0 protein when complementing 
an ICP0-null mutant virus and in reactivation of quiescent viral gene expression.  As 
mutations in the residues involved in CoREST binding did not have a major effect on 
complementing the PFE of an ICP0-null mutant virus or reactivation, it is unlikely that this 
mechanism plays a major role in the reactivation of viral gene expression.  
 
Cells expressing R8507 did not degrade PML completely to wt levels, with some SUMO 
unmodified PMLI/II remaining.  This is in agreement with previous work that showed that 
PML degradation is delayed in cells infected with R8507 (Gu & Roizman, 2009).  Recent 
work has shown that R8507 virus had a three-fold defect in plaque forming ability in 
HepaRG cells, while in HFs it was found not to be defective, and it was confirmed that 
PML degradation was slightly delayed in R8507 infected cells (Everett et al., 2014). Given 
that the R8507 mutations lie in a region that has some effects on ICP0 localisation and the 
rate of PML degradation (Ciufo et al., 1994; Everett et al., 2014; Everett & Maul, 1994; 
Maul & Everett, 1994), it is not possible to conclude whether the slight defects in the 
activity of the R8507 ICP0 protein can be attributed to its lack of interaction with CoREST 
or to ND10-related phenomena.    
 
6.4 Deletion of residues downstream from ICP0 RING 
finger domain that show sequence similarity between 
different alphaherpesviruses 
The region downstream from the RING finger domain of ICP0 shows sequence similarity 
between HSV-1, HSV-2 and herpesvirus B of macaque monkey (Figure 6.9).  This region 
has been shown to be important for the E3 ligase activity of ICP0, as deletion between 
residues 162-188, which does not include the RING finger domain, was E3 ligase negative 
in vitro (Boutell et al., 2002).  Further downstream from this region, a deletion mutant 
lacking residues 197-222 was negative for the ability to induce accumulations of 
conjugated ubiquitin (Everett, 2000).  
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Figure 6.9 The region downstream of the RING finger domain is conserved in HSV-1, 
HSV-2 and HVB.  
The asterisks denote completely conserved residues from the three herpesviruses.  Labelled 
are the deletion mutants ICP0Δ197-211 and ICP0Δ211-222, that were analysed in this 
study. 
 
 
 
In this section, the region downstream from the ICP0 RING finger domain between 
residues 197 and 222 was investigated (Figure 6.9).  This region contains two distinct 
sections of high sequence similarity between the related proteins referred to above. These 
could be substantially altered separately using existing ICP0 mutants that contain 
insertions of sequences including an EcoRI site, namely E13, R3 and E32. As described in 
the Methods chapter (section 2.2.4), plasmids were constructed that included deletions 
between the E13 and R3, or the R3 and E32 insertion sites. These plasmids were used to 
isolate mutant viruses containing deletions within ICP0 of residues 197-211 (ICP0Δ197-
211) and residues 211-222 (ICP0Δ211-222) by homologous recombination.  Isolation of a 
virus containing a deletion of this whole region from residues 197-222, which has been 
studied previously in the context of plasmid transfection experiments, was attempted but 
was not successful as any virus made repeatedly reverted back to an ICP0-null mutant 
virus. 
 
The aim of this section was to investigate the region downstream of the RING finger 
domain, to characterise the phenotypes of viruses containing deletions within this region, 
and to analyse their importance in the context of viral infection.   
 
6.4.1 The ICP0Δ211-222 virus has substantial defects in the 
plaque formation efficiency in HFs and HepaRG cells. 
Cell type can influence the apparent phenotypes of ICP0 mutant viruses and their PFE.  
Therefore, plaque assays were carried out in HepaRG cells and the more restrictive HFs, 
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and the plaques formed in these cell types were calculated as a ratio of those produced on 
the permissive U2OS cells.  The results are presented on a log scale as a proportion of 
plaques produced compared to wt virus (Figure 6.10).   
 
The deletion mutant ICP0Δ197-211 did not have a substantial defect in the formation of 
plaques in HFs, with 79% of wt activity.  In HepaRG cells this was lower at 56% of wt 
activity, but this is less than a two-fold reduction.  The deletion ICP0Δ211-222 caused a 
substantial decrease in PFE compared to wt, with over a 70-fold reduction in plaque 
numbers compared to wt in HepaRG cells, and a 500-fold reduction in the more restrictive 
HFs. 
 
 
 
 
 
Figure 6.10 PFE of ICP0Δ197-211 and ICP0Δ211-222 viruses in HepaRG cells and 
HFs.   
Plaque assays were conducted in cells infected with wt HSV-1 or ICP0 mutant viruses. The 
average PFE of the viruses in each cell type was calculated as a ratio of plaques formed in 
U2OS cells, and shown as a percentage of the wt value. The error bars represent the higher 
and lower percentages obtained from two repeat experiments. 
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6.4.2 ICP0Δ211-222 virus fails to degrade PML despite showing 
colocalisation 
In transfection experiments, a deletion within ICP0 from residues 197 to 222 was shown to 
be negative in the accumulation of conjugated ubiquitin (Everett, 2000).  The formation 
and localisation of conjugated ubiquitin is a good indicator of E3 ligase activity and the 
ability to induce the degradation of substrates via the proteasome.  Therefore, due to this 
deletion effect on the accumulation of ubiquitin, the mutants ICP0Δ197-211 and 
ICP0Δ211-222 that span this deletion were investigated for their abilities to colocalise with 
and degrade PML.   
 
The ability of the deletion mutants to colocalise with PML was investigated by 
immunofluorescence in HFs infected at MOI 10, and stained at two and four hour post 
infection (Figure 6.11).  In wt infected cells, the PML had been dispersed by two hours 
post infection.  This contrasts with non-infected cells, where the PML remained in distinct 
foci that were scattered throughout the nucleus.  In cells infected with ICP0Δ197-211, the 
PML signal was also dispersed at two hours post infection and was comparable to wt 
infected cells.  The ICP0Δ211-222 mutant did not induce the dispersal of PML even at four 
hours post infection, and ICP0 showed colocalisation with the PML foci.       
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Figure 6.11 Expression of ICP0 in HFs infected with ICP0Δ197-211 and ICP0Δ211-
222 and the ability of the mutants to colocalise with and disperse PML in infected 
cells.   
HF cells were infected at MOI of 10 with wt and mutant virus stained for ICP0 (green) and 
PML (red) at 2 hours (A) and 4 hours (B) post infection. 
 
 
 
The rate of PML degradation and viral gene expression in the mutant viruses was 
investigated by Western blot in HFs infected at an MOI 5 (Figure 6.12).  In wt infected 
cells, the majority of PML was degraded by two hours post infection, with only minimal 
amounts of unmodified PML remaining. PML degradation was slightly delayed to four 
hours post infection in ICP0Δ197-211 infected cells.  ICP0Δ211-222 showed reduced 
degradation of PML at the two and four hours post infections, which is consistent with the 
immunofluorescence results (Figure 6.11).  Some degradation of PML had occurred in 
ICP0Δ211-222 infected cells by the six hour and eight hour time-points. 
 
Viral gene expression was analysed at the same time as PML degradation at MOI 5 
(Figure 6.12).  Even at this high MOI which can potentially mask the true effects of ICP0 
mutations on viral gene expression, ICP0Δ211-222 shows a substantial delay in gene 
expression of the early UL42 and late capsid protein VP5, whereas the effect on ICP0 
expression was not as apparent. 
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Figure 6.12 Ability of ICP0Δ197-211 and ICP0Δ211-222 mutant viruses to degrade 
PML and their effects on the rate of viral gene expression during an eight hour 
infection.  
HFs were infected with wt or mutant viruses at an MOI of 5 and samples harvested at 2, 4, 
6 and 8 hours post infection.  The proteins were resolved on a 7.5% SDS gel, transferred to 
a nitrocellulose membrane, and detected by probing for ICP0, UL42 and VP5, representing 
IE, early and late classes of viral proteins, respectively.   
 
 
 
6.4.3 Viral gene expression was substantially delayed in 
ICP0Δ211-222 virus infections 
Viral gene expression was shown to be delayed in ICP0Δ211-222 infected cells, even at 
the high MOI of 5 (Figure 6.12).  Therefore, the effects of the deletions downstream of the 
RING finger on viral gene expression were investigated at the lower MOI of 1 over the 
course of an eight hour infection in HFs.  The results (Figure 6.13) show that the 
expression of ICP0 in both ICP0Δ197-211 and ICP0Δ211-222 was comparable to wt 
expression levels at each time point.  The differences in gene expression become apparent 
for expression of the early UL42 protein and late VP5 capsid protein.  In ICP0Δ197-211 
infected cells, gene expression of the early and late proteins was slightly lower than that 
seen with the wt virus but expression began at the same time points.  However, ICP0Δ211-
222 has a substantial effect on viral gene expression, with no expression of UL42 or VP5 
by eight hours post infection.  Therefore, although ICP0Δ211-222 does not have any 
considerable defect in ICP0 expression compared to wt, early and late gene expression is 
severely affected.   
194 
 
       
Figure 6.13 Comparison of the viral gene expression efficiencies of the ICP0Δ197-211 
and ICP0Δ211-222 mutant viruses compared to wt.   
HFs were infected at an MOI of 1 and then samples harvested at 2, 4, 6 and 8 hours post 
infection were analysed by Western blotting, probing for ICP0, UL42, and VP5 
representing IE, early and late classes of viral proteins.  Actin was the loading control. 
 
 
 
6.4.4 Conclusions and Discussion 
ICP0Δ197-211 showed a slight decrease in plaque forming ability compared to wt virus 
but was comparable to wt in gene expression and PML degradation.  The ICP0Δ211-222 
virus carrying deletion of residues directly downstream, however, showed major defects in 
PFE, PML degradation and gene expression of early and late proteins even in high MOI 
infections.  
 
The ICP0Δ197-222 region has previously been shown to be negative for the accumulation 
of conjugated ubiquitin in transfection experiments (Everett, 2000), but, in the virus 
infected cell experiments ICP0Δ197-211 did not affect ICP0s ability to degrade PML, and 
in ICP0Δ211-222 infected cells, PML degradation was severely delayed, although there 
was some degradation at six hours post infection.  Therefore, ICP0Δ211-222 must retain 
some ability to conjugate ubiquitin onto target proteins, albeit maybe less efficiently.  The 
ability of these mutant proteins to conjugate ubiquitin could be further investigated by 
immunofluorescence staining for ICP0 and conjugated ubiquitin (FK2 antibody).  Also, the 
E3 ligase activity of these mutants could be investigated in vitro for their ability to catalyse 
the formation of polyubiquitin chains in the presence of wt ubiquitin and E2 ubiquitin 
conjugating enzymes.   
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Residues 1-211 of ICP0 are active in in vitro ubiquitin conjugation assays (Boutell et al., 
2002), and therefore resides 211-222 cannot be absolutely required for core RING 
function.  Yeast-two-hybrid experiments showed that the N-terminal region of ICP0 
between residues 1-388 interacted with PML.I (Cuchet-Lourenço et al., 2012), and virus 
deletion studies showed that residues 212-311 within ICP0 are involved in the dissociation 
and degradation of PML (Perusina Lanfranca et al., 2013).  Therefore, the defect of 
ICP0Δ211-222 in degrading PML could be due to this region being involved in substrate 
recognition.  This hypothesis could be investigated by using cells expressing the different 
PML isoforms and analysing the effect that ICP0Δ197-211 (and ICP0Δ211-222) have on 
these compared to wt, in particular PML.I isoform cells.  If residues 211-222 are involved 
in PML substrate recognition, this would not completely explain the observed phenotype 
of this virus, and therefore this deletion may affect binding to other cellular or viral 
proteins.    
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7 Summary, Discussion and Future Prospects 
7.1 Summary 
The RING finger domain of ICP0 acts as an E3 ubiquitin ligase (Boutell et al., 2002), 
inducing the degradation and dispersal of ND10 proteins (Chelbi-Alix & de The, 1999; 
Everett & Maul, 1994; Parkinson & Everett, 2000), which are part of the cellular intrinsic 
antiviral defence mechanism.  The RING finger domain contains an alpha-helix and loop 
regions (Barlow et al., 1994), and these have been shown to be important for ICP0’s 
interaction with E2 ubiquitin-conjugating enzymes (Barlow et al., 1994; Vanni et al., 
2012).  Some of the studies presented in this thesis aimed to contribute more detail to the 
understanding of the alpha-helix of the RING finger domain.  Previous work using the 
inducible ICP0 expression system suggested that lytic infection and reactivation may 
involve differential activities of ICP0 that were revealed by a mutation in the alpha-helix, 
N151D (Vanni et al., 2012).  Therefore, to extend this work, mutations in the alpha-helix 
of ICP0 were investigated, including N151D and additionally K144E and the double 
mutant KE/ND using both the inducible ICP0 expression system and virus infection 
studies.  The experiments with the ICP0 inducible expression system confirmed the 
previous results and showed that the single mutants had a greater defect during reactivation 
than complementation.  The data using the virus infection studies showed a better 
correlation between the ability to degrade ICP0 substrates, and efficiencies of lytic 
infection and reactivation.  However, the reactivation experiments were carried out at an 
MOI where lytic infection was not severely impeded. Therefore, residues K144 and N151 
are important for ICP0’s activity, especially for reactivation of quiescent HSV-1.  These 
investigations indicated however that there is no strong evidence to suggest that ICP0 
utilises differential activities of its RING finger to mediate reactivation and the stimulation 
of lytic infection, despite the likely dissimilar nature of the viral chromatin structure in the 
two situations.   
 
Furthermore, as the RING finger shows a degree of sequence similarity among 
alphaherpesviruses, regions of homology that had not previously been investigated were 
studied along with motifs contained within ICP0 that had been reported to interact with E3 
ubiquitin ligases or other cellular proteins.  These studies indicated that a region 
downstream of the RING finger domain (residues 211-222) of ICP0 is important for 
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ICP0’s activity, but no major role was detected for motifs that potentially interact with 
SIAH-1, Nedd4 family ubiquitin ligases, or CoREST.     
 
7.2 Discussion  
Conclusion and discussion points have been discussed at the end of each results chapter.  
Therefore to avoid overlap, only information not discussed in these chapters is reviewed 
here. 
 
7.2.1 Residues in the alpha-helix are required for efficient ICP0 
activity during the lytic phase and are important for 
reactivation 
During lytic infection, mutant K144E was more defective than the N151D mutant, and this 
was especially apparent at low MOIs.  It has previously been shown that mutations in the 
RING finger region of ICP0 could affect the levels of ICP0 contained within the tegument 
(Delboy et al., 2010; Maringer & Elliott, 2010; Maringer et al., 2012).  It was reported that 
the virions of the K144E and FXE mutant viruses contained greatly reduced levels of 
tegument ICP0 and may have defects in transport of the capsid to the nucleus.  However, 
mutant N151D virions contained wt levels of tegument ICP0, which was detected in the 
nuclear periphery (Delboy & Nicola, 2011; Delboy et al., 2010).  The results from this 
thesis, showing that the K144E mutation caused a greater defect than N151D during lytic 
infection, could in principle be explained by lack of tegument ICP0 in K144E virions and 
defects in transportation of the capsid to the nucleus.  This would mean that fewer viral 
genomes entering the nucleus and therefore lower viral replication occurs.  The role of 
tegument ICP0, however, remains incompletely understood, and independent verification 
of these studies is required.  The replication of K144E virus was improved at higher MOIs, 
therefore genomes must be able to be transported and enter the nucleus if they are present 
in high enough copies, and the same must be true of ICP0 null mutant HSV-1.  However, 
the hypothesis of tegument ICP0 being involved with capsid transport does not fully 
explain the phenotypes observed with the N151D mutant virus.  Mutant N151D is reported 
to contain wt levels of tegument ICP0, but it shows an intermediate phenotype compared to 
wt during lytic infection.  Therefore, the tegument levels of ICP0 in the RING finger 
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mutant viruses and their defects during lytic infection should be investigated to determine 
if the replication defects are correlated with lack of tegument ICP0 and transport to the 
nucleus.      
  
The alpha-helix mutants reactivated quiescent HSV-1 poorly, even at multiplicities at 
which they replicated efficiently.  The data suggest that there may be a greater requirement 
for ICP0 activity during reactivation of chromatinised quiescent genomes than for 
stimulating gene expression from unchromatinised genomes at the beginning of infection.  
These mutations and their effects on reactivation confirm that ICP0 is almost essential for 
reactivation of quiescent HSV-1 genomes in cultured cells, even under conditions such as 
high input MOI, where it is dispensable for lytic infection.  
 
7.2.2 ICP0 has the ability to interact with multiple E2 ubiquitin 
conjugating enzymes and mutations in the alpha-helix may 
affect these interactions 
The yeast-two-hybrid experiments showed that wt ICP0 has the potential to interact with 
the E2 ubiquitin conjugating enzymes UBE2V1 and UBE2W, as well as the previously 
described UBE2D1 and UBE2E1 enzymes (UbcH5a and UbcH6) (Boutell et al., 2002; 
Vanni et al., 2012).  wt ICP0 could induce polyubiquitin chain formation in the presence of 
both UBE2D1 and the UBE2N-UBE2V1 heterodimer.  However, auto-ubiquitination of 
ICP0 was detected in the presence of UBE2D1 but not with UBE2N-UBE2V1.  These data 
are consistent with previous reports that UBE2N-UBE2V1 is involved in the formation of 
unanchored K63-linked polyubiquitin chains rather than the initial ubiquitin attachment 
event in the presence of E3 ubiquitin ligases CHIP and TRAF6 (Windheim et al., 2008; Xu 
et al., 2008).   
 
The interaction of the alpha-helix mutants in ICP0 with UBE2V1 was below the limit of 
detection in the yeast-two-hybrid experiment.  However, all the mutants retained some 
ability to catalyse polyubiquitin chains in the presence of UBE2N-UBE2V1, but these 
levels were below that of wt ICP0.  N151D had reduced ability compared to wt, and this 
activity was reduced further with the K144E mutant, and KE/ND had levels only slightly 
above the ICP0-2C mutant.  
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In the yeast-two-hybrid experiment, the interaction between UBE2W and KE/ND was lost 
on the highest selection plate or was below the limit of detection.  UBE2W attaches a 
single ubiquitin to the N-terminus of its substrates, as opposed to ubiquitination onto a ε-
NH2 group of a lysine residue (Tatham et al., 2013).  N-terminal ubiquitin is not dependent 
on lysine residues and has been shown to be involved in the degradation of certain proteins 
including p21 (a regulator of the cell cycle and DNA replication (Bloom et al., 2003)), 
MyoD (a transcription factor involved in muscle differentiation (Breitschopf et al., 1998)), 
latent membrane protein 1 of EBV, which is essential for the transformation of B 
lymphocytes (Aviel et al., 2000), and the E7 oncoprotein of human papillomavirus 16 
(Reinstein et al., 2000).  These proteins do not show homology between their N-terminal 
domains, so recognition must involve different members of the ubiquitin pathway 
(Ciechanover & Ben-Saadon, 2004).  The functional relevance of N-terminal ubiquitin 
remains unclear within the context of HSV-1 infection.  However, as the interaction 
between KE/ND and UBE2W was lost in the yeast-two-hybrid experiment and this mutant 
was negative for its ability to conjugate ubiquitin and in the degradation of PML, the role 
of UBE2W should be investigated.   
 
It is already known that different E2 enzymes produce different chain linkages or have 
different specificities.  It is possible that ICP0 utilises different combinations of E2 
ubiquitin conjugating enzymes for different functions, or that E2 ubiquitin conjugating 
enzymes work sequentially to produce polyubiquitin chains.  KSHV encodes two RING 
finger like E3 ubiquitin ligases termed K3 and K5 (MIR1 and MIR2) (Coscoy et al., 2001), 
and K3 has been shown to interact with UBE2D1-3 and UBE2N (Dodd et al., 2004).  To 
synthesise Lys63 linked chains, K3 uses the sequential action of two E2 ubiquitin 
conjugating enzymes.  The ubiquitin is first attached to the substrate by UBE2D2-D3 and 
then subsequent ubiquitin is linked via Lys63 chains by UBE2N (Duncan et al., 2006).  
The Lys63 polyubiquitin chains act in immune evasion by downregulating MHC class I to 
avoid CTL recognition (Duncan et al., 2006).  BRCA-1 RING finger E3 ubiquitin ligase 
has additionally been shown to interact with multiple E2 ubiquitin-conjugating enzymes, 
including UBE2E1, UBE2E2, UBE2N, UBE2K and UBE2W.  UBE2E2 and UBE2W are 
involved in chain initiation, whereas UBE2N-UBE2V1 and UBE2K carry out chain 
elongation, forming Lys63 and Lys48 chains respectively (Christensen et al., 2007).  
Therefore, like KSHV K3 and BRCA-1, ICP0 may interact with multiple E2 ubiquitin 
conjugating enzymes to achieve polyubiquitination with different chain specificities.  For 
example, ICP0 may interact with one E2 ubiquitin-conjugating enzyme that carries out 
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chain initiation or mono-ubiquitination events, and another that is involved in chain 
elongation.  As UBE2N-UBE2V1 is only involved in chain elongation, it is dependent on 
the initial mono-ubiquitination of a lysine residue within the substrate.  Therefore, the 
interaction with UBE2N-UBE2V1 and ICP0 is only functionally relevant if ICP0 is still 
able to interact with the E2 enzyme that carries out the initial ubiquitination event.   
 
7.2.3 Do the K144E and N151D mutations affect an interface that 
binds E2 ubiquitin conjugating enzymes? 
A study by Vanni et al. (2012) using homology modelling and site directed mutagenesis 
aimed to map the interaction interface between the ICP0 RING finger and E2 ubiquitin 
conjugating enzyme UBE2D1.  They found that ICP0 residues V118, T120, P154 and 
L155 located in the loop regions were likely to form contact residues with UBE2D1 (Vanni 
et al., 2012).  This thesis has found that residues N151 and K144 may also be involved in 
the interactions with E2 ubiquitin conjugating enzymes.  N151 and K144 are both 
predicted to be exposed on the alpha-helix based on the structure from EHV and could 
form a binding interface (Figure 7.1).  The double mutant KE/ND did not induce the 
degradation of PML and was defective in its ability to conjugate ubiquitin, although the 
single mutants retained the ability to conjugate ubiquitin and to degrade PML (albeit less 
efficiently, especially for K144E).  Therefore, mutating both K144 and N151 within the 
same protein may greatly affect the E3 ligase ability of ICP0 or prevent the binding of E2 
ubiquitin conjugating enzymes.  The interaction of UBE2W was lost for KE/ND and in 
vitro polyubiquitin chain formation was greatly reduced for KE/ND.   
 
Residue M147 is also predicted to be on the same interface as K144 and N151.  The Vanni 
et al. study found that mutating the M147 residue affected ICP0’s interaction with 
UBE2D1 and UBE2E1 and its ability to conjugate ubiquitin (Vanni et al., 2012).  
Therefore, this alpha-helix interface may also contribute to the binding of E2 ubiquitin-
conjugating enzymes.  Therefore, if as predicted this edge of the alpha-helix forms a 
binding interface, this residue should be studied alone and in combination with K144 and 
N151 and the previously described resides to investigate if this hypothesis is correct.  This 
study, along with previous studies, demonstrates that the alpha-helix residues are important 
for ICP0’s activity and have the potential to interaction with E2 ubiquitin-conjugating 
enzymes.  However, mapping the interaction interface is complicated by the lack of a 
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crystal structure for ICP0.  At present, the structure of the ICP0 RING finger domain and 
alpha-helix can only be predicted based on the structure of EHV-1 ICP0.    
 
 
 
 
 
 
Figure 7.1 The RING finger domain of HSV-1 ICP0 modelled on EHV EICP0. 
A) Comparison of ICP0 and its viral orthologue EICP0 from EHV. The zinc-binding 
resides are highlighted in grey and are conserved.  The alpha-helix resides that were the 
focus of this thesis are highlighted in red.  M147, which may form part of the same binding 
interface as K144 and N151, is highlighted in blue. 
B) Locations of residues K144 and N151 in EHV ICP0.  M147 may also form part of this 
binding interface and has been studied previously by Vanni et al. (2012).  
 
 
 
7.2.4 Assay dependence of specific results 
The results from this study appear to vary in detail between the different experimental 
systems used, such as the ICP0 inducible cell line and the virus infection studies in HFs 
and HepaRG cells.  The results differ in terms of ND10 disruption and PML degradation, 
with no degradation/disruption occurring with N151D mutant in the inducible cell line 
compared to N151D behaving in a similar manner to wt in virus infection studies, 
A 
B 
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especially at high MOIs.  The relative defects of the RING finger alpha-helix mutants also 
varied in detail between the two systems.  For each of the systems used, the readout is 
assay-dependent and can be influenced by the amount of ICP0 expressed and the length of 
time that it is expressed (in the case of the inducible cell line), and the cell type and MOI 
during virus infection studies.  All of these factors, which in many cases are the choice of 
the investigator, influence the results and their potential interpretation.  However, despite 
the variations in relative defects of the mutants when comparing between different 
experiments and assays, the results follow a similar trend. Mutant N151D had an 
intermediate defect that was less visible during higher MOI infections, a larger defect was 
observed with K144E, and the double mutant KE/ND was highly defective in all the assays 
and in both virus infection studies and the inducible cell line.        
 
The results about the E3 ligase activity of the alpha-helix mutants and their interactions 
with E2 ubiquitin conjugating enzymes should also be interpreted with care.  These assays 
may not truly represent the mutants’ ICP0 mediated ubiquitin ligase activity in vivo.    
Therefore, more work will be needed to investigate whether these residues in the alpha-
helix are important for interactions with components of the ubiquitin pathway in infected 
cells, and the potential roles of different E2 enzymes in the HSV-1 life cycle. 
 
7.2.5 Region downstream of the RING finger domain may be 
involved in substrate targeting  
The ICP0Δ211-222 virus had a severe plaque forming defect, exhibited poor expression of 
early and late proteins, and was defective in the ability to induce the degradation of PML.  
This region is however, outside of the core domain required for E3 ubiquitin ligase activity 
in vitro (Boutell et al., 2002), although it overlaps a larger deletion that was defective for 
production of conjugated ubiquitin chains in transfected cells (Everett, 2000). Previous 
studies have suggested that the region downstream from the RING finger domain may be 
involved in interacting with and degradation of PML.I (Cuchet-Lourenço et al., 2012; 
Perusina Lanfranca et al., 2013).  Therefore, the region of ICP0 within the deletion 211-
222 may play a role in the targeting of PML to the proteasome.  ICP0 targets a number of 
proteins for substrate mediated degradation, however, except for USP7 and RNF8, for 
most of these proteins the binding region between ICP0 and the target protein is unknown.  
ICP0 interacts with USP7 through a motif located in its C-terminal third between residues 
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618-634 (Meredith et al., 1995), and the cellular E3 ligase RNF8 via residue T67 
(Chaurushiya et al., 2012).  The hypothesis that the 211-222 region is involved in PML 
targeting can be investigated using a yeast-two-hybrid experiment looking for interaction 
between full length ICP0 and PML.I and truncated ICP0 mutants, including ICP0Δ211-
222.  Cells expressing different PML isoforms could be used to analyse the ability of 
ICP0Δ211-222 virus to induce PML degradation, in particular PML.I.  If this region does 
play a role in substrate targeting, this would not fully explain the observed phenotype of 
the virus, and therefore this region may affect interactions with other viral or cellular 
proteins.  Therefore, the E3 ligase activity of ICP0Δ211-222 should be investigated as well 
as interactions with key E2 ubiquitin conjugating enzymes.   
 
7.3 Future Prospects 
7.3.1 Do analogous alpha-helix mutations in other 
alphaherpesviruses have the same phenotype as those in 
ICP0 
The RING finger domain shows high sequence conservation of the zinc-binding residues 
due to structural constraints imposed by their binding (Barlow et al., 1994), and mutating 
these conserved cysteine and histidine residues impairs ICP0 activity (Lium & Silverstein, 
1997).  However, apart from the zinc-binding residues, there is only limited conserved 
homology within the RING finger domain with substantial diversity among sequences of 
different alphaherpesvirus proteins (Figure 7.2).  The alpha-helix lies in between the third 
and fourth pairs of zinc-binding residues, and therefore the orientations of the alpha-helix 
among related alphaherpesvirus ICP0 proteins is likely to be similar.   
 
An area of research that would be interesting for further study is to investigate the alpha-
helix region of related ICP0 proteins, such as those expressed by EHV-1 (EICP0), bovine 
herpesvirus 1 (BICP0), VZV protein Orf61 and pseudorabies virus protein EP0.  The 
advantage of including EICP0 is that there is a known structure available (Barlow et al., 
1994), so any apparent phenotype could be modelled and interaction partners investigated.  
EICP0, BICP0 and EP0 all have been shown to act as E3 ubiquitin ligases in vitro and are 
able to complement an ICP0-null mutant HSV-1 in the inducible cell line system (Everett 
et al., 2010).  Therefore, it could be investigated whether analogous mutations to K144E 
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and N151D in those alpha-helices cause the same phenotype, and further investigate 
mutations within these proteins that may affect the same interface.  Residue W146 is 
conserved among the alphaherpesviruses, however a number of studies have shown that 
this residue does not affect ICP0’s function when mutated (Boutell et al., 2002; Everett et 
al., 1995; Everett, 2000; Vanni et al., 2012).  This study has confirmed previous studies 
that mutating the conserved tryptophan residue does not have an effect in the context of 
ICP0’s activity during HSV-1 infections. 
 
Mutations in these ICP0 homologues could be investigated using the inducible cell line to 
investigate complementation of HSV-1 ICP0-null mutant virus, reactivation of quiescent 
virus, and effects on ND10.  All of these homologues of ICP0 have been shown to disrupt 
ND10, although their ability to degrade PML and Sp100 varies greatly between proteins 
(Everett et al., 2010).  It would be advantageous to analyse VZV, as it is the only other 
virus in the group to infect humans (HSV-1 and HSV-2 are similar).  For the others, it is 
not known if they utilise species specific E2 ubiquitin-conjugating enzymes or if there is a 
high conservation amongst E2 enzymes between species.  These experiments would give 
further insight into the role of the alpha-helix, as if the analogous mutations have similar 
phenotypes, it may point to an interaction interface and the phenotype caused by loss of 
interaction with a co-factor or protein. 
 
 
 
Figure 7.2 Amino acid alignment of the RING finger domains of ICP0 and related 
alphaherpesvirus proteins.  
The zinc coordinating residues are highlighted in grey and show homology within the 
alphaherpesviruses.  Residues K144 and N151 within ICP0 and the corresponding residues 
within the other viral proteins are highlighted in red and show no conservation (except 
between HSV-1 and HSV-2). Adapted from Boutell & Everett (2013).     
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7.3.2 Do mutations K144E and N151D affect ICP0s interactions 
with proteins or cofactors important for ICP0 activity 
This study suggests that mutations in the RING finger alpha helix may affect ICP0’s 
interactions with components of the ubiquitin pathway.  To investigate if K144E and 
N151D mutations either alone or in combination affect ICP0’s interactions with other 
proteins pull down experiments and mass spectrometry could be carried out.  The protocol, 
described in (Brymora et al., 2004), uses GST fusion proteins to pull down interacting 
proteins.  This could be investigated during virus infection or overexpressing the protein of 
interest however this has limitations due to non-physiological levels of protein being 
expressed.  Binding proteins could then be identified by SDS-PAGE, trypsin digests and 
mass spectrometry against known protein databases.  This process relies on direct protein-
protein interactions.  Each of the mutants could be analysed against wt ICP0 and mutant 
FXE to identify interaction partners for each virus and to determine which are common or 
if any interactions are lost in the alpha-helix mutants.  The results may also contain non-
specific contaminants that bind to the protein of interest non-specifically.  This method 
may not be sensitive enough to detect all the binding partners of ICP0, and it is not known 
if E2 ubiquitin conjugating enzyme interactions would be detected as they may be 
transient.  Any protein that was detected using this method would need to be confirmed by 
another method such as co-immunoprecipitation or knock-out methods to detect a positive 
interaction and if it is functionally relevant.   
 
7.3.3 Investigate the requirements of different E2 ubiquitin-
conjugating enzymes for ICP0 activity 
This study has shown that ICP0 has the ability to interact with different E2 ubiquitin-
conjugating enzymes, but at present it is unknown if these interactions are functionally 
relevant during the course of HSV-1 infection.  Therefore, it would be of value to 
investigate the requirements of different E2 ubiquitin-conjugating enzymes for ICP0 
activity and whether they act in combination with other E2 enzymes.  This could be 
investigated in vivo in the context of virus infection by immunofluorescence.  However, 
the lack of antibodies against endogenous E2 enzymes is problematic.  Therefore, the E2 
enzymes could be myc-tagged at their N-terminal end and expressed using the inducible 
cell line.  Using the inducible expression system may avoid toxicity issues of long term 
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over-expression of E2 ubiquitin conjugating proteins.  These tools could be used to 
investigate the localisation of E2 enzymes within cells and if they show colocalisation with 
ICP0.  
 
Knock-out or silencing methodologies, such as the use of siRNA to deplete endogenous E2 
ubiquitin-conjugating enzymes, could also be used to investigate if their absence impacts 
ICP0’s ability during lytic infection or reactivation.  This should be used to further 
investigate the role of UBE2W and UBE2N-UBE2V1 during HSV-1 infection, as in the 
RING finger mutants, the interactions with these enzymes could be impaired, which may 
explain their phenotypes.  In vitro E3 ubiquitin assays could be utilised to investigate 
whether E2 enzymes work as heterodimers such as in the case of UBE2N-UBE2V1, as 
ICP0 is likely to interact with multiple E2 ubiquitin-conjugating enzymes, some of which 
are only involved in chain initiation and elongation.  This should be explored, as if ICP0 
uses UBE2N-UBE2V1 in vivo, it must also interact with another E2 enzyme to initiate 
chain formation, as these enzymes are only involved in chain elongation.  Different E2 
ubiquitin-conjugating enzymes also govern chain linkage specificity and therefore 
function.  Chain linkage could be examined using linkage-specific antibodies or mass 
spectrometry to determine which chains ICP0 utilise and what role they play in the context 
of HSV-1 infection.   
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